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1.1 The discovery of HIV 
The observation of an accumulated number of Pneumocystis carinii and Candida albicans infected 
individuals with additional appearance of Kaposi´s sarcoma, caused by Human herpesvirus 8, was 
first described in 1981 in two hospitals located in the US (Gottlieb et al., 1981). This cluster of 
syndroms, associated with immunosuppression was defined as acquired immunodeficiency 
syndrome (AIDS) by the CDC in 1982. A few years later, the retrovirus was isolated from samples 
derived from infected patients by Luc Montagnier and Françoise Barré-Sinoussi (Barre-Sinoussi et 
al., 1983) at the Pasteur Institute, France. This virus was primarily termed LAV (lymphadenophathy 
associated virus) which was later described as HIV (Human immunodeficiency virus) (Brown, 
1986). The discovery of HIV was awarded the Nobel prize in 2008 to Barré-Sinoussi and 
Montagnier. After the discovery of the virus and the link between AIDS in HIV infection three 
decades ago, a vaccine was predicted to be produced within the next 6 months, but until today, no 
vaccine tested in humans has been shown to have a significant effect on inhibiting virus infection. 
Today, around 38 million people live globally with HIV infection. Despite intensive education and 
prevention programs or therapeutical opportunities, 2.5 million people became newly infected and 
1.7 million died of AIDS-related causes worldwide in 2011 (UNAIDS World AIDS Day report 2012). 
Momentarily, 78.000 Germans and 9000 Austrians are living with an HIV infection (Country 
Progress Report for UNAIDS, Austria; Robert Koch-Institut, Epidemiologische Kurzinformation) and 
new infections per year increased in 2012. 
 
1.2 HIV transmission and pathogenesis 
HIV can be transmitted via direct contact of contaminated body fluids containing a distinct number 
of viruses with mucosal surfaces or through direct blood to blood contact. The infection is mostly 
transmitted by sexual intercourse (vaginal, oral, anal) or directly from mother to child during birth or 
breastfeeding. Infection also occurs by blood transfusions or sharing of needles during drug abuse. 
Pathogenesis of HIV infection can be divided into 3 phases (early, acute, late) and are determined 
by the plasma viral load (Figure 1.1). HIV infection occurs predominantly via the mucosal barrier in 
the gut-associated lymphoid tissue, infecting cells displaying the CD4 and CCR5 receptor. Other 
target cells for HIV-1 infection represent mucosal Langerhans´ cells, expressing c-type L-lectins by 
binding to these L-lectins via gp120. Mucosal Langerhans cells, dendritic cells or macrophages 
mediate “trans” infection via transport of bound virus across the mucosal barrier, which 
subsequently infects CD4+ T-cells (Mascola et al., 2000a). Infected lymphocytes migrate to the 
local lymph nodes and persist for 2-6 weeks after infection. During this period, the infected 
individual may experience influenza-like symptoms with fever and joint pain (Cooper et al., 1985). 
Plasma viral loads peak around 104 – 108 particles per ml during the acute phase, which induces 
an extensive decrease in CD4+ cell counts following HIV-1 infection. About three to six weeks after 
infection, specific antiviral humoral and cellular immune responses are detected and associated 
with reduction of plasma viremia. Numbers of CD4+ cells slightly rebound after the acute phase, 
although never reach pre-infection levels (Clark et al., 1991; Graziosi and Pantaleo, 1998).  
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The chronic phase is characterized by fast turnover of CD4+ T-cells (Mellors et al., 1996), and a 
stabilized viral load of 103 – 105 particles per ml, defined as set-point. This plasma viral load at the 
set-point determines declining of CD4+ cells and the further progression towards AIDS (Mellors et 
al., 1996).  
 
Figure 1.1: HIV course of infection. The pattern of CD4+ T-cell decline and virus load largely varies between 
infected individuals (An and Winkler, 2010). The set-point viral load is defined as steady-state viral load in the 
chronic phase of infection. 
Continuous decline of CD4+ cells down to 200 CD4+ cells/µl defines the start of the late phase of 
the HIV-1 infection course. Reason for this extensive decrease is the cytolytic activity of the virus or 
apoptotic processes caused by production of antiviral cytokines and chemokines of infected 
monocyte and macrophages. This correlates furthermore with the change of coreceptor usage from 
CCR5 to CXCR4 in about 50% of HIV-1 infected individuals, termed as R5- or X4-tropism and is 
furthermore associated with a worsened prognosis (Kamp, 2009) of disease progression.  
 
Two types of HIV with 55% (Guyader et al., 1987) sequence homology were identified until today 
and are further differentiated into subclasses. HIV-2 is found predominantly in West-Africa and 
India, described as less virulent compared to HIV-1. HIV-1 is globally prevalent and can be divided 
into the subtypes of group M (main), O (outlier) and N (non-M, non-O). HIV-1 group M viruses are 
classified into nine clades A, B, C, D, F, G, H, J and K. clade B viruses are mostly prevalent in 
Northern America, Europe and Australia, causing 12% of all HIV infections. Viruses of clade C 
predominantly circulate in South Africa and are responsible for greater than 50% of HIV infections 
worldwide.  
The whole genomic spectrum of HIV subclasses is further expanded by mosaic viruses, evolving 
by co-infection of a single cell by different subtypes (Carr et al., 1996; Robertson et al., 2000). The 
diversity of viruses is also increased due to the lack of proof reading activity of the viral reverse 
transcriptase (Roberts et al., 1988), host selective immune pressure and the high production rates 
of 109 – 1010 viral particles per day. 
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1.3 Genome structure of HIV-1  
HIV belongs to the family of Retroviridae, genus of lentiviruses, each carrying two identical copies 
of positive and single stranded RNAs as genome. During the replication cycle, the RNA is 
transcribed into DNA which is subsequently integrated into the host´s genome.  
 
The 9800 bp genome of HIV-1 (Figure 1.2) and the 9000 bp genome of PERV encode the major 
viral enzymes (pol), the group-specific antigens (gag) and the envelope proteins (env), which are 
present in all retroviruses. 
 
Figure 1.2: Schema of the HIV-1 proviral genome. The genome is composed of 9 open reading frames env, 
gag, pol, tat, rev, vpu, vif, vpr and nef. (LTR) long terminal repeats (Weiss, 2006). 
The genus of lentiviruses encodes in contrast to other retroviruses additional regulatory and 
accessory proteins. These proteins are described in the following table: 
Gene Encoding protein Function 
nef 
(HIV-1 negative factor) 
Nef  
promotion of viral replication 
downregulation of CD4 receptor 
downregulation of MHC class II molecules 
modulation of cellular protein expression 
tat  
(transactivator of transcription) 
p16, p14 
transcriptional transactivators for the LTR promoter 
indirect phosphorylation and stimulation of RNA-polymerase II 
rev 
 (regulator of expression of 
virion proteins) 
p16, p14 
transport of unspliced viral mRNA from nucleus to cytoplasm 
activates transcription of viral genes 
vif  
(viral infectivity factor) 
Vif enhancing infectivity by inhibition of APOBEC3G 
vpr  
(virus protein rapid) 
Vpr transporting the pre-integration complex into the nucleus 
vpu  
(viral protein U) 
Vpu 
ubiquitination of CD4 
enhances budding of the virus 
Table 1.1: Regulatory and accessory proteins of HIV-1 
 
1.4 Morphology of HIV-1  
In addition to the two copies of viral RNA, the viral enzymes reverse transcriptase (RT), integrase 
(IN) and protease (PR) are packaged into the capsid. Reverse transcriptase transcribes the RNA 
into DNA with one error in 103 - 104 basepairs. This error-prone RT of HIV is responsible for the 
high genomic variability of the HIV-1 genome, since an ordinary DNA polymerase statistically 
produces one mutation in 10-7 to 10-9 basepairs (Preston et al., 1988; Roberts et al., 1988).  
The capsid is composed of the capsid protein p24, which is enveloped by the outer membrane 
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surface of the lipid membrane faces the matrix protein p17 and envelopes the inner virion with its 
viral enzymes, RNA, the RNA-associated nucleocapsid protein (p7) and the linker protein (p6) 
between p17 and the capsid. 
 
Figure 1.3: Schematic illustration of the HIV-1 virion structure (www.visualscience.ru). 
The envelope proteins (Env) are non-covalently linked heterodimers, composed of the 
transmembrane glycoprotein gp41 (TM) and the surface protein gp120 (SU), which are transcribed 
from the env gene as a 160 kDa precursor protein. This precursor protein is transported to the 
Golgi apparatus for oligomerization and extensive glycosylation which is required for stable folding 
(Fenouillet et al., 1994). After the glycans are modified by a number of enzymes (Wyatt and 
Sodroski, 1998), the precursor protein is digested into gp120 and gp41 by the furinprotease This is 
followed by the transport to the target cell membrane and inserted as trimer via the transmembrane 
domain in gp41. Although trimeric and correctly folded spikes are essential for effective infection, a 
number of non-functional glycoproteins (monomer, dimers, tetramers) are likely to be expressed at 
the viral membrane due to ineffective trimerization at the Golgi apparatus or incomplete digestion of 
SU and TM (Pantophlet and Burton, 2006; Parren et al., 1997). 
 
1.5 The replication cycle of HIV-1  
The replication cycle of HIV-1 can be divided into two phases: early and late. The early phase of 
virus infection is characterized by membrane fusion and integration of the transcribed viral DNA 
into the host´s genome as provirus. The virus binds via the surface protein gp120 to the CD4 
receptor of the host cell. Subsequent conformational changes in the spike proteins and binding to 
the coreceptor induce shedding of gp120 from gp41. After insertion of gp41 into the host cell´s 
membrane, gp41 folds into a six-helix bundle formation, mediating membrane fusion of the host cell 
and viral envelope with subsequent release of the capsid into the cytoplasm. After „uncoating“ of 
the viral RNA and enzymes, the reverse transcriptase transcribes the viral RNA into DNA, resulting 
in a RNA/DNA hybrid complex (Morrow et al., 1994). The transcription product is subsequently 
accumulated together with the co-transcriptional enzymes IN, MA, RT, the accessory protein Vpr 
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transports the complex into the cellular nucleus, followed by integration of the DNA into the host 
cell´s genome. The viral DNA integrates into DNA regions with predominantly high transcription 
frequency (Schroder et al., 2002), promoted by the viral integrase. 
The structure of integrated provirus includes flanking long terminal repeats (LTR), composed of U3, 
R and U5. LTRs are arranged in the same direction at the 5´ and 3´ end of the provirus. 
Transcription of provirus is driven by the promoter located at the 5´ LTR. Cellular transcription 
factors can additionally bind to the U3 region in order to induce transcription of provirus by the 
cellular RNA polymerase II (Pereira et al., 2000)  
 
The late phase in the HIV-1 replication cycle is characterized by expression of accessory proteins: 
Rev, Nef and Tat. Rev has its main role in transport of viral mRNAs, whereas Tat´s function relies 
in stabilization of viral gene transcription. The HIV-1 Env is synthesized as the precursor protein 
gp160 and co-translationally glycosylated at the endoplasmatic reticulum (Blay et al., 2007). After 
trimerization gp160 is cleaved into gp120 and gp41 by cellular proteases in the trans-Golgi network 
(Moulard and Decroly, 2000). Both envelope proteins are then transported to the cellular surface 
and inserted in the membrane via the transmembrane anchor of gp41. Gag and pol are transcribed 
as a single unspliced mRNA with different translational reading frames. The assembly of the capsid 
is regulated by local concentrations of Gag protein, starting from approximately 1500 copies. Two 
identical copies of unspliced viral mRNA containing the viral genome are assembled with Gag-Pol 
precursor proteins and transported to the cellular membrane. The immature particle buds 
subsequently from the host cell. Maturation of the viral particle is completed after Gag-Pol 
precursor proteins are cleaved into the structural proteins (MA, CA and NC) and viral enzymes (IN, 
RT and PR).  
 
1.6 The envelope proteins 
The surface unit gp120 of the viral envelope protein is composed of five conserved (C1-C5) and 
five variable (V1-V5) segments, organized to an inner and outer domain, connected by a bridging 
sheet. The first four variable segments V1-V4 form loops, which are predominantly exposed to the 
immune system. The conserved segments are responsible for gp41 interaction and receptor 
binding on the surface of the host cell (Kwong et al., 1998). Clusters of non-neutralizing antibody 
epitopes were detected in the inner domain, which is thus termed as non-neutralizing site of gp120 
(Moore et al., 1995; Parren et al., 1999). The main contact to the TM unit was described to be 
restricted to C1 and C5, whereas large parts of C2, C3 and C4 form a hydrophobic core at the 
center of gp120 (Moore et al., 1994; Pollard et al., 1992). The inner domain is rarely covered with 
carbohydrates (Wyatt et al., 1998), supporting its proximity and contact to gp41. The outer domain 
is largely covered by glycans, which in turn lowers the immunogenicity of the viral protein (Kwong 
et al., 2000).  
 
Highly immunogenic regions of the protein are detected in the V-domains and especially within the 
variable V1/V2 and V3-region (Hwang et al., 1991), which are suggested to be exposed to the 
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surface of gp120 and target of several neutralizing antibodies. Thus, the V1-V3 regions are subject 
to selective pressure, which induces a large number of escape mutants. Neutralizing antibodies 
directed against this region are mainly able to neutralize only the autologous virus. Due to the 
potential large part of the gp120´s outer domain, the protein is highly glycosylated with 26 
glycosylation sites (Cutalo et al., 2004). 
 
Figure 1.4: Organization of gp120 structure into inner domain (indicated in yellow) and outer domain (indicated 
in blue). The four-stranded bridging sheet is composed of two strands from the outer domain and the V1/V2 
stem from the inner domain. CD4 binding site is highlighted as red circle (Guttman et al., 2012). 
The 41 kDa TM protein (Figure 1.5) is organized into 3 sections (ectodomain, membrane spanning 
domain, endodomain) and this structural organization of the TM protein is common among 
retroviruses (gp36 of HIV-2 or p15E of PERV). The extraviral section or ectodomain is located at 
the N-terminal part of the protein, followed by the membrane spanning domain and the intraviral 
section at the C-terminal end. The ectodomain can further be divided into 6 subdomains, including 
the fusion peptide (FP), fusion peptide proximal region (FPPR), two heptad repeats (N-heptad 
repeat (NHR), C-heptad repeat (CHR)), the cysteine loop (C-C), immunodominant epitope (IDO) 
and the membrane proximal external region (MPER). The fusion peptide is responsible for insertion 
of gp41 into the host cell membrane with its hydrophobic amino acids (Freed et al., 1990; Pereira et 
al., 1997) and the subsequent membrane fusion.  
 
Figure 1.5: Schematic illustration of the TM protein gp41 (HIV-1), anchored in the lipid membrane. Main 
structure components represent the fusion peptide (FP), fusion peptide proximal region (FPPR), N-heptad 
repeat (NHR), cysteine loop (C-C); C-heptad repeat (CHR) and the membrane proximal external region 
(MPER). Definition of epitope region one and two (E1/E2) are equivalent with corresponding FPPR and MPER 
domains (Fiebig et al., 2009).  
gp41
512 597 604
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1.6.1 The role of the envelope proteins gp120 and gp41 in the attachment 
and membrane fusion process  
Between 14 and 72 Env trimers are located on the surface of one HIV-1 particle (Zhu et al., 2006), 
which mediates binding to the host´s CD4 target cells (Liu et al., 2008). The CD4 receptor is 
inserted into the cellular membrane of monocytes, macrophages and dendritic cells (DC), working 
as a coreceptor for the T-cell receptor and thus part of the adaptive immune system. HIV-1 
infection starts with the interaction of the conserved region C3 of gp120 with the CD4 receptor. 
Conformational changes enable accessibility of the V3 domain, which binds, together with V1/V2 
domains, to either one of the coreceptors, predominantly CXCR4 or CCR5 (Myszka et al., 2000). 
The sequence of the V3 region of the envelopes protein´s surface unit determines the tropism of 
the virus, infecting T-cells (X4 or T-tropism) or monocytes/macrophages (R5 or M-tropism) as 
reviewed in (Clapham and McKnight, 2002). This switch is due to two mutations within the V3-loop 
of gp120, resulting in the absence of a glycosylation site (Polzer et al., 2002).  
The coreceptor CCR5 is expressed on macrophages, monocytes, memory T-cells, activated CD4+ 
cells and dendritic cells, interacting usually with the chemokines RANTES, MIP-1α or MIP-1β. The 
natural ligand of CXCR4 is SDF-1α (stromal cell-derived factor) which was previously described as 
Fusin (Bleul et al., 1996). X5-tropic viruses are predominantly transmitted and persist during HIV-1 
infection (Weinberger and Perelson, 2011). It was previously demonstrated that individuals who are 
homozygous for a distinct deletion of 32 base pairs within the CCR5 gene (CCR5-Δ32) were not 
susceptible for infection by R5-tropic viruses (Liu et al., 1996; Samson et al., 1996). Heterozygous 
individuals are not resistant to CCR5-using HIV-1 variants, but the infection progresses more 
slowly towards AIDS in these individuals (Dean et al., 1996; Huang et al., 1996; Michael et al., 
1997). 
X4-tropic viruses emerge late in the infection course and infect the repertoire of cells expressing 
CXCR4 in contrast to R5-tropic viruses, predominantly infecting activated T-cells and macrophages 
(Bleul et al., 1997). Viruses infecting via the CXCR4 receptor induce syncytium formation (Johnston 
et al., 2003) and are controversially discussed to be more sensitive to neutralization (Bunnik et al., 
2007; Cecilia et al., 1998). 
 
Figure 1.6: Fusion process of viral and host cell´s membrane for HIV-1 entry mediated by envelope proteins 
gp120 and gp41 of HIV-1. NHR is depicted in grey, CHR in blue, respectively (Welch et al., 2007). 
Binding of the CD4 receptor to gp120 induces a shift within the C1 C4/5 regions, which interact 
already with gp41 (Moore et al., 1997). Interaction of the coreceptors with V1-3 of gp120 and 
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subsequent conformational changes within the Env protein induce attenuation of the non-covalent 
bond between SU and TM and allows subsequent shedding of gp120 and exposure of gp41. 
The fusion peptide of gp41 inserts into the cell membrane after shedding of gp120, which induces 
an intermediate pre-hairpin conformation of gp41 (Eckert and Kim, 2001; Finnegan et al., 2002; 
Jones et al., 1998), bridging the viral and cellular membrane (Figure 1.6). This conformation is 
metastable, and is followed by a hydrophobic interaction of amino acids in the CHR and NHR in an 
anti-parallel manner, forming a six-helix bundle (SHB). The six-helix bundle is composed of three 
gp41 monomers, in which three NHR subunits form a coiled-coil formation and the corresponding 
CHR is packed around. Formation of the SHB is essential for driving membrane fusion, bringing the 
viral and cellular membrane to close proximity (Buzon et al., 2010; Melikyan, 2008; Weissenhorn et 
al., 1997) with subsequent membrane fusion. 
 
1.7 Blocking the infection process by neutralizing antibodies against 
envelope proteins 
For the majority of viral infections, a vaccine based on neutralizing antibodies to prevent primary 
infection provides the most effective vaccine efficacy. Although other immune defence mechanisms 
can contribute to total virus clearance from the system, genome integrating viruses need one cell to 
infect and establish a permanent infection (Keele et al., 2008). Thus, the mechanism to neutralize 
virus before its entrance and subsequent integration is believed to be efficient for prevention of HIV 
infection.  
 
Enveloped viruses bind to the host cell receptors via the viral spikes, which are also essential 
targets for an effective antibody response. Therefore, the spike proteins contain one or more 
relatively conserved receptor binding sites, most likely to be exposed at least for a short time to the 
immune system during infection.  
Stimulation of non-neutralizing antibody responses against irrelevant viral structures were shown to 
occur relatively early (Figure 1.7) in infection (Richman et al., 2003). All infected individuals develop 
weakly neutralizing antibodies against autologous virus and about 20% of chronically infected 
establish an antibody response with moderate neutralizing capacity against 70-80% of HIV-1 
variants at later stages of infection (Doria-Rose and Connors, 2009; Sather et al., 2008; Walker 
and Burton, 2010). Only 2% of infected patients develop neutralizing antibodies that broadly 
neutralize all HIV-1 clades (Doria-Rose et al., 2008; Stamatatos et al., 2009).  
The development of antibody responses after infection with HIV-1 follows a distinct time course for 
certain HIV-1 Env-specific antibody populations (Tomaras and Haynes, 2009). Primary IgM 
antibody responses after initial HIV-1 infection are anti-gp41 specific, followed by detection of anti-
V3 antibodies (Figure 1.7). Antibodies capable of neutralizing autologous virus are detected 2-39 
months after infection and predominantly directed against non-conserved epitopes on Env. This 
first wave of NAb responses is followed by extensive viral escape due to these autologous virus 
NAb, enabling continuous viral replication (Deeks et al., 2006; Wei et al., 2003; Wrin et al., 1994) 




Figure 1.7: Time course of anti-Env antibodies within initial three months after infection. Primary antibody 
responses are anti-gp41 IgM antibodies, predominantly binding to the immunodominant loop, followed by anti-
V3 antibodies. The first, weakly neutralizing anti-V3 antibodies are observed about six weeks post-infection. 
The dotted line represents the detection limit of either plasma viremia or Env-specific antibodies (Figure was 
modified from (Tomaras and Haynes, 2009)). 
HIV-1 has developed several mechanisms to circumvent the generation of antibodies capable of 
virus neutralization. These conserved regions of the Env protein are relatively small and shielded 
by carbohydrates (Pantophlet and Burton, 2006; Wyatt et al., 1998) or the protein itself during the 
fusion process to prevent generation of neutralizing antibodies. Although the glycan shield of Env is 
relatively conserved, there is some evidence that glycosylation depends on establishment of the 
virus in the new host and selection pressure of nAbs (Mascola and Montefiori, 2010; Scanlan et al., 
2007). Another possible mechanism for virus escape is neutralizing antibody selection of escape 
mutants and genetic variants caused by the error-prone reverse transcriptase and the ability for 
RNA recombination (Kwong et al., 2011; Roberts et al., 1988). Low density of spike proteins on the 
surface (Zhu et al., 2006) and flexible conformations of gp120 and gp41 also hamper the 
development of antibodies capable to prevent virus infection. 
 
Since it was controversially discussed that high titers of NAb in serum of infected patients can 
delay the progression toward AIDS (Cecilia et al., 1999; Pilgrim et al., 1997; Scarlatti et al., 1996), 
isolation of these antibodies and monoclonalization for further characterization of distinct functions, 
structure, epitopes and neutralizing capacity was performed. The first bNAb to be isolated was b12 
in 1994 (Burton et al., 1994). Particular properties are described for bNAb, such as an extended 
CDRH3 (complementary determining region of the heavy chain). The antibody binds to the antigen 
with its complementary determining region formed by variable region of the antibody´s light and 
heavy chain. In order to increase affinity to the antigen, the antibody might undergo somatic 
hypermutation, which is induced by enhancement of Ig gene transcription and erroneously repaired 
double-strand breaks in the DNA. Since epitopes of bNAb are predominantly hidden on the HIV 
surface, this somatic hypermutation allows adaptation of these antibodies to engage certain 
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1.7.1 Broadly neutralizing antibodies binding to gp120 
Despite the high variability and strong glycosylation of gp120, a number of neutralizing antibodies 
against several subtypes were identified since 1994. Those antibodies are mostly directed against 
two conserved sites of gp120 which accessible during the infection process: the CD4 binding site 
and the coreceptor binding site. Since subtype B is prevalent in US and Western Europe, most 
monoclonal antibodies were isolated from clade B infected patient. Thus, predominantly clade B 
specific antibody structures together with their epitopes are described. 
The monoclonal antibody b12 (Burton et al., 1994) is a highly potent neutralizing antibody directed 
against gp120, recognizing and thus blocking the CD4 binding site of the virus. The broadly 
neutralizing capacity of b12 was described to be associated with its capability to bind monomeric 
and oligomeric Env (Sattentau and Moore, 1995), whereas non-neutralizing antibodies did not bind 
oligomeric Env structures on the viral membrane, most likely due to steric hindrance by the 
heterodimer itself or other Env molecules (Kwong et al., 2000; Wyatt et al., 1998). The crystal 
structure of the antibody (Saphire et al., 2001) shows specific properties, which are closely related 
to its broadly neutralizing capacity. Of note, the antibody contains an unusual long “long finger like” 
(Pantophlet and Burton, 2003) complementary determining region (CDR) H3 as it was  described 
for other bNAb, including a tryptophane at the apex and specific residues at the base of this loop 
which enables its binding to the hydrophobic pocket of the CD4 binding site in gp120 (Zwick et al., 
2003). Neutralization assays with pseudoviruses containing Env of primary HIV strains showed 
(Binley et al., 2004; Moulard et al., 2002) cross-clade neutralization capacity and inhibit infection of 
HIV-1 clades A, B, C, D, E, F and G. 
2G12 was the first isolated bNAb that binds to a glycosylated and discontinuous epitope in V4/C4 
of gp120 (Sanders et al., 2002). Binding of the monoclonal antibody depends in detail on α-1-2 
linked mannose residue on asparagines at the positions 295, 332 and 392 (Scanlan et al., 2002), 
whereupon the glycans are recognized via the variable region of the antibody´s heavy chain 
(Calarese et al., 2003). Since 2F12 recognizes only glycans as target and not the protein 
backbone, an antigen to induce this kind of antibody can be difficult to resemble. The antibody can 
neutralize clades A, B, D, F (Binley et al., 2004) but not clade C viruses which cause the highest 
percentage of infections worldwide.  
During the last 4 years, a large number compared to previous years of bNAb identification of new 
potent bNAb have been isolated. Two antibodies PG9 and PG16 were identified from a clade A-
infected donor with broadly neutralizing serum capacity (Walker et al., 2009), exceeding the 
potency of the control antibodies b12, 2G12, 2F5 and 4E10. Neutralization assays using a 
multiclade pseudovirus panel of HIV-1 showed neutralization of 119 and 127 out of 162 tested 
viruses for PG3 and PG16, respectively. This demonstrates higher neutralization potency 
compared to bNAb which were isolated previously. PG9 and PG16 also showed a unique epitope, 
recognizing conserved regions in V1/V2 and V3 loops in combination with glycans on the gp120 
trimer. Analysis of the antibodies’ variable genes showed a long CDRH3 loop, which was 
previously associated with polyreactivity (Ichiyoshi and Casali, 1994), but neither PG9 nor PG16 
bound to autoantigens.  
In the same time period three bNAb VRC01, VRC02 and VRC03 were isolated by screening B-cells 
for the strongest antibodies binding to the CD4 binding site (Wu et al., 2010). These antibodies 
  Introduction 
13 
 
neutralized 90% of circulating HIV-1 variants with an IC50<1 µg/ml. Of note, a newly discovered 
panel of 17 neutralizing monoclonal antibodies exhibited cross-clade neutralization and some of 
those were 10-100-fold more potent than previously identified antibodies (Walker et al., 2011). 
Furthermore, new neutralization targets were identified on gp120, similar to those of PG9 and 
PG16.  
Antibody Reference Epitope Neutralization breadth Characteristics 
2G12 Trkola et al., 1996 Scalan et al.,  2002 
V4/C4 region 
CD4 binding site 
Glycosylation N295, N332, 
N392 





Burton et al., 1994 
Zwick et al.,  2003 
Saphire et al., 2001 
V3 crown  
Overlapping CD4 binding 
site  Discontinuous epitope 
Clades A, B, C, D  
(Binley et al., 2004) 
Some clade E, F, G 
(Moulard et al., 2002) 
Interaction of gp120 with 
H3 required for antibody 
binding  
(Zwick et al., 2003) 
Polyreactive 
HJ16 Corti et al., 2010 
Adjacent to CD4 binding 
site  
 Discontinuous epitope 
Clades A, B, C, D  
(Corti et al., 2010) n/a 
HGN194 Corti et al., 2010 V3 crown / RRSVRIGPGQTF 
(A, B, C, AG)  
(Corti et al., 2010) n/a 
PG9 
PG16 
Walker et al., 2009 
McLellan et al., 
2011 
V1/V2/V3  
Conformational epitope  
glycan dependent 
Clades A, B, C, few clade 
D, AG, AE, F  
(Walkeret al., 2009 and  
Huang et al., 2012) 
Binds glycans,  
long CDRH3 loop 
mediates neutralization 





Walker et al., 2011 
Pejchal et al., 2011 
V3 loop / glycan shield 
Conformational epitope 
~70% of circulation HIV 
strains 
Neutralization mediated 
by crosslinking Env 
trimers (Pejchal et al., 
2011) 
VRC01/02 Wu et al., 2010 CD4 binding site Conformational epitope 
Clades A, B, C, D, AE, 
AG, G, BC 
Wu et al., 2010 
Zhou et al., 2010 
Increased neutralization 
potency of improved 
antibody NIH45-46 
(Scheid et al., 2011) 
3BNC117 Scheid et al., 2011 CD4 binding site 
Clades A, B, C, D, AE, 
AG, BC 
Huang et al., 2012 
n/a 
VRC-PG04 Falkowska et al., 2012 
CD4 binding site 
Conformational epitope 
Clades A, AE, AG, B, C, 




Bonsignori et al., 
2012 
CD4 binding site / V2/V3  
Conformational epitope 
Clades A, B, C, D, AE 
(Bonsignori et al., 2012) 
Long CDRH3 loop in 
CH01-04 mAb 
447-52D Gorny et al., 1994 
V3 region, GPGR 
Conformational epitope,  
Clade B  
(Gorny et al., 1994) n/a 
697-D Gorny et al., 1994 V2 loop,  Conformational epitope 
Clade B (Gorny et al., 
1994) n/a 
Table 1.2: Overview of isolated bNAb specific for gp120.  
1.7.2 Neutralizing antibodies binding to gp41  
More than ten bNAb targeting gp41 have been isolated from infected individuals in the last decade. 
Three of those were the monoclonal antibodies (mAb) 2F5, 4E10 and Z13, binding to epitopes 
located in the tryptophane-rich membrane proximal external region (MPER) of gp41. Binding of the 
MPER inhibits the membrane fusion process and therefore blocks viral entry (Binley et al., 2003). 
Since MPER amino acids are relatively conserved, this region (Liu et al., 2009; Salzwedel et al., 
1999) represents a vulnerable target for these kinds of antibodies. The precise function of this area 
is still unknown, but changes in amino acid composition in the MPER hamper and inhibit the fusion 
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process (Munoz-Barroso et al., 1999; Salzwedel et al., 1999). The bNAb 2F5 recognizes the 
strongly conserved amino acids ELDKWA (GenBank: AF324493), located in the MPER of gp41 
(Muster et al., 1993; Zwick et al., 2005), its core epitope is defined as (L)DKW (McGaughey et al., 
2003). Neutralization breadth of 2F5 is restricted to viruses containing the epitope sequence 
ELDKWA, whereas viruses of clade C with modified MPER sequence are not neutralized or only to 
some extent by high concentrations of 2F5 (Binley et al., 2004; Parren et al., 1998; Trkola et al., 
1998) due to altered amino acids within the core epitope. The potent neutralizing capacity of 2F5 is 
restricted to the strong avidity to its epitope. Previous reports indicated that 2F5-like antibodies 
were found in 0.3% of infected individuals, developing 15 to 20 months after infection (Shen et al., 
2009). 
The second potent bNAb, 4E10, targeting the MPER, was identified in 2001 (Zwick et al., 2001) 
together with another bNAb (Z13). 4E10-like antibodies are detected in 3% of HIV-1 infected 
individuals and these antibodies appear a few years after infection (Sather et al., 2008; Sather and 
Stamatatos, 2010). The epitope of 4E10 is located C-terminal to the 2F5 epitope in proximity to the 
transmembrane domain, which is partly inserted in vivo into the lipid bilayer of the viral membrane, 
comprising amino acids WNWF(N/D)IT. 
In the last two years, about four neutralizing antibodies targeting gp41 were discovered, although 
with limited neutralization breadth. D5, DN9 or HK20 predominantly neutralize clade B viruses and 
recognize epitopes often covered during the fusion process (Gustchina et al., 2010; Luftig et al., 
2006). 
Antibody Reference Epitope Neutralization breadth Characteristics 
10E8 Huang et al., 2012 WNWFNITNWLWYIR WNWFN blocked neutaliz. 
Clades A, AC, AD, AE, 




Trkola et al., 1995 
Bryson et al., 2009 
MPER (aaELDKWA) 
Parker 2001 
Clades A,B,D,E, F 
(Binley et al., 2004) Polyreactive 
4E10 
Zwick et al., 2001 
Cardoso et al., 
2005/2007 
MPER (aaWNWF(D/N)IT) 
Clades A, B, C, D, E, F, 
G 





Zwick et al., 2001 
Nelson et al., 2007 
MPER 
(aaWASLWNWF(D/N)ITN) 
Clades B, E, C 
(Binley et al., 2004) n/a 
M66/M66.6 Zhu et al., 2011 MPER (aaDKW, L(660,663) Clades A, AE, AG, B 
Long CDR-H3 loop 
M66.6 reactivity to self- 
antigens 
D5 Miller et al., 2005 Luftig et al., 2006 
Hydrophobic pocket in NHR 
(aaLLQLTVWGIKQLQARIL) 
 
Clade B No atypically long CDR 
HK20 
Corti et al., 2010 
Sabin et al., 2010 
NHR 
(aaQQHLLQLTVWGIKQL) Clades A, B, C, D 
Enhanced neutralization 
of Fab compared to IgG 
DN9 Nelson et al., 2008 Trimeric NHR, overlap with D5 epitope Clades B, C n/a 
8K8 Nelson et al., 2008 
Trimeric NHR, overlap with D5 
epitope Clades B, C n/a 
Table 1.3: Overview of isolated bNAb binding to gp41. (CDR) complement determining region. 
1.8 Passive immunization using neutralizing antibodies 
The next step after identification and isolation of bNAb implicated in vivo experiments to investigate 
whether isolated bNAbs are able to prevent or at least inhibit the host´s infection. In order to test 
the inhibitory effect of neutralizing antibodies, passive immunization was performed in macaques 
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challenged with hybrid viruses containing simian immunodeficiency virus sequences combined with 
HIV envelope proteins (SHIV).  
The first passive transfusion studies with passively administered bNAb were performed in 1999, 
using the mAb 2G12 or 2F, given alone or in combination (Mascola et al., 1999; Shibata et al., 
1999). The study of Mascola and his colleagues showed a correlation of protection and passive 
administration of a combination of bNAb before SHIV challenge, although macaques who received 
2F5 or 2G12 alone prior challenge became infected and developed high-level plasma viraemia. 
2G12 was later shown to protect in vivo from SHIV infection, particularly when 2G12 was 
administered in combination with other NAb (Baba et al., 2000; Ferrantelli et al., 2004; Hofmann-
Lehmann et al., 2001; Mascola et al., 1999; Mascola et al., 2000b). The antibody was also used for 
infusion experiments of HIV infected patients under retroviral therapy (Trkola et al., 2005) showing 
that administration of 2G12 was essential for the delay of viral rebound after stop of the therapy. 
Several combinations of the bNAb were  tested in a number of intravenous (Baba et al., 2000; 
Mascola et al., 1999), intravaginal (Parren et al., 2001), oral (Baba et al., 2000; Hofmann-Lehmann 
et al., 2001), or intrarectal (Hessell et al., 2010) challenge regimens, demonstrating protection in 
macaques.  
The bNAb b12 was also tested in passive immunization of macaques, demonstrating that the 
antibody protects in vivo against challenge virus (Parren et al., 2001; Veazey et al., 2003), which 
has been additionally demonstrated for the MPER directed antibodies 2F5 and 4E10 (Hessell et al., 
2010).   
A number of studies demonstrated thereafter protection from infection after intravenous SHIV 
challenge, although high titers of antibodies were required. Further development of these studies 
allowed different challenge regimens in order to simulate the “more natural” route of infection via 
mucosal contact to virus. These studies required lower titers of NAb present in plasma to prevent 
infection (Hessell et al., 2009a; Hessell et al., 2009b).  
 
1.9 Additional characteristics of vaccine induced antibodies 
Additional aspects with regards to antibody function and control of virus infection by other 
mechanisms than neutralization have been brought to focus in the recent years. One important 
vaccination study described the induction of binding antibodies responsible for protection in the 
macaque challenge model, although this protection did not correlate with neutralizing capacity 
(Demberg et al., 2007). Of note, the closer evaluation of Thailand RV144 study outcome also 
indicates a correlation of non-neutralizing antibodies with modest protection (Rerks-Ngarm et al., 
2009).  
This protection was identified to be related to other effector functions of binding or neutralizing 
antibodies besides Fab-mediated neutralization of virus. Such antibodies mediate biological activity 
through binding with their C-terminal Fc region to the Fcγ receptor located on a number of different 
effector cells. Natural killer cells (NK), dendritic cells, monocytes and neutrophils are those effector 
cells which mediate ADCC (antibody dependent cellular cytotoxicity) or ADCVI (antibody 
dependent cell mediated virus inhibition) with its bound antibody. In both ADCC and ADCVI, the 
antibody binds with its Fab region to the infected cell, presenting the antibodies’ epitope. The Fc 
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region of the antibody then binds the FcγIII receptor on the effector cells which induces lysis of the 
infected cell. In an experimental setup, infected cells are marked and ADCC activity can be 
measured by counting the numbers of killed HIV-1 infected cells. ADCVI assays measures 
inhibition of virus yield by NK or other cells (Forthal et al., 2005). In addition to these effector 
functions, antibody-mediated activation of these effector cells can also induce production of 
antiviral chemokines and cytokines (Forthal et al., 2001), inhibiting HIV-1 infection. 
 
1.10 Vaccine development against HIV  
1.10.1 Live-attenuated and inactivated vaccines 
The discovery that immunizations with a nef-deleted SIV (SIVΔnef) variant induced protection after 
challenge with a pathogenic SIV strain in macaques served as important benchmark for life 
attenuated vaccine development (Daniel et al., 1992). However, long-term studies of this 
immunization regimen showed an establishment of a vaccination virus life-long persistent, low-
grade infection, which protected macaques from challenge with pathogenic virus but did not protect 
against superinfection (Girard et al., 2011). Follow-ups of these studies also indicated that the 
attenuated vaccination virus regains virulence and causes disease, especially in neonate 
macaques (Baba et al., 1995; Baba et al., 1999; Hofmann-Lehmann et al., 2003). This regimen 
was never tested in humans due to lack of safety. 
Attempts to induce protective antibody responses with inactivated virus particles (Huang et al., 
2012) or VLP (virus-like particle) (Kim et al., 2007) have not been very successful, although 
immunogenicity of VLPs was enhanced when priming with DNA (Wardemann and Nussenzweig, 
2007). 
 
1.10.2 Subunit immunogen design  
Protein based subunit vaccines are known as strong antibody inducers and are predominantly used 
in HIV-1 immunogen design. First immunization regimens used monomeric and soluble derivatives 
of the HIV-1 envelope protein in combination with an aluminum salt used as adjuvant: gp160, 
gp120 only or gp140 (Belshe et al., 1993; Dolin et al., 1991). These experiments induced 
neutralizing antibodies directed against V3 of gp120, although effective neutralization and 
protection after challenge was only observed with autologous virus (Berman et al., 1990; Fultz et 
al., 1992). Gp120 was further used in a number of clinical trials in combination with alum, QS-21, 
MF59 or MPL® (McElrath et al., 1996) but remained largely unsuccessful.  
Trimerization of immunogens creates structures resembling native Env conformation and enables 
the generation of antibodies more likely binding to the trimeric structure on native viruses. This was 
tested with derivatives of the envelope protein (Kovacs et al., 2012; Yang et al., 2001). This 
trimerization can also be stabilized by the co-expression of other “carrier” proteins to favor trimeric 
structures (Yang et al., 2002). Trimeric molecules elicited low titers of neutralizing antibodies, 
mostly only neutralizing autologous virus (Barnett et al., 2001; Li et al., 2006; Xu et al., 2006). 
Glycans and quaternary structures represent another category of immunogens since the broadly 
neutralizing antibodies 2G12 recognize a carbohydrate dependent epitope on the outer domain of 
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gp120 (Trkola et al., 1996). PG9 and PG16 as recently discovered bNAb recognize similar 
epitopes, indicating a potent target site for antigen design as it was reported for the bNAb CH01-
CH04 (Bonsignori et al., 2011).  
One of the main targets of neutralizing antibodies within the envelope protein represents the CD4 
binding site since a number of new bNAb was recently identified to bind to this region (Bonsignori 
et al., 2012; Falkowska et al., 2012; Scheid et al., 2011). Presentation of the outer domain of gp120 
using SU as recombinant protein (Feng et al., 2012; Kovacs et al., 2012), expressed by viral 
particles, as a DNA vaccine or computer designed scaffolds induced neutralizing antibodies in a 
number of studies although with weak cross-clade neutralizing capacity (Nkolola et al., 2010; 
Sundling et al., 2010).  
 
Antigen design to target the largely conserved TM protein of HIV-1 is a challenging field compared 
to those focused on gp120. As above mentioned, gp41 undergoes several structural modifications 
during the fusion process, presenting a number of conformational epitope variants at different time 
points and time periods, which impedes the antigen design due to non-static presentation of the 
potential antigen.    
Specifically the MPER located in gp41, juxtaposed to the viral membrane, is a highly conserved 
region and target of five bNAb: 2F5, 4E10, Z13, M66.6 and the recently identified 10E8 (Huang et 
al., 2012). This region represents one of the main targets important for vaccine design, although its 
proximity to lipids complicates immunogen design since the lipid environment could modify 
conformation of the MPER compared to the protein in aqueous solution (Dennison et al., 2011b; 
Sun et al., 2008). This target region was used in different vaccination approaches such as synthetic 
peptides in combination with virosomes and recombinant proteins (Bomsel et al., 2011; Wang et 
al., 2011), DNA immunization strategies and virus-like particles (Arnold et al., 2009; Ye et al., 2011) 
comprising the MPER sequence achieved moderate success to induce MPER specific antibodies 
capable of neutralising HIV-1, but not with broad neutralising capacity.  
 
1.10.3 Lipopeptides and liposomes 
Liposomes are phospholipid bilayer vesicles and were primarily used as immunological adjuvants 
in 1974 (Allison and Gregoriadis, 1974; Gregoriadis and Allison, 1974). At that time, about eight 
liposome-adjuvanted vaccines were tested in clinical trials, focussing on immunization against 
influenza, hepatitis but also on HIV vaccines (An and Winkler, 2010). Since that, lipid vesicle carrier 
and liposomes were established as important adjuvant system for vaccines to induce both humoral 
and cellular responses. Liposomes were shown to be well tolerated and safe as demonstrated by 
extensive studies with a liposomal adjuvanted anti-cancer drug (Airoldi et al., 2011; Kamp, 2009). 
In addition to that, liposomes showed low anti-lipid antigenicity when liposomes were applied as 
adjuvants for various vaccines (Guttman et al., 2012; Laguette et al., 2011). Thus, around eight 
different liposome carrier formulations are currently approved for human use. 
 The lipid particles are composed of phosphatidylcholine or cholesterol, occurring naturally as 
cellular membranes in the organism and thus not recognized as foreign. According to different lipid 
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combinations, size and inclusion of additional proteins or immunostimulatory agents, liposomes can 
be differentiated into several categories:  
• Cationic liposomes include a neutral helper lipid (cholesterine or phosphatidylcholine) 
together with one cationic lipid (1,2-dioleoyl-3-trimethylammonium propane = DOTAP,  3β-
[N-(N´,N´-dimethylaminoethane)-carbamoyl]cholesterol = DC-Chol or DDA = 
dimethyldioctadecyl-ammonium) 
• Ordinary liposomes are composed of neutral or anionic lipids combined with an 
immunostimulatory adjuvants such as stimulators of Toll-like receptors 
• Virosomes are reconstituted membranes derived from influenza virus including 
phospholipids, influenza antigens and additional phosphatidylcholine 
• Lipoplex/Lipopolyplex are types of vesicles with cationic lipid, mostly in complex with 
plasmid DNA and helper lipids such as cholesterol; lipopolyplex particles includes an 
additional polycation   
• Niosomes are composed of cholesterol and single-alkyl chain non-ionic surfactant 
 
Agonists for diverse pattern recognition receptors (Toll-like receptors (TLR) or  NOD-like 
(nucleotide-binding oligomerization domain) receptors are often added to liposome formulations for 
subunit vaccines (Forthal and Moog, 2009) in order to increase immunogenicity of liposomes. 
Potent stimulators are predominantly TLR-agonists like MPLA (monophospholipid A), activating 
stimulatory pathways via TLR4 (Alving and Rao, 2008) or unmethylated cytosine-phosphate-
guanine motives (CpG) binding to TLR9 (Bunnik et al., 2007; Cecilia et al., 1998). MPL® is a low-
toxicity derivative of LPS (MPLA), licensed in Europe in combination with Glaxo-Smith-Kline´s 
subunit vaccine against Hepatitis B (Forthal et al., 2001). 
 
Figure 1.8: Mode of antigen attachment to liposomes (Watson et al., 2012). (A) Covalent conjugation to the 
liposomal surface by cholesterol. (B) Non-covalent attachment. (C) Encapsulation of the antigen within the 
lumen of the vesicle. (D) Antigens in complex with lipids with opposite charge. (E) Inserted into the liposomal 
membrane with lipophilic residues or adsorbed on the surface (Watson et al., 2012). 
One of the most important steps in liposome preparation is the physical or chemical association of 
the antigen with the vesicles (Figure 1.8). Peptides or proteins can be associated before or after 
formation of the vesicles by covalent lipid conjugation, non-covalent attachment (by affinity 
between Ni-NTA and 6x histidine tags), encapsulation, adsorption on the surface of liposomes or 
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insertion by lipophilic residues into the lipid membrane. With regards to this, covalently associated 
antigen to the surface of liposomes induced superior antibody responses as reported previously 
(Therien et al., 1990; Vannier and Snyder, 1988). 
 
1.10.4 Candidate HIV vaccines and clinical trials 
Although extensive efforts were made to design a vaccine capable to prevent HIV-1 infection, only 
three vaccines have been tested in phase IIB or phase III clinical trials with weak or no effect. 
One of the earlier phase III clinical trials included recombinant Env immunizations with gp120 
(AIDSVAX), administered in combination with alum adjuvant, which failed to inhibit HIV-1 infection, 
reduce viral loads or prolong progression towards AIDS (Flynn et al., 2005). The STEP study 
performed by Merck was the second attempt of a phase IIb clinical study, performed in North 
America, the Caribbean, South America and Australia. The participants received three injections of 
the MRKAd5 HIV-1 gag/pol/nef vaccine, composed of a mixture of three different replication-
defective Ad5 DNA vectors, one expressing the gag gene, one expressing pol and one expressing 
the nef gene – each from a different HIV-1 strain (Buchbinder et al., 2008).  Despite the positive 
preclinical and phase I clinical trial outcomes, the vaccine failed to prevent HIV-1 infection or to 
inhibit virus replication. Of note, the vaccinated group showed a higher risk for HIV-1 acquisition 
compared with the placebo for a reason which still has to be investigated.  
The most promising and recent phase III clinical study in Thailand (RV1444) was conducted as a 
heterologous prime-boost regimen using a canary poxvirus vector (ALVAC, vCP1452) expressing 
the products of several HIV-1 genes combined with recombinant gp120 from the AIDSVAX study 
(Rerks-Ngarm et al., 2009). The effective outcome of the study is still controversially discussed, but 
despite the failure to control virus load or inhibit decrease of CD4+ cells, the vaccine had a slight 
effect on acquisition of HIV-1. This effect was not restricted to elicitation of neutralizing antibodies 
or to anti-HIV-1 CD8+ mediated T-cell responses. It is being suggested that the inhibitory effect 
may correlate with effector functions of non-neutralizing antibodies.  
 
1.11 The porcine endogenous retrovirus 
1.11.1 Phylogeny and genome organization 
The genus of gammaretroviruses, such as the porcine endogenous retrovirus (PERV), koala 
retrovirus (KoRV) and feline leukaemia virus (FeLV) belong to the family of Retroviridae 
(Figure 1.9). Gammaretroviruses endogenous, which are transmitted vertically via the germ line 
and integrated into the genome of the corresponding host species. The 9 kb provirus is ubiquitous 
distributed in the genome of all pig species and can be further differentiated into three replication 
competent PERV subtypes based on the class of the used receptor for cell entry: PERV-A, 
PERV-B and PERV-C (Ericsson et al., 2001; Le Tissier et al., 1997; Mang et al., 2001; Patience et 
al., 2001). 
PERV proviruses are organized like typical retroviruses with identical LTRs on the 5´ and 3´ end for 
reverse transcription. The PERV genome comprises two different reading frames, the first encoding 
Gag and retrovirus specific viral enzymes (Pol), the second one the envelope proteins. The 
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genome of PERV does not include regulatory or accessory proteins as it is described for 
lentiviruses. 
 
Figure 1.9: Phylogeny of retroviruses (Weiss, 2006). Retroviruses are classified according to complexity of 
their genomes: simple retroviruses (Alpha-, Beta-, Gamma-, Epsilonretroviruses) and complex retroviruses 
(Lenti-, Delta-, and Spumaviruses). Simple retroviruses (as indicated with asterisks) became endogenous in 
the corresponding host.  
 
1.11.2 Morphology, replication and pathogenic potential 
The morphology of PERV virions is those of typical retroviruses, comprising two identical RNA 
copies together with integrase, reverse transcriptase and protease assembled within the capsid. 
The capsid is further enclosure with the matrix proteins. The structure and composition of the 
envelope proteins is strongly similar to those of HIV-1, also determining tropism of the virion.   
 
Figure 1.10: Schematic presentation of the TM proteins gp41 (HIV-1) and p15E (PERV), anchored in the lipid 
membrane. Main structure components represent the fusion peptide (FP), fusion peptide proximal region 
(FPPR), N-heptad repeat (NHR), cysteine loop (C-C); C-heptad repeat (CHR) and the membrane proximal 
external region (MPER). Definition of epitope region one and two (E1/E2) are equivalent with corresponding 
FPPR and MPER domains (Fiebig et al., 2009). 
The PERV envelope protein is composed of SU (gp70) and TM (p15E), assembled as 
heterodimers in a trimeric configuration on the viral membrane as described for HIV-1. SU of 
PERV-A and PERV-B comprise seven and five N-glycosylation sites, respectively, which are 
essential for receptor binding (Ericsson et al., 2003). There is also some evidence that changes in 
the glycosylation pattern hamper infectivity of PERV (Hazama et al., 2003). 
Tropism is determined by gp70, which comprises sequence differences, located at a distinct 
“receptor binding domain”. TM is homologous within the three subtypes of PERV (PERV-A, PERV-
gp41
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B, PERV-C) and comprises the same subdomains with comparable function as described for HIV-1 
(Figure 1.10). Binding of SU to the corresponding cellular receptor induces conformational changes 
within SU and TM, resulting in fusion of viral and cellular membrane (Barnett et al., 2003; Barnett et 
al., 2001) with a similar mechanism as proposed for HIV (1.6.1, Figure 1.6). 
PERV-A and PERV–B infect human and non-human cell lines in vitro, whereupon PERV-C 
infection is restricted to porcine cells. Pathogenic potential of PERV was not observed in the 
natural host, although random integration of proviruses might bear tumor-inducting potential 
(Dieckhoff et al., 2007).   
 
1.12 The rationale of designed hybrid proteins based on 
gammaretroviruses 
Viral envelope proteins of HIV-1 and PERV share structural homologies despite their evolutionary 
distance (Figure 1.9) due to the same function with regards to fusion of viral and cellular membrane 
of the host cell. These proteins are thus relatively conserved since small mutation can already 
result in strong structural modifications, resulting in impairment of viral infection.  
Immunization studies in a number of animal species (rats, guinea pigs, goat etc.) using the 
ectodomain of the PERV TM protein showed that neutralizing antibodies against PERV were easily 
induced (Fiebig et al., 2003; Kaulitz et al., 2011). This attempt was primarily evaluated in terms of 
virus safety in organ transplants (as reviewed in (Denner, 2011)). Epitope mapping of these 
neutralizing sera identified a cluster of epitopes located in the fusion peptide proximal region 
(FPPR) of p15E, designated as epitope region 1 (E1) and in the MPER (E2). Further investigations 
with relevance to binding specificities of immune sera, anti-p15E antibodies demonstrated a 
possible influence of peptides derived from the N-terminal end of PERV p15E avidity to the on 
MPER region (Fiebig et al., 2003).  
  
Further immunization studies using the recombinant TM ectodomain of other gammaretroviruses 
could also demonstrate the induction of neutralizing antibodies in a number of animal species. This 
was demonstrated for koala retrovirus (KoRV) (Fiebig et al., 2006), and feline leukemia virus 
(FeLV) (Langhammer et al., 2005, 2010; Langhammer et al., 2006). The neutralizing potential of 
these antibodies has further been demonstrated in vivo. When cats immunized with p15E of FeLV 
were challenged, 50% of the animals were protected from antigenemia (Langhammer et al., 2011).  
 In alignments of different gammaretroviruses´ TM proteins with gp41 of HIV-1 were furthermore 
sequence homologies within the MPER detected. The E2 epitope (FEGWFN) in p15E is conserved 
within all gammaretroviruses and includes three identical amino acids, partial homologous with the 
epitope of the bNAb 4E10 (NWFNIT, identical amino acids in bold) (Fiebig et al., 2009; 
Langhammer et al., 2005; Langhammer et al., 2006). Epitope mappings of the bNAb 4E10 and 2F5 
showed only epitopes located in the MPER (Fiebig et al., 2009), whereas other studies 
demonstrated additional binding of 4E10 to the FPPR of gp41 (Hager-Braun et al., 2006). 
Structural interaction of the MPER and the FPPR had been suggested as a reason for an 
increased binding of 2F5 to their epitopes in the presence of peptides corresponding to the FPPR 
(Fiebig et al., 2009; Lorizate et al., 2006). In addition, a direct molecular interaction of FPPR and 
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MPER sequences (Bellamy-McIntyre et al., 2007) and a stabilization of the 6-helix-bundle 
formation by peptides corresponding to the MPER and FPPR have been demonstrated (Noah et 
al., 2008). Some viruses comprising the “DKW” core epitope within the MPER are resistant to 2F5 
neutralization (Montero et al., 2008; Morris et al., 2011), which suggests that additional regions in 
the protein are involved in formation of the epitope.  These results allow speculations that an 
interaction of the FPPR with the MPER, possibly in a hairpin-like conformation, may be required to 
induce neutralizing 2F5-like and 4E10-like antibodies. Thus, hybrid proteins were designed in order 
to graft gp41 MPER and FPPR into a scaffold of p15E derived from PERV. 
 
1.13 Aim of the thesis 
Infection with HIV is still a death sentence for people living in poor countries with underdeveloped 
health-care systems. Despite improvement of efficacy in antiretroviral therapy, a vaccine to prevent 
initial infection would be an important step to keep the epidemic in bay. Efforts to achieve vaccine 
induced protection have met with limited success when using gp120 as antigen, due to high 
variability and promotion of escape mutants. Thus, vaccine development targeting gp41 represent 
a good alternative since the transmembrane envelope protein provides relatively conserved 
domains for some potent bNAbs, like 2F5 and 10E8. The exact mechanism required to induce 
these bNAbs is still to be investigated and a large number of approaches failed to develop antigens 
able to induce such antibodies. On the other hand, antibodies capable to neutralize the porcine 
endogenous retrovirus (PERV) were induced by immunization with the ectodomain of the 
transmembrane envelope protein p15E. These neutralizing immune sera bound to two epitopes in 
p15E, corresponding to the FPPR and MPER.  
On the basis of these observations, hybrid antigens should be designed by substitution of these 
neutralizing epitopes in p15E by the FPPR and MPER derived from gp41 in order to target immune 
responses towards the TM protein of HIV-1 but provide the scaffold of p15E maybe essential for 
the induction of neutralizing antibodies. These hybrid proteins should be generated by aligning 
p15E and gp41 sequences to identify homologies and to optimize substitution of FPPR and MPER 
in the p15E scaffold. Expression constructs for these hybrid antigens should be cloned, expressed 
in E. coli and purified for immunization studies in different animal species. Immune sera derived 
from these immunization studies should be collected and evaluated in detail for anti-gp41 antibody 
responses and antibody-antigen binding properties. Furthermore, neutralization capacity of these 
immune sera is to be evaluated by different neutralization assays. In case of HIV-1 neutralization, 
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2. Materials and Methods 
2.1 Materials 
2.1.1 Primers 
Primers and probes for real-time PCR were obtained from Sigma-Aldrich, Steinheim, Germany. 
Primer Primer description 5´-sequence-3´ 
002 FWD pQE30XaN1 cloning  GCA GTT GGT ATT GGT GCA C 
005 FWD pQE30Xa sequencing AAAATTTATTTGCTTTGTGAGCG 
006 REV pQE30Xa sequencing CCAGATGGAGTTCTGAGGTCA 
007 FWD pQE30Xa-N3 cloning GCA GCC GGT AGC ACC ATG 
008 REV pQE30Xa-N3 cloning ATA CCA CAG CCA ATT GGT AA 
009 FWD pQE30XaN2 cloning  GAACCGATTAGCCTGACCCTGGCA 
010 REV pQE30Xa-N2 cloning TCGACTACTTACTTAAACGGTCAGTAACAG 
011 REV pQE30Xa-N4 cloning CTG CTG CTG AAC AAT ACC AGA 
012 FWD pQE30Xa-N4 cloning AGC CTG AGC GAA GTT GTT CTG 
015 FWD DREP sequencing TAG ATT GGT GCG TTA ATA CAC AG 
016 REV DREP sequencing TCG TCG AAT TAA GCT CCT AGG TT 
021 FWD pDisplay-N1 with ApaI cloning TATATAGGG CCCGAGCTGTCGGAATCG 
022 REV pDisplay-N1 with SalI cloning GAGTAGTCGACGGCCGCACTAGTTTA 
024 FWD DREP-N5 cloning GCAACCGCCAGGGCCGCAGCCGGGTCAACAATGGGTGCTGC 
025 REV DREP-N5 cloning GCAGCACCCATTGTTGACCCGGCTGCGGCCCTGGCGGTTGC 
026 FWD pDisplay-N5 cloning CCAGATTATGCTGGGGCCCGAGCAGCCGGGTCAACAATGG 
027 REV pDisplay-N5 cloning CCATTGTTGACCCGGCTGCTC GGGCCCCAGCATAATCTGG 
T7 FWD pDisplay sequencing TAATACGACTCACTATAGGG 
T7 REV pQE30XaN1 cloning GAGTAGTCGACGGCCGCACTAGTTTA 
BGH REV REV pDisplay sequencing TAGAAGGCACAGTCGAGG 
68spez HIV-1NL4-3 Real time PCR GGAGCAGCAGGAAGCACTATGG 
69spez HIV-1NL4-3 Real time PCR CCCCAGACTGTGAGTTGCAACA- 
HIV-1 Probe Real time PCR FAM–TGACGCTGACGGTACAGGCCAGAC-BHQI 
44 FWD GAPDH Real time GGCGATGCTGGCGCTGAGTAC 
45 REV GAPDH Real time TGGTCCACACCCATGACGA 
GAPDH 
Probe Realtime HEX-TTCACCACCATGGAGAAGGCTGGG-BHQI 
 
Table 2.1: Overview of primers used in cloning procedures and for real-time based neutralization assays. 
 
2.1.2 Plasmids 
Recombinant proteins were expressed in E. coli, using the plasmid pQE30Xa (Qiagen, Hilden, 
Germany). Two eukaryotic expression vectors were used for DNA immunization via Gene-Gun to 
present membrane associated recombinant proteins. Therefore, the pDisplay vector (Appendix) 
was used, which included the export signal and provided an internal transmembrane domain for 
anchoring the proteins in the cell membrane. The DREP vector (Nordstrom et al., 2005), kindly 
provided by Prof. Peter Liljeström), was modified according to a previously reported internalization 
of export signal due to the fact that the provided vector was designed to express the reporter gene 
EGFP in the cytosol (2.2.7).  





Fast-Digest ® Restriction Rnzymes Fermentas, St. Leon-Rot, Germany 
T4 Ligase Fermentas, St. Leon-Rot, Germany 
Shrimp Alkaline Phosphatase Invitrogen, Karlsruhe, Germany 
Pfu DNA Polymerase Invitrogen, Karlsruhe, Germany 
Pfu Turbo DNA Polymerase Stratagene, Heidelberg, Germany 
AmpliTaq Gold DNA Polymerase Applied Biosystems, Darmstadt, Germany 
Proteinase K Invitrogen, Karlsruhe, Germany 
Benzonase Invitrogen, Karlsruhe, Germany 
Table 2.2: Overview of enzymes used for cloning procedures, purification of proteins and real-time based 
neutralization assays. 
 
2.1.4 Bacterial strains 
Bacterial  
strain Genotype Application Reference 
One Shot® Top10 F- mcrA Δ(mrr-hsdRMS-mcrBC) 
φ80lacZΔM15 ΔlacX74 recA1 araD139 








E. coli recA1 endA1 gyrA96 thi-1 hsdR17 (rK– 
mK+) supE44 relA1 (for SCS1) Recombinant protein 
expression 
(Bussow et al., 1998) 
C3030H MiniF lysY (CamR) / fhuA2 lacZ::T7 gene1 
[lon] ompT ahpC gal λatt::pNEB3-r1-cDsbC 
(SpecR, lacIq) ΔtrxB sulA11 R(mcr-
73::miniTn10--TetS)2 [dcm] R(zgb-210::Tn10 -
-TetS) endA1 Δgor ∆(mcrC-mrr)114::IS10 
Recombinant protein 
expression 
New England Biolabs, 
Frankfurt, Germany 






Table 2.3: Overview of bacterial strains used for cloning procedures and expression of recombinant proteins.  
 
2.1.5 Bacterial media 
Media Composition 
LB 1% tryptone, 0.5% yeast extract, 1% NaCl,  
TB 1.2% tryptone, 2.4% yeast extract, 72 mM K2HPO4, 17 mM KH2PO4, 0.4% glycerol 
2YT 1.6 % tryptone, 1% yeast extract, 0.5% NaCl 
SOC 2% tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10mM MgSO4, 20 mM glucose 
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2.1.6 Peptides, Pepspot-Membranes and Peptide-Microarrays  
Peptides used for ELISA were all purchased from Genaxxon (Ulm, Germany).  
Peptides Amino acid sequence 
FPPR /gp41 AASMTLTVQARQLLS 
MPER / gp41 ELLELDKWASLWNWFNITNWL 
Table 2.5: Overview of peptides used for ELISA to determine concentrations of peptide specific serum 
antibodies. 
Peptide amino acid sequences for membranes and microarrays correspond to the ectodomains of 
gp41 (clade B, HIV-1NL4-3, Genbank: AF324493; clade B, HIV-1HXB2, GenBank: K03455) or p15E 
(PERV C, Genbank: AJ133817). Nitrocellulose PepSpot™ membranes or microarray glass slide 
epitope mappings were purchased from JPT, Berlin, Germany. 
2.1.7 Antibodies 
Antibodies Dilution Company 
2F5 (human monoclonal antibody varied 
obtained through the NIH AIDS Research and Reference 
Reagent Program, Division of AIDS, NIAID, NIH from Dr. H. 
Katinger (Muster et al. 2003) 
4E10 (human monoclonal antibody varied 
obtained through the NIH AIDS Research and Reference 
Reagent Program, Division of AIDS, NIAID, NIH from Dr. H. 
Katinger (Stiegler et al. 2001) 
Polyclonal goat anti-mouse-HRP 1:2000 1:4000 DakoCytomation, Glostrup, Denmark 
Polyclonal goat anti-rat-HRP 1:4000 DakoCytomation, Glostrup, Denmark 
Polyclonal goat anti-human-HRP 1:5000 DakoCytomation, Glostrup, Denmark 
Polyclonal rabbit anti-goat-HRP 1:2000 DakoCytomation, Glostrup, Denmark 
Polyclonal goat anti-rabbit-HRP 1:2000 DakoCytomation, Glostrup, Denmark 
Polyclonal goat anti-guinea pig-HRP 1:1000 DakoCytomation, Glostrup, Denmark 
RGS-His antibody  1:4000 Qiagen, Hilden, Germany 
 
Table 2.6: Overview of antibodies used for ELISA, Western blot analysis, neutralization assays and 
immunufluorescent staining. 
 
2.1.8 Cell lines 
Cell line Cell type/origin Reference 
293T Human embryonic kidney cells Pear et al., 1993 
TZM-bl (JC53-bl, Clone 13) HeLa cells  (cervical cancer) NIH AIDS reagent program 
C8166 Human leukaemia T-cell s Sodroski et al., 1984 
 




The molecular clone of HIV-1NL4-3 and one HIV-1 primary isolates (clade F, HIV-1BR 93/020) was 
obtained from the NIH Research and Reference Reagent Program.  




2.2.1 Molecular biology 
2.2.1.1 Plasmid amplification/isolation  
Amplification of plasmids was performed by transformation of the required circular plasmids into 
electro- or chemocompetent Top10 E. coli. 1.5 ml bacterial cultures for Mini Plasmid Preparations 
(Invitek, Berlin, Germany) were incubated overnight and plasmids isolated according to the 
manufacturer´s protocol. Endo-Free Maxi Preparations (Qiagen, Hilden, Germany) of plasmids 
were required for transfection and DNA immunization of eukaryotic expression constructs due to 
inhibition of transfection efficacy by endotoxins present in the DNA preparation and were performed 
according to recommendations of the manufacturer.  
The concentration of nucleic acids was measured using ND-1000 Nano-Drop® (Peqlab, Erlangen, 
Germany). 
 
2.2.1.2 Purification of DNA fragments 
DNA fragments were purified in order to eliminate template DNA after PCR or enzymes by agarose 
electrophoresis. Desired fragments were cut out of the gel, extracted with the Invisorb® Spin DNA 
Extraction Kit (Invitek, Berlin, Germany) and eluted in 30 µl nuclease free water (Promega, 
Mannheim, Germany). Desalting and concentration of DNA fragments was performed with the 
MSB® Spin PCRapace Kit (Invitek, Berlin, Germany). 
 
2.2.1.3 Transformation 
Plasmid DNA was transformed into electrocompetent Top10 E. coli after cloning procedures using 
the Gene-Pulser 2 (Bio-Rad, Munich, Germany). Competent E. coli Top10 bacteria were thawn on 
ice, 1 µl of ligation mix added to bacteria and transferred to pre-chilled cuvettes. Transformation 
was performed by pulsing the bacteria with 25 µF/200 Ω. 250 µl of SOCS media were added after 
transformation, incubated under shaking conditions at 37ºC for 60 min and subsequently plated on 
pre-warmed agar plates containing the required antibiotics. 
Retransformation of plasmids and transformation into protein expression strains was performed 
using chemical transformation. The DNA was incubated with thawed bacteria for 20 min, heat-
shocked for 60 sec at 42ºC, recovered 5 min on ice and incubated with SOCS media under 
shaking conditions for at least 30 min. Bacterial cultures were then plated on agar plates containing 
the required antibiotics. 
 
2.2.1.4 Colony PCR and sequencing of positive clones 
For the detection of bacterial colonies carrying the plasmid with the insert of interest, at least 10 
colonies were picked from the agar-plates, plated out on a new agar-plate, 1.5 ml of required E. coli 
growing medium were inoculated for subsequent Mini-Prep plasmid isolation of positive clones and 
the rest of the colony was scratched into PCR tubes for colony PCR. In order to perform the colony 
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PCR, 20 µl of PCR master-mix containing 1x PCR Buffer, 15 mM MgCl2, 0.8 mM dNTP mix (both 
Fermentas, St. Leon-Roth, Germany), 4 pmol of forward and reverse primer, 1 unit Hot-start Taq 
polymerase were resuspended in PCR tubes containing the colony. Cycling conditions were as 
follows: initial denaturation at 95ºC for 15 min, followed by 30 cycles of denaturation (95ºC for 30 
sec), annealing (55ºC for 30 sec) and elongation (72ºC for 30 sec). The PCR reactions were 
analysed on 1% agarose gels. Positive bacterial clones were inoculated in 1.5 ml LB-media, 
shaken overnight (O/N) at 37ºC and plasmid DNA of positive clones was isolated the next day.   
DNA of positive clones was used for sequencing PCR with BigDye Premix 3.1 (Applied 
Biosystems, Darmstadt, Germany) according to the manufacturer´s protocol. Briefly, 150-300 ng of 
plasmid DNA were used in each 10 µl sequencing reaction (10 pmol vector-specific, 
forward/reverse sequencing primer; 1 µl ABI sequencing buffer (Applied Biosystems, Darmstadt, 
Germany)). Cycle conditions were as follows: initial denaturation at 96ºC for 2 min, followed by 25 
cycles of denaturation (96ºC for 10 sec), annealing (55ºC for 5 sec) and elongation (60ºC for 4 
min). Samples for sequencing were stored at -20ºC until purification by gel filtration and read-out of 
the sequencing reaction was carried out by the sequencing core facility at the Robert Koch-
Institute. Sequences were analysed using the BioEdit and Geneious software. 
 
2.2.1.5  Cloning strategies for recombinant hybrid proteins (prokaryotic expression 
system) 
DNA constructs of hybrid proteins N1 and N2 were purchased from Geneart (Regensburg, 
Germany) with a codonoptimized sequence corresponding to the expression organism. N1 was 
cloned into the pQE30Xa expression vector using the restriction sites StuI/BamHI. N2 was 
generated by PCR amplification using primers 009/010 (Table 2.1) and inserted blunt end into the 
pQE30Xa expression vector via the StuI restriction site. Primers 007/008 amplified the construct N3 
with pQE30Xa-N1 used as template and also inserted blunt end via StuI into the multiple cloning 
site.  The linear PCR product was subsequently purified by 1% agarose electrophoresis, extracted 
from the gel with the Invisorb® Spin DNA Extraction Kit (Invitek, Berlin, Germany) and religated 
blunt end. The construct pQE30Xa-N4 was cloned from pQE30Xa-N3 by truncation of 26 amino 
acids via PCR using the primers 011/012. Purification and ligation of the PCR product was 
conducted as described for N3. The detailed amino acid sequences of the hybrid proteins are 
described in the appendix. 
 
2.2.1.6  Cloning strategies for recombinant hybrid proteins (eukaryotic expression 
system) 
Two different mammalian expression systems for DNA immunization of hybrid proteins were 
applied to compare the quality of immune responses in prokaryotic and eukaryotic expression 
systems. The pDisplay™ (Invitrogen, Karlsruhe, Germany) was selected to present hybrid proteins 
on the cell surface and simulate viral spike-like presentation of HIV-1 envelope sequences to the 
immune system. The vector included all required components such as (i) a human cytomegalovirus 
promoter to provide high expression of the recombinant protein, (ii) a murine Ig κ-chain leader 
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sequence to target the expressed proteins to the secretory pathway and (iii) a bowine growth 
hormone derived polyadenylation signal. The HIV-1 transmembrane domain was included in all 
expressed construct and used as membrane anchor to provide insertion of the hybrid proteins into 
the cellular membrane and facilitate optimal folding. Thus, hybrid proteins were cloned in-frame 
with promoter and signal peptide sequence into the multiple-cloning site of the pDisplay™ vector. A 
STOP-codon at the C-terminal end of the hybrid protein sequence prohibited transcription of the 
platelet-derived growth factor receptor transmembrane domain (PDGFR-TM) downstream of the 
sequence encoding the hybrid protein and a myc-tag which was already included in the vector. 
Hybrid proteins N1 and N5 (N3 + transmembrane domain) were used for DNA immunization using 
the Gene-Gun vaccine application system (3.7). The construct N1 was purchased from GeneScript 
(Piscataway, USA) and codonoptimized for the mouse organism since mice were used for 
immunization experiments. Additional restriction sites ApaI/SalI were included by PCR using the 
primer 021/022 (Table 2.1) and inserted into pDisplay™. N5 was amplified by QuickChange™ in 
vitro mutagenesis (Stratagene, Heidelberg, Germany) using the vector pDisplay-N1 as template 
with the primers 028/29, which were designed accordingly to the manufacturer´s instructions. This 
method is primarily used for in vitro site directed mutagenesis in the target sequence but was here 
applied for cloning procedures to delete 13 amino acids from the pDisplay-N1 construct. Primers 
with a length of 25 to 45 bp were designed, overlapping about 20 bp on both sides of the sequence 
to be deleted. After amplification of the construct, circular DNA of pDisplay-N1 was digested with 
methylation sensitive DpnI to deplete non-mutated vector background, which was then used for 
transformation into electrocompetent Top10 E. coli. Clones were picked, sequenced and Endofree 
Maxi preparations of plasmid DNA were performed to isolate DNA for preparation of the gene gun 
ammunition. Design and cloning procedures of Semliki Forest Virus vectors expressing N1 or N5 
are described in section 1.7 and the appendix.  
 
2.2.2 Working with proteins and peptides 
2.2.2.1 Expression of recombinant hybrid proteins (prokaryotic expression) 
All constructs cloned in to the pQE30Xa expression plasmid contained N-terminally located 
hexahistidine tags for purification procedures. Plasmids were transformed into E. coli expression 
strains (BL21(DE3)pLysS, C3030H, SCS1/SE111) and 3 clones of each bacterial strain were 
tested for optimal expression conditions (Figure 3.3) by SDS-PAGE and Western blot analysis 
using mAbs 2F5 and RGS-His. The SCS1/pSE111 strain (Bussow et al., 1998) remained the only 
tested strain expressing the recombinant hybrid proteins of interest. Transformants were grown in 
2YT medium at 37°C containing 100 µg/ml ampicillin and protein expression was induced at OD600 
of 0.7 with 1 mM isopropyl-β-D-1-thiogalactopyranoside (IPTG) for 3 h at 220 rpm. The cells were 
pelleted at 10,000 rpm/4ºC for 20 min. Supernatant and pellet were tested for expressed protein 
and aggregated protein was only detected in the pelleted bacteria. Thus the pellets were used for 
further processing.  
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2.2.2.2 Purification procedures of recombinant hybrid proteins 
Recombinant proteins N1 and N2 were aggregated in inclusion bodies and thus difficult to 
solubilize in physiological and denaturing buffers. Thus, cell pellets from expression cultures were 
resuspended in 6 M guanidine hydrochloride buffer (Buffer C, Qiagen, Hilden, Germany) and 
subsequently sonicated (three pulses of 60 sec, break 60 sec using a Branson Sonifier II 250, 
Danbury, CT, USA), followed by centrifugation (0.5 h/10,000 rpm at room temperature). This 
procedure was repeated five times and supernatants were collected. The 4th and 5th supernatant 
fractions containing purified proteins N1 or N2 were dialysed against double distilled water (ddH2O) 
for further concentration.  
N3 and N4 were purified by affinity chromatography using the ÄKTAexplorer 100 (GE Healthcare, 
Uppsala, Sweden) with denaturing purification protocols (8 M Urea buffer) for initial immunizations 
in rats, guinea pigs and one rabbit. Pelleted bacteria expressing N3 or N4 were resuspended in 
8 M urea buffer (8 M urea, 100 mM NaH2PO4, 10 mM TrisCl, lysozyme, pH=8) and lysed by 
sonication as described above. Crude lysates were centrifuged (1 h, 20,000 rpm at room 
temperature), supernatants were added to Ni-NTA agarose (Qiagen, Hilden, Germany) and 
incubated for 1 h/RT (room temperature) on a rotating shaker. The column was then washed with 
30 column volumes (cv) of urea buffer (pH=6.3) and eluates were collected in 1.5 ml fractions. 
Eluates containing purified protein were dialysed against ddH2O and used for immunizations.  
In addition, the purification protocol was further modified to increase solubility of the purified 
proteins and promote optimal refolding by milder purification conditions. Thus, pelleted bacteria 
expressing recombinant proteins N3 or N4 of 1L expression culture were resuspended in 10 ml 
PBS containing lysozyme, sonicated as described above and centrifuged for 60 min/4ºC at 
16,000 g. Supernatants were discarded, the remaining pellets resuspended in 10 ml PBS, 
containing 1% N-Laroyl-Sarcosine (Sigma-Aldrich, Steinheim, Germany) with 20 mM imidazole and 
incubated at 4ºC O/N on a rotating shaker. The suspensions were then centrifuged at 16,000 g/30 
min and the supernatants diluted with 90 ml PBS/20 mM imidazole to obtain a final concentration of 
0.1% N-Laroyl-Sarcosine. Purification of recombinant proteins was performed using the 
ÄKTAexplorer 100 (GE Healthcare, Uppsala, Sweden) with a 5 ml HIS FF crude column (GE 
Healthcare, Uppsala, Sweden). Recombinant proteins were eluted with a gradient protocol by 
increasing the imidazole concentration from 20 mM to 500 mM over 30 column volumes. 1.5 ml 
elution fraction were then dialysed against PBS/0.1% N-Laroyl-Sarcosine and used for 
immunization of rats and 1 goat. 
 
2.2.2.3 Purification procedures of analytical recombinant proteins  
The recombinant protein comprising the ectodomain of p15E (expression plasmid kindly provided 
by Danny Kaulitz) used for analysis of rat pre-immune sera was expressed and purified as 
previously described (Fiebig et al., 2003; Kaulitz et al., 2011). 
The histidine-tagged recombinant ectodomain of gp41 (aa533-681, GenBank: AB221005), 
provided by Rayk Behrendt) used for the analysis of induced anti-rgp41 responses in immune sera 
was expressed analogous to N3 and N4. Pelleted bacteria obtained from 2L of expression culture 
were resuspended in 120 ml of 6 M guanidine hydrochloride buffer (6 M guanidine hydrochloride, 
10 mM Tris base, 100 mM NaH2PO4), centrifuged for 10 min/16,000 g and subsequently 
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centrifuged for 30 min/20,000 g. The recombinant protein was purified using the ÄKTAexplorer 100 
(GE Healthcare, Uppsala, Sweden) with a 5 ml HIS FF crude column (GE Healthcare, Uppsala, 
Sweden). Clarified lysates were applied to the purification column and eluted with a stepwise 
gradient purification protocol. The column was washed with an 8 M urea buffer (8 M urea, 20 mM 
imidazole, 150 mM NaCl, pH=8) and proteins eluted into 1.5 ml fractions by increasing application 
of elution buffer (8 M urea, 500 mM imidazole, 150 mM NaCl, pH=8).  
The expression construct gp41-CHR (HIV-1; Genbank: K03455, aa605-681, the expression 
construct was kindly provided by Daniel Effert) was fused with GST for native purification. Pelleted 
bacteria of 1 L BL21 (DE3) expression culture expressing the recombinant CHR of gp41 were 
resuspended in 50 ml PBS/1% glycerine/10 mM dithiothreitol, sonicated as described above and 
centrifuged for 20 min at 25,000 g/4ºC. Then, the supernatant was applied to the Glutathion 
Sepharose 4B (GE Healthcare, Uppsala, Sweden) and incubated on a rotating shaker at 4ºC for 2 
h. After five subsequent washing steps with PBS/1% glycerine, the recombinant protein was eluted 
in 2 ml elution buffer fractions (50 mM Tris HCl, 10 mM reduced glutathione, pH=8). Purification of 
1 L expression culture resulted in 5 mg of purified protein, which were dialysed against PBS. 
 
2.2.2.4 Insertion of recombinant proteins N1, N3 and N4 into Liposomes 
Recombinant hybrid proteins N1, N3 and N4 were sent to Polymun (Vienna, Austria) for insertion of 
the proteins into the lipid bilayer of liposomes. Immunization experiments using N1 în liposomes 
included two different vaccine batches with different liposome preparations.  
Recombinant hybrid proteins were mixed with a lipid/MPLA/ethanol solution via the patent-
registered process technology from Polymun to prepare the both batches. Afterwards, the liposome 
suspension was diluted with PBS for the first batch of recombinant protein N1 in liposomes to 
reduce residual ethanol or detergent and subsequently ultra- and dia-filtrated in order to remove 
detergent, ethanol or non-incorporated proteins. Lipid composition in the protein/liposome 
suspension was defined by Polymun as 5 - 7 mg/ml dimyristoylphosphatidylcholine (DMPC), 0.5 - 
0.8 mg/ml dimyristoylphosphatidylglycerol (DMPG), 2 - 3 mg/ml cholesterol, and 0.15 – 0.2 mg/ml 
MPLA.  
Preparation of the second batch of N1 in liposomes was performed by filtration of recombinant 
hybrid protein solution through a 0.2 µm filter prior to lipid incorporation and filtration of the 
recombinant hybrid proteins via the Polymun liposome processing technique. 
Recombinant hybrid proteins N3 and N4 were processed as described for the first batch of N1 
liposome insertion, although the last step of ultrafiltration to remove residual unbound recombinant 
hybrid protein was omitted, since both proteins did not include a transmembrane domain and were 
thus not expected to be inserted into the lipid bilayer of the liposomes.  
 
2.2.3 Immunological methods 
2.2.3.1 PAGE and Western blot analysis 
The purified recombinant proteins were characterized by 10% tricin sodium dodecylsulfat 
polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot analysis using the mAbs 2F5 
and 4E10. Briefly, 0.5 to 5 µg of recombinant protein were mixed 1:2 with Laemmli sample buffer 
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(62.5 mM Tris-HCl pH=6.8, 25% glycerol, 2% SDS, 5% β-mercaptoethanol, 0.01% Bromphenol 
Blue) and boiled for 5 min at 95°C in non-reducing sample buffer (62.5 mM Tris-HCl pH=6.8, 40% 
glycerol, 0.01% Bromphenol Blue). Protein samples were loaded on SDS-PAGE and subsequently 
blotted as described below.  
Sera of immunized animals were assayed for antibody properties binding to purified recombinant 
gp41 or the p15E ectodomain. Electrophoresis was performed with a complete preparative 10% 
SDS-PAGE using 5 µg of purified rgp41 protein or rp15E, which was equivalent to 0.5 µg per lane. 
Proteins were transferred to a 0.45 µm nitrocellulose membrane via semi-dry blotting (Trans-Blot® 
SD semi-dry transfer cell, Biorad, Munich, Germany). Membranes were washed twice with 
phosphate buffered saline (PBS, pH 7.2), and blocked by incubation with blocking buffer (5% 
nonfat milk powder in PBS/0.05% Tween 20) overnight at 4ºC. After washing procedures for three 
times with washing buffer (PBS containing 0.05% Tween 20), the membranes were clamped into a 
Mini-Protean Multiscreen apparatus (Biorad, Munich, Germany) and subsequently incubated with 
diluted sera (1:400 in blocking buffer) for 2 h at room temperature. Following serum incubation, 
blots were washed for 0.5 h with washing buffer and incubated with horseradish peroxidase-
conjugated secondary antibody (Dako, Glostrup, Denmark) for 1 h in blocking buffer at room 
temperature at concentrations described in section 2.1.7. After secondary antibody incubation, 
membrane was washed five times with washing buffer for five minutes each and detection was 
performed using Pierce ECL substrate (Thermo Scientific, Bonn, Germany). 
 
2.2.3.2 Isolation of immunoglobulins 
Total IgG fractions were isolated from serum using Protein G HP Spin Trap (GE Healthcare, 
Munich, Germany) according to the manufacturer´s protocol. Briefly, decomplemented serum was 
diluted 1:4 with resin binding buffer (20 mM sodium phosphate, pH 7.0) and incubated with Protein 
G Sepharose for 15 min. Four washing steps with binding buffer were followed by two elution steps 
using 200 µl elution buffer (0.1 M glycine-HCl, pH=2.7). Elution fractions were immediately 
neutralized with 1 M Tris-HCl, pH 9.0, pooled and dialysed against PBS for 48 h at 4ºC to allow 
refolding of the purified antibodies. IgG concentration was normalized to the IgG concentration in 
serum by an ELISA, using rgp41 as antigen.  
 
2.2.3.3 Isolation of gp41-CHR specific antibodies from goat serum 
The gp41-CHR recombinant protein was coupled to CNBr Sepharose in order to isolate and 
concentrate CHR-specific antibodies from goat serum. 0.5 g of freeze-dried CNBr-activated 
sepharose 4B (~1.5 g gel matrix) were washed with 100 ml of 1 mM HCl and subsequently 
equilibrated with freshly prepared matrix coupling buffer (0.1 M NaHCO3, 0.5 M NaCl). Gp41-CHR 
protein was dialysed against coupling buffer and concentrated to 0.5 µg/ml. 20 ml of protein 
solution was incubated with the sepharose O/N at 4ºC on a rotation shaker to couple the protein to 
the sepharose. Unbound ligand was washed away with 20 ml of coupling buffer and unspecific 
binding sites were blocked with blocking buffer (0.1 M Tris-HCl buffer, pH=8) for 2 h. Then, the 
protein-coupled sepharose was washed three times with altering pH (0.1 M NaAc, 0.5 M NaCl, 
pH=4 and pH=8), applied to the column and subsequently washed with PBS. Goat serum obtained 
three and eight weeks after the third immunization was diluted 1:3 and applied to the column, 
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circulating O/N. The next day, the column was washed with PBS and CHR binding antibodies were 
eluted in 1.5 ml fractions with elution buffer (0.1 M glycine.HCl, pH=2.7) and immediately 
neutralized with 1 M Tris-HCl, pH=10. Eluted fractions were analysed by SDS-PAGE and fractions 
containing high antibody concentration were pooled and dialysed against PBS. Antibody 
concentration was determined by NanoDrop 1000 Spektrophotometer at 280 nm (Thermo 
Scientific, Bonn, Germany). 
 
2.2.3.4 Peptide and anti-lipid ELISA  
96-well plates (Nunc, Roskilde, Denmark) were coated with 100 ng of rgp41 or peptides 
corresponding to the FPPR or MPER of gp41 (aa532-546 or aa657-681; Genbank: K03455, 
AB221005) per well. Evaluation of antibody reactivity with lipids was performed by coating 1 µg 
cardiolipin or sphingomyelin (Sigma), respectively (Haynes, 2005; Matyas et al., 2009a). Plates 
were blocked with 0.05% Tween 20 and 5% BSA in PBS for 2 h at 37ºC and subsequently washed 
with PBS containing 0.05% Tween 20 (washing buffer). Sera were diluted in PBS containing 2.5% 
BSA and 0.05% Tween 20 and incubated for 1.5 h at 37ºC. Plates were washed three times, 
followed by incubation with peroxidase-conjugated secondary antibody (Dako, Glostrup, Denmark) 
diluted in PBS containing 2.5% BSA and 0.05% Tween 20 for 1 hour at 37ºC. Prior addition of 
freshly prepared o-phenylenediamine dihydrochloride/H2O2 solution (Merck, Darmstadt, Germany), 
plates were washed seven times with washing buffer. The colour reaction was stopped after a 
maximum time of 12 min with 5N H2SO4 and optical density was measured at 492/620 nm. 
Endpoint titers of binding antibodies were defined as reciprocal of the highest serum dilution that 
gives a value at OD492/620 nm above the cut-off. The cut-off value was equivalent to the mean value 
of the negative control sera plus three times the standard deviation value.  
 
2.2.3.5 Epitope mapping 
Two different methods of epitope mapping were performed, using 15-mer peptides, overlapping 12 
amino acids spotted on microarray glass slides or linked to nitrocellulose membrane (both JPT, 
Berlin, Germany). Each slide or membrane comprised the complete ectodomain of gp41 and was 
incubated with sera diluted 1:400. Incubation procedures were performed using the suppliers´ 
standard protocol. Binding of antibodies to peptides was detected by peroxidase-conjugated 
secondary antibody (Dako, Glostrup, Denmark) and Pierce ECL substrate (Thermo Scientific, 
Bonn, Germany). The readout of the microarray glass slides, incubated with Dylight649 (Thermo 
Scientific, Bonn, Germany), was performed using a Genepix 4000B Microarray scanner (Molecular 
Devices, Ismaning, Germany).  
 
2.2.3.6 Surface plasmon resonance analysis (SPR) 
Apparent KD values of 50% binding equilibrium of the mAbs 2F5 and 4E10 to the N3 and N4 
antigen were estimated using a BIAcore X100 (GE Healthcare, Waukesha, Wisconsin, USA). A 
sensor chip CM5 containing a carboxymethylated dextran matrix was coated with 4,000 RU of N3 
on flow cell 2 (Fc2) and flow cell 1 (Fc1) was left uncoated as control. Affinity determination by 
steady-state analyis was carried out in 1x HBS-EP+ running buffer containing 10 mM Hepes, 150 
mM NaCl, 3 mM EDTA, 0.05% surfactant P20, pH 7.4 at a constant temperature of 25°C. To 
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determine apparent KD values, mAbs 2F5 and 4E10 were diluted in running buffer and tested by 
injecting 50 µl (600 sec, flow rate 5 µl/min) of diluted protein solution at concentrations ranging from 
113 ng/ml to 1.13 ng/ml for 2F5 and 119.4 µg/ml to 0.1194 µg/ml for 4E10. Apparent affinity of 2F5 
to the hybrid protein N4 was measured at concentrations ranging from 22.6 µg/ml to 0.226 µg/ml. 
4E10 was tested at equivalent concentrations as used for affinity testing to N3. The chips were 
regenerated for 60 sec with 50 mM glycin/HCl pH 1.5 and results evaluated with the Biacore X100 
software 1.0. 
 
2.2.4 Animal experiments  
2.2.4.1 Animals used for immunization experiments with recombinant antigens  


































Recombinant N3 / CFA or IFA 250 µg 4 




























Recombinant N4 / CFA or IFA 250 µg 3 
Goat N4z#1 Recombinant N4 / CFA or IFA 500 µg 3 
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2.2.4.2 Animals used for immunization studies with recombinant hybrid antigens on 
liposomes 










Recombinant N1 on Liposomes / MPLA 
 
 
Empty Liposomes / MPLA 
250 µg 3 

















Empty Liposomes / MPLA 
250 µg 3 
 
2.2.5 Application of antigens 
2.2.5.1 Application of recombinant hybrid protein antigens 
Preimmune sera of rats, guinea pigs, rabbits or goats were collected before the first immunization. 
The two groups of guinea pigs immunized with N1 and N3, respectively, were chosen as initial test 
of responses due to previously observed antibodies against rp15E in naïve rats (Behrendt et al., 
2012b). When preimmune sera of rats were tested negatively for p15E antibodies, rats were 
included in this immunization study. Immune sera were taken 19 days after each immunization 
(Figure 2.1). Animals were immunized subcutaneously (s.c.) and/or intramuscularly with 
recombinant proteins diluted in PBS and mixed 1:1 with complete Freund´s adjuvant (Thermo 
Scientific, Bonn, Germany) for primary immunizations and with incomplete Freund´s adjuvant 
(Thermo Scientific, Bonn, Germany) for booster immunizations unless otherwise noted. Four 
applications of 250 µg or 500 µg of recombinant antigen were chosen for primary immunization 
studies in a 3 week immunization schedule unless otherwise noted. Immunizations with 
recombinant proteins in liposomes and DNA vaccination studies were performed with 3 
applications of 250 µg antigen in a three week immunization schedule.  
 
Figure 2.1: Immunization schedule of guinea pigs and rats immunized with 250 µg of recombinant hybrid 
proteins N1, N2, N3 or N4 mixed with complete Freund´s adjuvant for initial immunization or incomplete 
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2.2.6 Cell culture 
2.2.6.1 Transfection of 293T cells  
Expression of DNA vectors used for DNA immunization experiments in mice was tested by 
transfecting 293T cells and surface expression of hybrid proteins was verified via 
immunofluorescent staining. 293T cells were maintained with complete D-MEM (10% FKS, 100 
µg/ml penicillin/streptomycin, 4 mM glutamine). The day prior transfection, 4x105 cells were seeded 
per 6-well in order to obtain 80-90% confluency the day of transfection. Four µg of vector was 
diluted in D-MEM and mixed with 6 µl of Transfectin (BioRad, Munich, Germany) transfection 
reagent, incubated for 20 min and subsequently added to the cells. Media was changed after 4 
hours and cells were harvested after 48 h to assess expression of transfected constructs. 
 
2.2.6.2 Immunofluorescent staining of transfected 293T cells 
6 wells containing transfected 293T cells were trypsinized and resuspended with 1 ml of D-MEM. 
Cells were subsequently washed three times with warm PBS, fixed in 2% PFA for 1 h at 37°C, 
again washed with PBS and incubated in PBS overnight. The cell pellet obtained from one 6-well 
was resuspended in 100 µl PBS and one drop (20 µl) of the suspension was used per 
immunofluorescence sample to stain. Cells were dropped on Poly-L-Lysine coated slides, dried at 
37°C and rehydrated in PBS. Samples were blocked with blocking buffer (PBS with 0.1% BSA ) for 
60 min and incubated with 5 µ/ml 2F5 and 4E10 primary antibodies diluted in blocking buffer for 45 
min. Slides were subsequently washed with PBS and incubated with the secondary antibody 
coupled to AlexaFluor®488 for 30 min. Nuclei of cells were then stained with 0.25 µg/ml bis-
enzimide diluted in PBS. After washing with PBS, slides were monted with Mowiol and stored at 
4°C until analysis by Laser Scanning Microscopy (LSM). 
 
2.2.6.3 Virus propagation 
HIV-1NL4-3 was produced by transfecting 293T cells with the moleclular clone. Media was changed 4 
hours after transfection, supernatants collected after 48 hours and stored at -80°C.  
The primary isolate of clade F (HIV-1BR 93/020) was propagated on PBMC isolated from buffy coats 
by Ficoll density gradient centrifugation. 
Titration of virus stocks was performed on TZM-bl cells in a 96-well format. Briefly, 2x104 cells were 
seeded per well and grown for 24 hours. Virus was serially diluted 1:10 in D-MEM, added to the 
cells and incubated for 48 h. Then, cells were washed with PBS and fixed with 2% 
paraformaldehyde. Staining of HIV-1 infected cells was performed by adding 80 µl of 
β-galactosidase solution (5 mM K3Fe(CN)6, 5 mM K4Fe(CN)6.3H2O, 2 mM MgCl2, X-gal, diluted in 
PBS) to previously washed cells and incubated for 16 h. Titers were determined by counting blue 
cells per well, each representing one infectious particle. 
 
2.2.6.4  In vitro neutraliziation assays 
2.2.6.4.1 TZM-bl neutralization assay 
The HIV-1 neutralizing activity of the sera or the purified IgG antibodies was measured in a 96-well 
format using reporter TZM-bl cells (Montefiori, 2009) and HIV-1NL4-3 (clade B, Genbank: AF324493). 
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Briefly, 2x104 cells were seeded per well and grown for 24 h. Sera or purified IgG antibodies used 
at concentrations comparable to those in serum were diluted 1:20 in Dulbecco´s Modified Eagle´s 
Media followed by four steps of two-fold serial dilution. 25 µl of virus (infectious titer 5x105/ml) and 
25 µl serum/IgG dilution were pre-incubated for 30 min at 37°C and subsequently transferred to the 
cells. After incubation for 48 h at 37°C, neutralization activity was estimated using the Bright-Glo™ 
Luciferase Assay System (Promega, Mannheim, Germany). In this assay, luciferase activitiy 
induced by HIV-1 Tat protein was measured by a GloMax®-96 luminometer (Promega, Mannheim, 
Germany). The cut-off for neutralization was set at 50% RLU (relative luminescence units) value 
measured with an untreated virus infectivity control.   
 
2.2.6.4.2 Real-time based neutralization assay 
Sera which recognized the 2F5 epitope as shown by the epitope mappings in the first immunization 
study or sera inhibiting HIV-1 infection detected by TZM-bl neutralization assay were also tested in 
a neutralization assay based on the measurement of the reduction of provirus integration taken as 
a marker for neutralization capacity (Behrendt et al., 2009; Fiebig et al., 2009). Briefly, 10 µl serum 
dilution was mixed with 90 µl virus dilution (MOI=1) and incubated for 30 min/ 37°C. C8166 cells or 
PHA (5 µg/ml) stimulated PBMC (5x104 cells in 100 µl) were added and incubated for 65 hours, 
followed by aspiration of the supernatants. Cell pellets were lysed as previously described and 
provirus integration was assessed by duplex real-time PCR using HIV-1NL4-3 specific probe (2.1.1 
Table 2.1) and primers (68spez, 69spez). Equal load of cells was simultaneously monitored by 
amplification of human GAPDH as a housekeeping gene (GAPDH probe, primers 44FWD, 45REV). 
Duplex real-time PCR was performed using MX3000P (Stratagene, La Jolla, USA) with the 
following cycle conditions: 95ºC/10 min, 95ºC/1 min, 52ºC/1 min, 72ºC/30 sec. Delta-CT values of 
preimmune serum plus 3 times the standard deviation were taken as cut-off value and a inhibition 
of infection more than 50% was defined as positive neutralization.        
2.2.7 DNA vaccination with the Semliki Forest Virus vector system 
2.2.7.1 Expression system overview 
Semliki Forest virus (SFV) belongs to the family of Togaviridae, genus of Alphaviruses. The SFV 
genome comprises a single stranded RNA (11.4 kb) of positive polarity, packaged into a capsid 
that is further enveloped by a lipid bilayer. The genomic RNA constitutes two open reading frames 
(ORF), the 5´ ORF encoding the viral replicase or non-structural proteins nsp1-4. Capsid protein 
(C) and spike proteins (E1, E2, E3 and 6K) are encode within the second reading frame of the SFV 
genome. A translational enhancer (b1) is additionally encoded within the capsid gene in order to 
provide high expression levels of structural proteins (Sjoberg et al., 1994).  
After release of the viral RNA into the host cell, the early RNA polymerase (nsp1-3 as a 
polyprotein, nsp4 as cleaved protein) transcribes a complementary, negative strand RNA (Koff et 
al., 2006). The polyprotein of nsp1-3 is thereafter cleaved and assembles to form the replicase 
complex together with nsp4. This complex therafter transcribes a positive-sense genomic RNA and 
a subgenomic RNA. Structural proteins are translated as polyprotein and subsequently cleaved into 
capsid protein and the spike proteins (E1, E2, E3 and 6k).  
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Peter Liljeström and Henrik Garoff developed the Semliki Forest virus vector system (Liljestrom 
and Garoff, 1991), substituting the genes of the SFV structural proteins by the relevant gene of 
interest. The vector system was primarily developed to produce recombinant SFV particles in order 
to generate high amounts of heterologous protein, which was further modified to an alphaviral 
replicon based (DREP) DNA vector system (Berglund et al., 1998). A number of studies 
demonstrated enhanced antibody responses and antigen specific CD8+ T-cell responses after 
immunization with DREP compared to the immunogenicity of a conventional DNA vector (Leitner et 
al., 2006; Naslund et al., 2011; Naslund et al., 2007; Nordstrom et al., 2005).  
 
Figure 2.2: Schematic presentation of the DREP expression system in comparison with the wild type SFV 
genome. Arrows represent internal subgenomic promotors, start of translation for the foreign gene by the 
vector encoded replicase.  Expression constructs included the translational enhancer (enhancer), the 
ribosomal slippery sequence (SD) and the antigen of interest.  
Animals and antigens used for the DNA immunization study are described in the following table: 

















































pDisplay-N5 with GM-CSF 2 µg pDisplay-N5  2 µg GM-CSF 3 























rN3 100 µg  Incomplete Freud´s adjuvant 3 
 
The DREP vector was used in this project for the induction of potent antibody responses against 
HIV-1, expressing two different hybrid proteins. Recombinant hybrid proteins N1 and N5 were 
cloned into the DREP vector as described in section 3.7 and the appendix. 
Wild type SFV Replicase Capsid E3 E2 6k E1
DREP EGFP Replicase Enhancer SD EGFP
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2.2.7.2 Preparation of gene-gun ammunition and application of DNA expression 
plasmids 
Ballistic immunization procedures were utilized with antigen/adjuvant-coated Tefzel tubes in 
combination with the Helios GeneGun® (Biorad) according to the manufacturer´s protocol. Briefly, 
Tefzel tubes were washed with 100% ethanol and dried with nitrogen for 1 h prior antigen coating. 
25 mg of gold particles were resuspended in 100 µl of 0.05 M sperimidin and subsequently 
vortexed and sonicated. 100 µg plasmid DNA of the expression vectors encoding hybrid antigens 
and 100 µg of the GM-CSF-encoding plasmid were added to the gold particle mixture, followed by 
dropwise addition of 1 M CaCl2 solution for DNA precipitation. After 10 min of incubation, golden 
particles coated with precipitated DNA were washed with 100% ethanol and then resuspended in 3 
ml of 0.025 mg/ml Polyvinylpyrrodidon (in 100%) ethanol. The plasmid-gold particles were coated 
onto the inner surface of the Tefzel tubes using the Biorad Tubing Prep Station® by rotation and 
subsequent drying via nitrogen. The tube was then cut into 1-2 cm segments, resulting in 1 µg of 
vaccine and adjuvant expression plasmid each per shot. 
Application of antigens in the DNA immunization study was performed using Helios® GeneGun 
system. Plasmid DNA was delivered intracutaneously to shaved abdominal skin of mice via two 
shots, 1 µg of DNA each at a helium pressure of 400 p.s.i. 
 




3.1 Titer assessment of virus stocks 
Sera derived from immunization studies were tested for neutralizing capacity, using HIV-1NL4-3 as 
standard virus, which was previously described as neutralization sensitive to bNAb 2F5 and 4E10 
(Binley et al., 2004). Titer evaluation of propagated virus stocks were tested via TZM-bl 
neutralization assay, ranging from 5*105 - 107 infectious particles/ml. 
 
3.2 Design of hybrid proteins 
Four recombinant hybrid proteins (N1, N2, N3, N4) possessing p15E and gp41 sequences were 
designed on basis of protein sequence alignment of the PERV and HIV-1 TM proteins (Figure 3.1) 
in order to optimize substitutions of sequences in the p15E backbone. 
 
Figure 3.1: (A) Alignment of HIV-1 and PERV TM protein sequences for the design of hybrid proteins. (B) 
Composition of protein sequences in hybrid proteins. Boxed sequences in blue indicate HIV-1 sequences, 
sequences boxed in green squares correspond to PERV sequences. Multiple sequence alignments were 
performed with Seqman software (DNAStar, Madison, USA). 
 
The hybrid proteins N1 – N4 were extended towards the N-terminal end compared to previous 
constructs designed by Rayk Behrendt (Behrendt, 2009). Moreover, some constructs included the 
fusion peptide to allow close proximity or potential interaction of N- and C-terminal end of the 
protein (Bellamy-McIntyre et al., 2007) in order to engage a hairpin-like conformation resembling 
the six-helix-bundle formation. Homologies between the bNAb 4E10 epitope in the MPER of gp41 
and a sequence located in the MPER of p15E, recognized by PERV neutralizing sera, were also 
-AVGIG-ALFLGFLGAAGSTMGCTSMTLTVQARQLLSDIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGIWGCS HIV-1 pNL4-3 Clade B AF324493 gp41.pro
-AVGIG-AVFLGFLGAAGSTMGAASMTLTVQARLLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARVLAVERYLRDQQLLGIWGCS HIV-1 BaL Clade B  AB221005 gp41.pro
-AVGIG-ALFLGFLGAAGSTMGAASMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGIWGCS HIV-1 HXB2 Clade B K03455 gp41.pro
EPISLTLAVMLGLGVAAG--VGTGTAALITGPQQLEKGLS----NLHRIVTEDLQALEKSVSNLEESLTSLSEVV--LQNRRGLDLLFLK PERV A AJ293656 p15E.pro
EPISLTLAVMLGLGVAAG--VGTGTAALITGPQQLEKGLS----NLHRIVTEDLQALEKSVSNLEESLTSLSEVV--LQNRRGLDLLFLK PERV CA AY953542 p15E .pro
GKLICTTAVPWNASWSNKSLEQIWNNMTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNITNWLWYIKLFIMIV HIV-1 pNL4-3 Clade B AF324493 gp41.pro
GKLICTTAVPWNASWSNKSLNKIWDNMTWMEWDREINNYTSIIYSLIEESQNQQEKNEQELLELDKWASLWNWFDITKWLWYIKIFIMIV HIV-1 BaL Clade B  AB221005 gp41.pro
GKLICTTAVPWNASWSNKSLEQIWNHTTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNITNWLWYIKLFIMIV HIV-1 HXB2 Clade B K03455 gp41.pro
EGGLCVALK-----------EECC--F-YVDHSGAIRDSMSKLRERLEKRHKEKEAGQG---------WFEGWFNKS--PWVTTLLSALT PERV A AJ293656 p15E.pro
EGGLCVALK-----------EECC--F-YVDHSGAIRDSMNKLRERLEKRRREKETTQG---------WFEGWFNRS--PWLATLLSALT PERV CA AY953542 p15E .pro
GGLVGLRIVFAVLSIVNRVRQGYSPLSFQTHLPIPRGPDRPEGIEEEGGERDRDRSIRLVNGSLALIWDDLRSLCLFSYHRLRDLLLIVT HIV-1 pNL4-3 Clade B AF324493 gp41.pro
GGLIGLRIVFSVLSIVNRVRQGYSPLSFQTHLPASRGPDRPGGIEEEGGERDRDRSGSLVNGFLALIWVDLRSLFLFSYHRLRDLLLIVT HIV-1 BaL Clade B  AB221005 gp41.pro
GGLVGLRIVFAVLSIVNRVRQGYSPLSFQTHLPTPRGPDRPEGIEEEGGERDRDRSIRLVNGSLALIWDDLRSLCLFSYHRLRDLLLIVT HIV-1 HXB2 Clade B K03455 gp41.pro
GPLVILLLLLTV------------------------G---P----------------CLINRFVAFVREQVSAVRIMVLR---------- PERV A AJ293656 p15E.pro
GPLIVLLLLLTV------------------------G---P----------------CIINKLIAFIRERISAVQIMVLR---------- PERV CA AY953542 p15E .pro
RIVELLGRRGWEALKYWWNLLQYWSQELKNSAVNLLNATAIAVAEGTDRVIEVLQAAYRAIRHIPRRIRQGLERILL              HIV-1 pNL4-3 Clade B AF324493 gp41.pro
RIVELLGRRGWEVLKYWWSLLQYWSQELKNSAVSLLNTIAIAVAEGTDRVIEVLQRAVRAILHIPRRIRQGLERALL              HIV-1 BaL Clade B  AB221005 gp41.pro
RIVELLGRRGWEALKYWWNLLQYWSQELKNSAVSLLNATAIAVAEGTDRVIEVVQGACRAIRHIPRRIRQGLERILL              HIV-1 HXB2 Clade B K03455 gp41.pro
--------------------QQYQGLPS                                                               PERV A AJ293656 p15E.pro





GGLCVALKEECCFYVDHSGAIRDSMNKLRERLEKRRREKETTQGELLELDKWASLWNWFNITNWLWYIKLFIMIVGGLVGLRIVFAV    N1
GGLCVALKEECCFYVDHSGAIRDSMNKLRERLEKRRREKETTQGELLELDKWASLWNWFNITNWLWYIKLLSALTGPLIVLLLLLTV    N2
GGLCVALKEECCFYVDHSGAIRDSMNKLRERLEKRRREKETTQGELLELDKWASLWNWFNITNWLWY                        N3
GGLCVALKEECCFYVDHSGAIRDSMNKLRERLEKRRREKETTQGELLELDKWASLWNWFNITNWLWY                        N4
A
B
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observed in these alignments as previously reported (Fiebig et al., 2003). Sequences of the HIV-1 
TM protein were “grafted” based on prior alignments with regard to sequence homologies into the 
TM protein p15E of PERV after removal of the epitopes in p15E which were recognized by these 
PERV neutralizing sera (Figure 3.1B). 
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3.3 N1 and N2 hybrid proteins  
3.3.1 Design, expression and characterization of recombinant hybrid 
proteins N1 and N2 
 
Figure 3.2: Schematic presentation and characterization of gp41, p15E and antigens N1 and N2 containing 
sequences of gp41 of HIV-1NL4-3 (GenBank: AF324493) and p15E of PERV-A (GenBank: AY953542). Dark 
grey squares indicate sequences of gp41 of HIV-1; light grey squares represent sequences of p15E of PERV-
A. The FPPR and MPER domains are derived from gp41, substituting analogue domains in p15E. N1 and N2 
contain the fusion peptide (FP), the membrane spanning domain (MSD) and a truncated 
intraviral/intracytoplasmic tail from gp41 (N1) or p15E (N2).  
 
Initially, hybrid proteins N1 and N2 contained the fusion peptide (FP), the membrane spanning 
domain (MSD) and a truncated intraviral/intracytoplasmic tail as flanking regions for the HIV-1 
FPPR and MPER were designed in order to provide the approximate full length TM protein for 
optimal folding. The recombinant hybrid protein N1 contained FP, MSD, a truncated 
intraviral/intracytoplasmic tail and the FPPR and MPER domains derived from gp41 (Figure 3.2) 
grafted into the backbone of p15E. For the design of construct N2, only sequences in p15E 
recognized by PERV neutralizing sera obtained from immunization studies using the PERV TM 
protein as antigen were substituted by the corresponding FPPR and MPER from gp41. N2 was 
designed to allow a similar folding as in p15E in order to present potential neutralizing epitopes in a 
p15E scenario.  
Both constructs remained difficult to express with ordinary expression strains, which required 
optimization procedures. Expression optimization was performed with three E. coli bacterial strains 
SCS1SE111, C3030H and BL21(DE3)pLysS at 25°C or 37°C (Figure 3.3). Sufficient 
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Figure 3.3: Representative expression optimization of hybrid protein N1 with two different expression clones in 
E. coli expression strains SCS1/SE111 and C3030H at 37°C. Samples of lysed expression cultures were 
taken before induction (0 h), 1 h and 3 h after induction with 1 mM IPTG. (A) SDS-PAGE of E. coli lysates 
after expression were stained with Coomassie brilliant blue. (B) Expression of recombinant protein N1 was 
detected on Western blot with monoclonal antibodies 2F5 and RGS-His (C). Arrows indicate monomeric (MM) 
or dimeric (DM) recombinant proteins.   
 
Purification using the N-terminal histidine tag (RGS-His) was insufficient due to aggregation of the 
recombinant proteins N1 and N2 in inclusion bodies and insolubility in native buffers without 
detergent. Thus, the bacterial lysate was therefore washed with PBS and the remaining pellet 
subsequently solubilized with guanidine hydrochloride in order to solubilized hydrophobic proteins, 
resulting in a hybrid protein solution with a purity of 70%. The purified recombinant proteins N1 and 
N2 were recognized by the two bNAb 2F5 and 4E10 in Western blot analysis (Figure 3.4). N1 was 
used for immunizations in 4 rats and 4 guinea pigs, the recombinant hybrid protein N2 was used for 
immunizations in 4 rats. Animals were immunized four times in a three week immunization 
schedule (2.2.5.1, Figure 2.1).  
 
Figure 3.4: Characterization of the purified proteins N1 and N2 on reducing SDS-PAGE (A) stained with 
Coomassie brilliant blue. (B) Western blot analysis of purified proteins with monoclonal antibodies 2F5 and 
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3.3.2 Immune responses induced by immunizations with N1 and N2 
Sera specimens derived from guinea pigs (N1g#1-4) and rats (N1r#1-4; N2 r#1-4) after the third 
booster immunization were screened for reactivity against the recombinant ectodomain of gp41 by 
Western blot and ELISA. All immune sera recognized recombinant gp41 in Western blot analysis 
(3.5A). 
 
Figure 3.5: (A) Western blot analysis of rat immune sera derived after the third immunization boost, using 
rgp41 as antigen on SDS-PAGE. Serum antibody titers against rgp41 (B) or peptides corresponding to either 
FPPR or MPER of gp41 (C).  
 
Sera collected after the fourth immunization were further tested in ELISA using rgp41 (Figure 3.5B) 
and peptides corresponding to the gp41 FPPR or MPER (Figure 3.5C) to evaluate gp41-specific 
antibodies. Moderate anti-rgp41 titers between 104 and 106 were detected in every immunized 
animal but one guinea pig immunized with N1. Anti-MPER responses were weak (1:250) or not 
detected in guinea pigs or rats, which received N1 recombinant protein. All sera from rats 
immunized with N2 reacted with FPPR and MPER peptides. 
Epitope mappings of immune sera derived from rats immunized with N1 induced antibodies binding 
to the FPPR, which confirmed previous ELISA results (Figure 3.6). Sera from rats immunized with 
N2 also recognized the sequence TLTVQARQL in N-terminal region of gp41. Peptides 
corresponding to the MPER were not recognized by sera from animals immunized with N2, 
although these sera reacted in an ELISA with a longer peptide comprising the complete MPER 
sequence (Figure 3.5C), suggesting an influence of the peptide-length and -conformation on 
antibody binding.  
 
Figure 3.6: Representative epitope mapping of one rat each, immunized with N1 or N2, respectively. 
Sequences corresponding to the FPPR and the MPER of gp41 in the hybrid constructs are underlined. Boxed 
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Antisera derived after the third booster immunization with N1 or N2 were all tested in the TZM-bl 
neutralization assay but none of the sera or isolated IgG inhibited HIV-1NL4-3 infection (Figure 3.7A-
C). 
 
Figure 3.7: Neutralization assay with immune sera or isolated IgG from rats (A) and guinea pigs (B) 
immunized with N1 derived after the third immunization boost. (C) Neutralization assay off immune sera after 
four immunizations with recombinant hybrid protein N2. PI describes preimmune sera used as negative 
control, PBS represents PBS control wells, PBS was added instead of serum. Purified IgG isolated from 
immune sera were used in dilutions (corresponding to the dilution in the original serum) from 1:20 followed by 
1:2 dilution steps. 2F5 was used as control in concentrations of 50/12.5/3.125/0.78 µg/ml. Luciferase reporter 
activity is presented as RLU (relative luminescence units) and the dotted line indicates the cut-off defined as 
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3.4 N3 and N4 hybrid proteins 
3.4.1 Design, cloning, expression and characterization of recombinant 
hybrid protein N3 
 
Figure 3.8: Schematic presentation of gp41, p15E and antigen N3 containing sequences of gp41 of HIV-1NL4-3 
(GenBank: AF324493) and p15E of PERV-A (GenBank: AY953542). Dark grey squares indicate sequences of 
gp41 of HIV-1; light grey squares represent sequences of p15E of PERV-A. The FPPR and MPER domains 
are derived from gp41, substituting analogue domains in p15E. Construct N3 was designed to remove FPPR 
and MPER flanking regions to prevent potential masking of bNAb binding sites.  
The hybrid N3 was designed to eliminate potential masking of FPPR or MPER by flanking regions 
removing FP and MSD sequences and to increase solubility of the recombinant protein 
(Figure 3.8). N3 was cloned, expressed and initially purified by affinity chromatography under 
denaturing conditions using 8M Urea, achieving a purity of 95% (Figure 3.9). The recombinant 
protein was purified under denaturing conditions and used for immunization experiments in four 
rats, four guinea pigs and one rabbit. Further analysis of the proteins showed dimerization on 
reducing SDS-PAGE (red.) and oligomers on non-reducing SDS-PAGE (non-red.). Presence and 
accessibility of the MPER was tested by mAbs 2F5 and 4E10 in Western blot analysis 
(Figure 3.9B).  
 
Figure 3.9: (A) Characterization of purified recombinant protein N3 on 10% SDS-PAGE stained with 
Coomassie brilliant blue G 250. Protein samples were treated with sample buffer containing β-
mercaptoethanol (red.) or native sample buffer without reducing agent (non-red.). Arrows show recombinant 
proteins as monomers (MM), dimers (DM), trimers (TM) and oligomers (OM). (B) Western blot analyses of 
purified recombinant N3 using the monoclonal antibodies 4E10 and 2F5.  
 
Recombinant hybrid protein N3 was further characterized by SPR analysis and binding affinities 
were assessed for the bNAb 2F5 and 4E10 to the recombinant antigens. 2F5 bound N3 with an 
apparent KD value of 0.3448 nM, showing a 100-fold higher affinity value to N3 compared to that 
gp41
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measured for 4E10 (32.0 nM). N4 was bound by 2F5 with a 20-fold lower apparent KD value of 
18.34 nM compared to the affinity for 4E10 (344.8 nM) to the recombinant hybrid protein.  
 
3.4.2 Immunization of 4 guinea pigs and 4 rats and 1 rabbit with N3 
To evaluate the immunogenicity of N3, four guinea pigs, four rats and one rabbit were immunized 
with the recombinant hybrid protein. Guinea pigs and rats received 4 injections of 250 µg antigen, 
mixed with CFA/IFA in a 3-week immunization schedule (2.2.5.1, Figure 2.1).  
Sera specimens derived from immunized animals were screened for reactivity against the 
recombinant ectodomain of gp41 by Western blot and ELISA. All immunized animals reacted 
specifically with rgp41 in Western blot (Figure 3.10A) which was also demonstrated in ELISA, using 
rgp41 and peptides corresponding to the FPPR or MPER (Figure 3.10B and C). Anti-rgp41 titers 
between 104 and 106 were observed in immune sera of the rats and guinea pigs, immunized with 
N3. Strong reactivity against the FPPR-derived peptide was observed in every anti-serum from four 
rats and three guinea pigs immunized with N3. This guinea pig showed a strong anti-MPER 
response and an anti-FPPR antibody titer. To be noticed, a significant increase of anti-MPER 
responses was detected in antisera of rats immunized with N3 compared to N1 immunized rats. 
Differences in the arrangement of HIV-1 derived sequences in the p15E backbone in N1, N2 and 
N3 might have modified accessibility of the HIV-1 MPER and thus increased the antibody response 
towards the MPER. 
 
Figure 3.10: (A) Western blot of immune sera from animals immunized with N3, using rgp41 as antigen. (B) 
Titers of antibodies specific for rgp41 in the sera of animals immunized four times with the hybrid protein N3. 
(B) Comparison of anti-FPPR and anti-MPER antibody titers (using FPPR and MPER derived peptide as 
antigens). Asterisks indicate significant differences in antibody titers between two groups of animals evaluated 
by Mann-Whitney test (p<0.05).  
 
Sera from rats immunized with N3 also recognized epitopes in the N-terminal region of gp41, 
mainly the sequence TLTVQARQL (Figure 3.11). Antisera from three guinea pigs and three rats 
immunized with N3 reacted with MPER derived peptides, specifically binding the core epitope of 
2F5 (ELDKWA) (Figure 3.11). Representative epitope mapping on a nitrocellulose membrane of 
the serum from guinea pig N3g#3 shows one epitope in the FPPR and another in the MPER 
including the 2F5 epitope. Reactivity of the serum with two additional peptides derived from gp41 
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Unspecific binding of serum components could have bound to the membrane due to insufficient 
regeneration since the membrane was used repeatedly for epitope mapping. Furthermore, 
microarray chips used for epitope mapping of this serum did not show binding to these peptides.  
Of note, the serum from guinea pig N3g#4 immunized with N3 recognized only the ELDKWA 
epitope in the MPER, but did not recognize sequences in the FPPR in epitope mappings. This 
recognition pattern corresponds to the pattern of bNAb 2F5 in the same epitope mapping.  
 
Figure 3.11: (A) Epitope mappings of the antisera derived from animals immunized with the recombinant 
hybrid protein N3. (A) Representative epitope mapping on a nitrocellulose membrane of the serum from 
guinea pig N3g#3. showing one epitope in the FPPR and another in the MPER including the 2F5 epitope. (B) 
Summary of epitope mappings of all sera from guinea pigs and rats immunized with N3. Sequences 
corresponding to the FPPR and the MPER of gp41 in the hybrid constructs are underlined. Boxed sequences 
indicate epitopes of mAb 2F5 (ELDKWA) and mAb 4E10 (NWFNIT).  
 
Sera from animals immunized with N3 which recognized rgp41 were further tested for 
neutralization activity by a neutralization assay based on TZM-bl cells with HIV-1NL4-3, but no 
neutralizing activity of immune sera or IgG isolated from these sera was observed, despite that 
some of these sera bound to the same epitope as the broadly neutralizing antibody 2F5 
(Figure 3.12A and B). Sera and IgG from rats and guinea pigs immunized with N3 which reacted 
with the 2F5 epitope were also analysed in a neutralization test based on C8166 cells or PHA 
stimulated PBMCs. None of the analysed sera in different dilutions (1:20 or 1:50) or isolated IgG 
were able to inhibit provirus integration in C8166 cells to a greater extent than the corresponding 
preimmune serum (Appendix; A1A and B). Surprisingly, the serum of guinea pig N3g#4 weakly 
inhibited provirus integration in the PBMC-based real-time neutralization assay despite the 
negative results in the two other neutralization assays. 
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Figure 3.12: (A) Comparison of mean values of rgp41 binding antibodies in sera and isolated IgG fractions. (B) 
Neutralization assay using sera and isolated IgG from guinea pigs (A) and rats (B) immunized with N3. PI 
indicates IgG isolated from preimmune serum. Purified IgG were used in dilutions (corresponding to the 
dilution in the original serum) from 1:20 followed by 1:2 dilution steps. 2F5 was used as control in 
concentrations of 50/12.5/3.125/0.78 µg/ml. Luciferase reporter activity is presented as RLU (relative 
luminescence units) and the dotted line indicates the cut-off defined as 50% of untreated virus infectivity 
control. Error bars represent the standard deviation (n=2). 
 
The immunization study with the rabbit was performed in Hungary in cooperation with our 
Euroneut-41 cooperation partners at the Central Agricultural Office in Budapest in order to evaluate 
the immunogenicity of N3 in an additional animal species. Two batches of 250 µg antigen for each 
immunization were mixed each 1:1 with Montanide at a total volume of 500 µl and sent to the 
testing site. The rabbit was immunized for primary and booster immunization with 100 µl i.m. in 
each hind leg and received 300 µl subcutaneously. Serum was taken after each immunization (S1, 
S2) and sent back to the Robert Koch-Institute for evaluation of antibody responses induced by 
immunization. 
Since the rabbit was only immunized twice, immune sera from this immunization study were first 
tested for reactivity against the N3 and rgp41, showing antibodies binding to the proteins already 
three weeks after the first immunization (Figure 3.13A). Titers of anti-gp41 antibodies in immune 
sera obtained after the fourth immunization were comparable to those observed in rats and guinea 
pigs after the same number of booster immunizations (Figure 3.13B). Antibody responses against 
the FPPR were moderate, whereas anti-MPER responses remained weak and were thus not 
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When testing the rabbit immune sera in the neutralization assay, no inhibition of HIV-1NL4-3 infection 
was observed (Figure 3.13D). 
 
Figure 3.13: (A) Immune sera of the rabbit immunized with N3 derived after 1st and 2nd immunization (S1, S2), 
recognizing N3 and gp41, diluted 1:400. (B) Comparison of antibodiy responses after 1st and 2nd immunization 
against rgp41, FPPR and MPER derived peptides; serum diluted 1:2000. Error bars represent the standard 
deviation (n=3). (C) Microarray-based epitop mapping of rabbit immune serum. (D) Neutralization assay with 
preimmune (PI) and immune serum derived after the 2nd immunization (S2). Error bars represent the standard 
deviation (n=2). 
It was demonstrated that immunizations with N3 of guinea pigs and rats induced increased titers of 
anti-MPER antibodies compared to previous immunizations with hybrid proteins N2 or N2, although 
the amount of gp41 and FPPR binding antibodies in immune sera remained comparable to those 
observed after N1 or N2 immunizations. N3 vaccination of one rabbit induced moderate titers of 
anti-FPPR antibodies but no MPER specific antibodies. Despite successful induction of antibodies 
binding exactly to the epitope of 2F5 after immunization with N3 in rats and guinea pigs, none of 
the sera or isolated IgG neutralized HIV-1NL4-3 in the TZM-bl or C8166 cell-based neutralization 
assay. Only the serum of one guinea pig showed a weak inhibition of HIV-1NL4-3 infection in the 
PBMC-based real-time assay. 
 
3.4.3 Design, expression and characterization of recombinant hybrid 
protein N4 
Previous immunization studies with N3 in rats and guinea pigs resulted in antibodies responses 
binding precisely to the ELDKWA epitope, showing a moderate focus on the MPER but no 
neutralization of HIV-1. Since a number of previous studies have shown MPER binding antibodies 
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Toukam et al., 2012; Law et al., 2007; Shen et al., 2010), the construct N4 was designed with focus 
on optimal amino-acid composition and location of different domains within the hybrid protein. 
Thus, 26 amino acids were deleted in the p15E backbone of N3 (Figure 3.14), expecting a closer 
proximity of the FPPR and MPER region within the folded protein. In addition, purification 
procedures were optimized for N3 using imidazole (2.2.2.2) to reduce denaturation of the protein 
during purification.  
 
Figure 14: Schematic presentation of gp41, p15E and antigen N3 and N4 containing sequences of gp41 of 
HIV-1NL4-3 (GenBank: AF324493) and p15E of PERV-A (GenBank: AY953542). Dark grey squares indicate 
sequences of gp41 of HIV-1; light grey squares represent sequences of p15E of PERV-A. The FPPR and 
MPER domains are derived from gp41, substituting analogue domains in p15E. Construct N3 was designed to 
remove FPPR and MPER flanking regions to prevent potential masking of bNAb binding sites. 
The recombinant protein was expressed and purified with an identical purification protocol using 
imidazole as elution component, achieving a purity of 95% (Figure 3.15A). Analysis of N4 on 
denaturing and reducing SDS-PAGE showed monomers and dimerization of the recombinant 
protein with Coomassie brilliant blue staining (Figure 3.15A), also detected with 2F5 and with 4E10 
(Figure 3.15B). N4 treated with native sample buffer without reducing agent (non-red.) showed 
formation of mono-, di-, tri-, and oligomers on SDS-PAGE, which were bound by 2F5 and 4E10. 
 
Recombinant hybrid protein N4 was also characterized by SPR analysis and binding affinities were 
assessed for the bNAb 2F5 and 4E10 to the recombinant antigens. N4 was bound by 2F5 with a 
20-fold lower apparent KD value of 18.34 nM compared to the affinity for 4E10 (344.8 nM) to the 
recombinant hybrid protein.  
 
Figure 3.15: (A) Characterization of the purified recombinant protein N4 on 10% SDS-PAGE stained with 
Coomassie brilliant blue G 250. Protein samples were treated with sample buffer containing β-
mercaptoethanol (red.) or native sample buffer without reducing agent (non-red.). Arrows show recombinant 
proteins as monomers (MM), dimers (DM), trimers (TM) and oligomers (OM). (B) Western blot analyses of 
purified recombinant proteins using the monoclonal antibodies 4E10 and 2F5.  
gp41
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3.4.4 Immunization of rats with N3 and N4 
Purified recombinant proteins N3 and N4 were used for further immunizations of rats in groups of 
four animals each. One group received 250 µg N3 (N3r#5-8), four animals were immunized with 
250 µg (N4#r1-4) or 500 µg N4 (N4r#5-8), respectively. Hybrid protein N3 was used in this 
immunization regiment in order to compare immune responses after immunization of rats directly 
side by side and evaluate the impact on immunogenicity of gp41 FPPR and MPER due to 
backbone modification. 
 
Figure 3.16: (A) Western blot analysis of immune sera (after 4th immunization), diluted 1:400 from animals 
immunized with N3 (N3r#5-8) or N4 (N4r#1-8), using rgp41 as antigen. (+) 2F5 diluted 1:100 000 and (PI) or 
(-) represents preimmune serum. (B) OD492 values of serum antibodies diluted 1:2000 specific for FPPR and 
MPER derived peptides of animals immunized four times with the hybrid protein N3 or N4. (C) OD492 values 
of MPER-specific antibodies in immune sera after immunization with N3 or N4 (D), diluted 1:250. Error bars 
represent the standard deviation (n=3). 
Anti-rgp41 Western blot analysis showed moderate antibody titers against the ectodomain of the 
HIV-1 TM protein (Figure 3.16B) in N3 and N4 immunized animals. Anti-rgp41 titers in sera from 
N3 immunized animals (3.16B) were comparable to those observed in the previous immunization 
experiment (Figure 3.10B) but remained higher compared to those observed in immune sera 
obtained after immunization with 250 µg N4. Detailed analysis of binding antibodies by ELISA 
using FPPR and MPER derived peptides as antigens (Figure 3.16B) showed predominant FPPR 
directed responses in immune sera derived from N3 or N4 immunized animals. Comparing immune 
sera of rat groups immunized with 250 µg or 500 µg, respectively, administration of 500 µg N4 
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to immune sera derived from the rats which received 250 µg (Figure 3.16B). Immunization with 
500 µg of N4 recombinant protein induced lower antibody titers of anti-FPPR antibodies compared 
to rats immunized with half the amount of antigen. Anti-MPER responses of N3 and N4 immunized 
animals tested in ELISA remained overall lower in this immunization study (Figure 3.16B) except 
rat N3r#7, which was in contrast to the previous immunization study using N3 as antigen 
(Figure 3.16C and D).  
 
Figure 3.17: Representative epitope mapping of antisera derived from animals immunized with the 
recombinant hybrid protein N3 or N4. Mappings were performed on microarray chip at a serum dilution of 
1:400, showing epitopes in the FPPR and MPER region in the MPER including the 2F5 epitope.  
Epitope maps of serum derived from one animal immunized with N3 (N3r#7) are consistent with 
previous peptide ELISA results, demonstrating a MPER responses with binding antibodies specific 
for the 2F5 epitope (Figure 3.17). Immunization with N4 induced higher titers of MPER-specific 
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antibodies compared to N3 immunization studies (Figure 3.16 D), the ELDKWA epitope was also 
recognized by the immune sera (Figure 3.17A and B). 
 
To summarize, gp41-specific antibody titers of induced by immunizations with N3 were comparable 
to those observed in the previous study. Vaccination with N4 induced lower titers of anti-gp41 
antibodies, compared to N3 immunizations, although a stronger anti-MPER antibody response was 
induced after immunization with N4. 
 
Since all sera reacted with rgp41, neutralization assays were performed with HIV-1NL4-3. 
Surprisingly, three rat immune sera obtained after the third immunization showed an inhibitory 
effect on HIV-1 infection (Figure 3.18) in the TZM-bl neutralization assay compared to the PBS 
immunized control animal, whereas this effect was not observed in immune sera derived after the 
fourth immunization. As a consequence, IgG were isolated from these sera derived after the third 
immunization and the neutralization assay was repeated, using the same concentration of rgp41 
specific antibodies as in the immune sera. IgG isolated from rat sera N4r#2 and N4r#4 showed 
weak inhibition of virus infection at a dilution of 1:20. In addition to that, antisera from those three 
rats derived after first and second immunizations were tested to further investigate the influence of 
primary and booster immunizations on neutralization capacity of the sera. Sera from animals N4r#2 
and N4r#7 derived after the third immunization with N4 exhibited the strongest virus inhibition 
capacity compared to sera obtained after the other immunizations. Of note, the serum S2 from 
animal N4r#4 but not S3 showed the strongest inhibition of virus infection in the assay, although S3 
was still capable to inhibit HIV-1 infection to a minor extent.  
 
 
Figure 3.18: TZM-bl neutralization assay of sera and isolated IgG from animals N4r#2, N4r#4, N4r#7 derived 
after each immunization (S1 = serum derived after 1st immunization, S2 = 2nd immunization, S3 = 3rd 
immunization, S4 = 4th immunization). Sera and IgG were used in two-fold dilutions from 1:20 to 1:160. 2F5 
was used as control in concentrations of 50/12.5/3.125/0.78 µg/ml. The cut-off line represents 50% of RLU 
measured for virus infection without serum or antibodies. 
 
In addition to the TZM-bl neutralization assay, sera from animals N4r#2, N4r#4 and N4r#7 derived 
after the third and fourth immunization were then furthermore tested in the real-time based 



























































Figure 3.19: Real-time based neutralization assay of sera from animals N4r#2, N4r#4, N4r#7 derived after 
third and fourth immunization (S3 = 3rd immunization, S4 = 4th immunization). Sera were used in a 1:20 
dilution. Serum from a control animal which received only PBS was used as negative control. Error bars 
represent the standard deviation (n=3). 
 
Serum from animals N4r#4 and N4r#7 derived after the third immunization did not inhibit HIV-1NL4-3 
infection compared to serum from the PBS control animal (Figure 3.19). Of note, S3 from rat N4r#2 
significantly reduced virus infections comparable to 1.25 µg of 2F5, although this effect is not 
observed when testing sera derived after the fourth immunization.This was also observed in the 
TZM-bl neutralization assay, but isolated IgG from this serum did not inhibit virus infection (Figure 
3.18). Due to limited serum volumes derived from rats after the third immunization (1 ml), additional 
neutralization tests could not be performed and therefore the immunization study was repeated 
with eight rats and one goat.  
 
3.4.5 Immunization study of four rats and one goat with N4  
Since immune sera after the third immunization derived from the previous immunization regimen 
with antigen N4 exhibited weak neutralizing activity and serum volumes were insufficient for 
additional neutralization tests, the immunization of rats was repeated with three instead of four 
immunizations to obtain more blood from the final bleed.  
 
Immunization of 8 rats with 250 µg recombinant hybrid protein N4 induced anti-gp41 titers of 104-
106 after the second boost which were comparable to those observed in the previous immunization 
experiment with N3 as antigen (Figure 3.10A and B). Further detailed evaluation of immune 
responses directed against the FPPR or MPER domains showed again a dominant FPPR 
response and relatively weak anti-MPER responses but animal N4r#11, exhibiting a balanced anti-
FPPR and anti-MPER response (Figure 3.20C). In this experimental set-up, animal N4r#10 died 
during the bleed after the first, animal N4r#12 after the second and animal N4r#16 after the third 
immunization since the animal facility used another anesthetic instead of the previously used 











































Figure 3.20: (A) Western blot analysis of rat immune sera (obtained after the 3rd immunization: N4r#9; N4#r11; 
N4#13-16; serum of animal N4r#10 derived after the 1st immunization), diluted 1:400, using rgp41 as antigen. 
(+) 2F5 diluted 1:100 000 and (-) represents preimmune serum. (B) Anti-gp41 antibody titers of rat immune 
sera, diluted 1:1000. (C) OD492 values of serum antibodies diluted 1:400 specific for FPPR and MPER derived 
peptides. PBS KO represents serum from the control animal immunized three times with PBS plus 
corresponding adjuvant. Error bars represent the standard deviation (n=3).  
 
Evaluation of neutralization mediated by immune sera after the third immunization showed a 50% 
inhibition of HIV-1 infection at a dilution of 1:40 by the immune serum of animal N4#r9, comparable 
to a concentration of 0.3 µg/ml 2F5 (Figure 3.21A). It was thus necessary to isolate IgG from these 
sera but the inhibitory effect was not detected in subsequent neutralization assays when using the 
same amount of rgp41 specific antibodies as in the serum (Figure 3.21B). 
 
Figure 3.21: TZM-bl neutralization assay of sera (A) and isolated IgG (B) from rats derived after second (S2) 
or third (S3) immunization. Sera and IgG were used in two-fold dilutions from 1:20 to 1:160. 2F5 was used as 
control in concentrations of 50/12.5/3.125/0.78 µg/ml. The cut-off line represents 50% of RLU measured for 
virus infection without serum or antibodies. Error bars represent the standard deviation (n=2). 
 
Immunization experiments with N4 induced predominantly FPPR-specific antibodies in rats. Sera 
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the serum and not to isolated IgG from these sera. Serum volumes of rats received from the animal 
facility varied between 300 and 800 µl after each bleed which were insufficient volumes for antigen 
specific antibody purification. Therefore, a goat was immunized three times with 500 µg of the 
recombinant hybrid protein N4 and bled after each immunization. Anti-rgp41 antibody responses 
were detected after the first immunization (Figure 3.22A and B) whereas a moderate rgp41 and 
peptide response was detected after the second immunization boost (Figure 3.22B).  
 
Figure 3.22: (A) Western blot analysis of goat immune sera (obtained after the each immunization (S1-S3), 6 
weeks after the third immunization (S4) and isolated gp41-CHR-specific antibodies from sera S3 and S4 
(MPER-Ab). Sera and antibodies were diluted 1:400. (+) 2F5 diluted 1:100 000 and (-) represents preimmune 
serum. (B) OD492 values of serum antibodies diluted 1:1000, binding to N4, rgp41, FPPR or MPER derived 
peptides after each immunization. Error bars represent the standard deviation (n=3). (C) Epitope mapping of 
rgp41CHR-specific antibodies, binding to ELDKWA as core epitope.   
 
The sera were then tested in the TZM-bl neutralization assay, showing an inhibitory effect on HIV-1 
infection by the serum derived after the second booster immunization, diluted 1:20. This effect was 
stronger than 50% of the RLU value measured with virus infection and as well stronger than the 
preimmune serum diluted 1:20 and thus defined as neutralizing. Of note, the goat was bled again 9 
weeks after the third immunization (S4), and this serum did not exhibit virus neutralizing activity.  
To evaluate whether this neutralizing effect was restricted to antibodies induced by immunization 
with the hybrid protein, CHR/MPER-specific antibodies were isolated from the serum by affinity 
purification, using a recombinant protein comprising the CHR of gp41 (aa605-681, Genbank: 
K03455). CHR-specific antibodies were concentrated to twice the amount compared to serum 
concentrations and bound exactly the core epitope of the bNAb 2F5 (Figure 3.22C).  
Sera and isolated concentrated antibodies were tested again for neutralization of HIV-1NL4-3 and a 
primary isolate of HIV-1 clade F. Although the goat immune serum obtained after the third 
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mediated by MPER antibodies (Figure 3.23). Furthermore, neither serum nor CHR/MPER-specific 
antibodies neutralized HIV-1BR 93/020. 
 
Figure 3.23: TZM-bl neutralization assay of sera and isolated IgG with viruses HIV-1NL4-3 clade B (A) and a 
clade F primary isolate HIV-1BR 93/020. Sera and CHR-specific antibodies were used in two-fold dilutions from 
1:20 to 1:160. 2F5 was used as control in concentrations of 50/12.5/3.125/0.78 µg/ml. The cut-off line 
represents 50% of RLU measured for virus infection without serum or antibodies. Error bars represent the 
standard deviation (n=2). 
 
In summary, immunization of one goat with N4 induced CHR/MPER-specific antibodies, which also 
bound the epitope of 2F5 as observed in previous immunizations of rats. The immune serum 
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3.5 Immunization with recombinant N1 in liposomes 
Since immunization of the N1 hybrid protein predominantly induced FPPR specific responses, 
optimization of potential neutralizing epitope presentation of the MPRE was required. The 
recombinant protein was thus incorporated into liposomes in order to present the MPER in a lipid 
context, since native MPER structure depends on lipidic environment (Coutant et al., 2008; Sun et 
al., 2008). N1 purified recombinant protein was sent to Polymun (Vienna, Austria) and inserted into 
the lipid bilayer of manufactured liposomes in combination with the adjuvant MPLA (2.2.2.4). 
Liposome technology of Polymun was already tested in a phase I clinical trial (Katinger et al., 2012) 
and was shown to induce potent immune responses against a gp41 derivative. 
The protein/liposome suspension (N1Lip) was analyzed on reducing SDS-PAGE. Recombinant 
hybrid proteins inserted into liposomes formed monomers and dimers on SDS-PAGE, also bound 
by 2F5 in Western blot, which demonstrates accessibility of the MPER in the monomeric and 
dimeric form (Figure 3.24).  
 
Figure 3.24: Analysis of immunogen N1Lip (batch 1) received from Polymun by Coomassie brilliant blue 
stained 10% SDS-PAGE and Western blot analysis with 2F5. 
 
The non-filtrated batch one of N1Lip was used for immunization of two guinea pigs and one goat, 
one guinea pig received batch two (recombinant protein suspension was filtrated prior liposome 
preparation) and one guinea pig received empty liposomes in a three week immunization schedule 
with one primary immunization and two boosts. 
Immune responses of four immunized guinea pigs and one goat against rgp41, FPPR and MPER 
after immunization were tested by Western blot analysis and ELISA. Sera from guinea pigs 
immunized three times with batch one of N1Lip developed weak antibody responses against rgp41 
(1:1000), focused on the FPPR. Immunization of one guinea pig with batch two did not result in 
significantly stronger anti-rgp41 responses compared to the control animal, which received empty 
liposomes. Immunization of the goat did not induce detectable anti-gp41 antibodies even after the 
third immunization. Neutralization assays did not show any inhibition of HIV-1NL4-3 infection by pre-
incubation with neither goat (Figure 3.25B) nor guinea pig (Figure 3.25A) sera obtained after 


















Figure 3.25: TZM-bl neutralization assay of sera from goat (B) and guinea pigs (A) immunized with N1Lip. Sera 
were used in two-fold dilutions from 1:20 to 1:160. Four-fold serial dilution of 4E10 and 2F5 was used as 
positive control, starting at a concentration of 25 µg/ml. The cut-off line represents 50% of RLU measured for 
virus infection without inhibitory agents. Error bars represent the standard deviation (n=2). 
 
3.6 Immunization with recombinant N3 and N4 in liposomes 
Immunization experiments in guinea pigs, rats and one goat with recombinant hybrid proteins N3 
and N4 induced promising antibody responses against the FPPR and MPER, binding precisely to 
the epitope of 2F5. Sera derived from these immunized animals were capable to marginally inhibit 
HIV-1NL4-3 infection of TZM-bl cells, although this inhibition was not restricted to isolated IgG or 
CHR-specific antibodies isolated from these sera. In order to present the MPER in a lipid context, 
the purified recombinant hybrid proteins N3 and N4 were also sent to Polymun for manufacturing a 
mixture of liposomes containing MPLA as adjuvant and hybrid proteins N3 and N4, respectively. 
The batches received were analyzed on reducing SDS-PAGE, showing formation of monomers 
and dimers, both conformations bound by 4E10 and 2F5 (Figure 3.26). 
 
Figure 3.26: Comparative immunogen analysis of N3Lip and N4Lip received from Polymun with recombinant 
proteins only. (A) Coomassie brilliant blue stained reducing SDS-PAGE. (B) Western blot analysis with 2F5 or 
4E10 (C). Arrows indicate recombinant proteins forming monomers (MM) and dimers (DM). 
 
Analysis of rgp41 binding antibodies showed varying titers, whereupon the strongest anti-rgp41 
responses were detected in rats immunized with N4Lip (Figure 3.27A). Moderate titers of anti-FPPR 
antibodies were measured in two rats immunized with N3Lip and three N4Lip immunized animals, 






































































Figure 3.27: (A) OD492 values of rat serum diluted 1:250 after the second booster immunization, binding to 
rgp41, FPPR or MPER derived peptides. (B) TZM-bl neutralization assay of sera from rats immunized with 
N3Lip, N4Lip. Sera were used in two-fold dilutions from 1:20 to 1:160. 2F5 was four-fold diluted, starting at a 
concentration of 50 µg/ml. The cut-off line represents 50% of RLU measured for virus infection without 
inhibitory agents. Lipr#1 represents control serum of one rat which received empty liposomes diluted 1:250 for 
the ELISA (A) or starting from 1:20 in the neutralization assay (B). Error bars represent the standard deviation 
(n=2). 
 
All sera inhibit HIV-1NL4-3 infection of TZM-bl cells in the neutralization assay, although not to a 
greater extent than the immune serum of one rat which only received empty liposomes 
(Figure 3.27B). To evaluate the inhibitory effect on virus infection, IgG were isolated from these 
sera but did not inhibit HIV-1 infection. Unspecific inhibitory effects which are not antibody 
restricted were kindly tested by Dr. Uwe Fiebig with a real-time base reference neutralization 
assay, using SIVmac293 as control virus (Figure 3.28). Two sera derived after the second 
immunization with N3 (N3Lipr#1) or N4 (N4Lipr#4) showed a weak inhibitory effect on HIV-1 infection 
compared to the negative control sera, respectively. This was also true for SIVmac293 infection 
which indicates non-virus specific inhibitory effects on cell infection by the rat immune sera. A 
cytotoxic effect was partially excluded due to parallel measurement of the GAPDH reference gene 
in the same real-time PCR assay. 
 
Figure 3.28: Real-time based neutralization assay of sera from rats immunized with N3Lip, N4Lip or empty 
liposomes (Lipr#1) derived after the second (S2) or third (S3) immunization. Sera were diluted 1:20. Dotted 
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In summary, immunization with N1, N3 and N4 in MPLA containing liposomes induced a weaker 
anti-gp41 response with focus on the FPPR than previous immunization studies with recombinant 
hybrid proteins in combination with complete/incomplete Freund´s adjuvant and neutralization of 
HIV-1NL4-3 infection by immune sera was observed.  
 
  Results 
62 
 
3.7 DNA immunization with recombinant hybrid antigens in 2 different 
expression vector systems 
Previous immunization experiments with the recombinant hybrid antigens expressed by prokaryotic 
organisms did not induce MPER-specific antibodies, which are able to significantly neutralize 
HIV-1. Advantages of immunizations with prokaryotically expressed proteins relied on the relatively 
large amount of purified antigen and immunogenicity of protein immunization. Application of a 
certain amount of antigen was distinct although the vigorous mixing of antigen suspension and 
adjuvant resulted in a viscous fluid and thus, challenging to immunize subcutaneously and 
intramuscularly. An additional instable factor when using recombinant proteins expressed from 
prokaryotic organisms was post-translational folding in a non-eukaryotic. A certain conformation of 
the hybrid proteins composed of PERV and HIV-1 sequences was suggested to engage a distinct 
conformation required to induce HIV-1 neutralizing antibodies. The approach to transfer this 
immunization experiment hypothesis into a DNA immunization regimen was to obtain eukaryotic in 
vivo protein expression, folding and glycosylation of the expressed protein.  
Two eukaryotic expression systems were chosen to evaluate the antibody responses induced by 
immunization with the vector encoded hybrid proteins and HIV-1 neutralizing capacity of immune 
sera. One system designed for surface antigen expression was the previously tested pDisplay 
expression vector (Behrendt et al., 2012a), expressing hybrid proteins composed of PERV 
sequences combined with HIV-1 gp41 domains. These gene gun immunization experiments in rats 
induced antibody responses up to 1:32,000. Thus, the pDisplay expression system was applied to 
express modified hybrid constructs N1 and N5 (Figure 3.29). The hybrid proteins N1 and N5 were 
designed and thus cloned into the pDisplay expression vector (2.2.1.6).  
 
Figure 29: Schematic presentation of gp41, p15E and antigen N1 and N5 containing sequences of gp41 of 
HIV-1NL4-3 (GenBank: AF324493) and p15E of PERV-A (GenBank: AY953542). Dark grey squares indicate 
sequences of gp41 of HIV-1; light grey squares represent sequences of p15E of PERV-A. The FPPR and 
MPER domains are derived from gp41, substituting analogue domains in p15E. Construct N5 was designed 
on basis of N3 with the additional membrane spanning domain (MSD) and a truncated cytoplasmic tail derived 
from gp41 to insert the hybrid protein in the cellular membrane after in vivo expression. 
The DNA replicon vector (DREP) expression system (kindly provided by Prof. Peter Liljeström 
(Karolinska Institute, Stockholm) was used as second expression system. This vector is based on 
the Semliki Forest Virus expression system (Berglund et al., 1998; Nordstrom et al., 2005) and thus 
carries intrinsic adjuvant properties (Naslund et al., 2011). Due to presence of the Semliki Forest 
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Virus replicase encoded in the vector, transfection of the DNA results in production of self-
replicating mRNA. The DREP vector (received from Karolinska Institute) did not include an export 
signal to transfer the antigen to the cell surface. Therefore the vector was modified and the export 
signal (ES) derived from Semliki Forest Virus was included in the vector on the basis of a 
previously published design (Forsell et al., 2007), showing to enhance antigen-specific antibody 
responses.  
Sequences of N1 with the N-terminal located SFV export signal were codon optimized for the 
mouse organism since mice were used as test animals. The construct was synthesized by 
Genescript (Piscataway, USA) and cloned in-frame with the translational enhancer and the 
ribosomal skipping domain (SD), using HindIII/SpeI restriction sites. The construct N5 comprised 
the complete sequence of N3 plus the transmembrane domain (TM) derived from HIV-1 to anchor 
the translated protein into the cellular membrane (Figure 3.29, 3.30). DREP-N5 was amplified by 
QuickChange™ in vitro mutagenesis (Stratagene, Heidelberg, Germany) using the vector DREP-
N1 as template with the primers 024/025, which were designed accordingly to the manufacturer´s 
instructions. This method was applied for cloning procedures to delete the fusion peptide (13 amino 
acids) from the DREP-N1 construct. The pDisplay-N1 and pDisplay-N1 expression vectors were 
cloned as described in section 2.2.1.6 and coated on gold particles at a 1:1 ratio with the cytokine 
GM-CSF (Granulocyte macrophage colony-stimulating factor) used as adjuvant, also codon 
optimized for the mouse organism. Since antibody responses of DNA vaccines were previously 
shown to be enhanced by additional immunization with plasmid-encoded GM-CSF (Brave et al., 
2005; Ou-Yang et al., 2002), the adjuvant was used for the pDisplay immunization regimen 
encoding the hybrid proteins. DREP-N1 and DREP-N5 constructs were coated on gold particles 
without additional adjuvants since the DREP vector carries intrinsic adjuvant properties (Naslund et 
al., 2011). 
 
Fig 3.30: Schematic presentation of the DREP expression system with inserted hybrid antigens N1 and N5. 
Arrows represent internal subgenomic promotors, start of translation for the foreign gene by the vector 
encoded replicase. Expression constructs (DREP-N1, DREP-N5) include the viral replicase, the internal 
translational enhancer (enhancer), the ribosomal slippery sequence (SD) and the export signal (ES) from SFV. 
Foreign antigens N1 and N5 including the transmembrane domain (TM) derived from HIV-1 are cloned 5´ in 
frame with the second open reading frame.  
  
In order to test expression of recombinant hybrid proteins encoded in the two different expression 
vectors, 293T cells were transfected with the constructs N1 and in N5 cloned into the DREP or 
pDisplay expression system. Transfected cells were either stained extracellularly with 2F5 and 
Wild type SFV Replicase Capsid E3 E2 6k E1
DREP EGFP Replicase Enhancer SD EGFP
DREP N1 Replicase SD ES N1Enhancer
DREP N5 Replicase SD ES N3 TM
N5
Enhancer
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4E10 for immunofluorescence analysis, investigating localization and accessibility of the MPER on 
the cellular surface, or lysed for Western blot analysis using the antibodies mentioned above. 2F5 
and 4E10 bound only to cells transfected with the expression constructs N1 and N5 in pDisplay or 
DREP, showing expression of the antigen in the cell lysate of 293T (Figure 3.31) cells and on the 
cellular membrane (Figure 3.32) of transfected cells after immunofluorescent staining. Cellular 
lysates of 293T cells transfected with a molecular clone of HIV-1NL4-3 was used as a positive control 
and hence also recognized by 2F5. 
 
 
Figure 3.31: Western Blot analysis of cell lysates derived from transfected 293T cells. Membranes were 
incubated with 2F5 or 4E10 1:50 000 and secondary HRP-conjugated anti-human antibody 1:5000. 
 
 
Figure 3.32: LSM analysis of 293T cells transfected with eukaryotic expression constructs N1 and N5 in 
pDisplay and DREP used for DNA immunization experiments stained with 5 µg/ml 2F5 and anti-human 
AlexaFluor488 1:200. (A) pDisplay-N1. (B) DREP-N1. (C) pDisplay gp41. (D) pDisplay-N5. (E) DREP-N5. (F) 
untransfected 293T cells stained with primary and secondary antibody. 
 
Groups of five mice each were immunized three times with two shots containing 1 µg of plasmid 
encoding the codon optimized hybrid antigens for the mouse organism, the pDisplay vectors 
combined with 1 µg of plasmid encoding the murine GM-CSF adjuvant, in a three-week 
immunization schedule. Recombinant antigens N1 and N3 mixed with incomplete Freund´s 
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immunization, mice were sacrificed and finally bled three weeks after the last immunization in order 
to receive sufficient serum volume in order to test antigen specific antibody responses and 
neutralization of HIV-1NL4-3. Immune sera derived from mice which received the hybrid proteins as 
DNA vaccine did not recognize rgp41 expressed by E. coli. Immunizations with purified 
recombinant hybrid antigen N1 induced anti-rgp41 antibodies in three animals out of five 
immunized mice, two immune sera from mice which received N5 as immunogen reacted with 
rgp41. Sera were in further tested by Western blot analysis with cellular lysate of HIV-1NL4-3 infected 
C8166 cells to evaluate reactivity of serum to eukaryotically expressed HIV-1NL4-3 envelope proteins 
but no reactivity to gp41 or gp160 was detected. This surprisingly demonstrates low 
immunogenicity of the plasmid-encoded antigens in the mice model in contrast to previously 
published immunization studies (Brave et al., 2005; Ou-Yang et al., 2002; Rodriguez et al., 2012), 
although GM-CSF was co-immunized with the DNA vectors encoding hybrid proteins as an 
antibody stimulator. Control groups of mice which received prokaryotically expressed recombinant 
antigen could not develop a robust antibody response as it was the case in previous rat and guinea 
pig immunization regimens. 
Despite the low reactivity of immune sera against rgp41 and eukaryotically expressed gp41 
derivatives, sera of mice derived after the second immunization boost were tested in the TZM-bl 
neutralization assay. Immune sera from mice immunized with pDisplay or DREP encoding N1 did 
not inhibit of HIV-1NL4-3 infection to a greater extent compared to the preimmune serum, neither the 
immune serum derived from mice immunized with recombinant N1 protein. Marginally more than 
50% inhibition of HIV-1NL4-3 infection was mediated by sera diluted 1:20 and 1:40 derived from mice 
immunized with DREP expressing N5. Significant inhibition of virus infection by the immune serum 
sample of one animal immunized with N3 was also detected by the TZM-bl neutralization assay. 
Since this inhibition of HIV-1NL4-3 infection remained not stronger than the inhibition by sera of 
control animals immunized with empty (pDisplay) or EGFP expressing DREP vector and antibodies 
specific for rgp41 were absent in immune sera, this observed inhibitory effect was not antibody 
specific.  




Figure 3.33: TZM-bl neutralization assay of sera from mice immunized with plasmids pDisplay or DREP 
expressing hybrid proteins N1 or N5. Sera were used in two-fold dilutions from 1:20 to 1:80. 2F5 was diluted 
1:4, starting at a concentration of 50 µg/ml. The black and dotted cut-off line represents 50% of RLU 
measured for virus infection without inhibitory agents, the light grey cut-off line represent RLU value of 
preimmune serum at the 1:20 dilution. Medium indicates RLU negative control values of lysed TZM-bl cells 
without HIV-1NL4-3 virus particles. Error bars represent the standard deviation (n=2). 
 
In order to summarize the above mentioned results, immunization of hybrid proteins in the DNA 
immunization regiment expressed in vivo by two different vector systems did not induce rgp41 
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3.8 Testing of sera for reactivity to lipids  
Broadly neutralizing antibodies directed against the MPER of gp41 were controversially discussed 
to exhibit autoreactive properties (Haynes, 2005). Since the MPER was included in all hybrid 
proteins used as antigen for our immunization experiments, sera derived after these immunizations 
were screened for potential reactivity with two different lipid antigens (cardiolipin and 
sphingomyelin) although no inhibition of HIV-1 infection was observed. 
Binding of 2F5 and 4E10 to sphingomyelin or cardiolipin was tested as reference for reactivity of 
serum to both lipids. The anti-lipid ELISA showed binding of 4E10 to cardiolipin, whereas 2F5 
exhibited no affinity to both lipids (Figure 3.35) in contrast to previous reactivity to cardiolipin and 
other lipids (Haynes et al., 2005; Matyas et al., 2009b; Sanchez-Martinez et al., 2006a; Sanchez-
Martinez et al., 2006b).  
 
 
Figure 3.34: Detailed analysis of immune sera from rats or guinea pigs immunized with N1, N2 or N3 for 
reactivity against lipids. Dotted lines represent the cut-off value estimated by the mean value from a pool of 4 
preimmune sera plus three times the standard deviation. Error bars represent the standard deviation (n=3). 
 
As expected, none of the anti-sera derived from immunizations with recombinant hybrid proteins 
N1, N2, N3 the significantly reacted with sphingomyelin or cardiolipin, which is consistent with the 
fact that only antibodies binding to the FPPR and the 2F5 epitope in epitope mappings were 



















































































Figure 3.35: Analysis of bNAb 2F5 and 4E10 binding to cardiolipin and sphingomyelin. Error bars represent 
the standard deviation (n=3). 
 
Sera of rats, guinea pigs and one goat immunized with recombinant antigens in liposomes were 
also tested for reactivity to lipid antigens. Surprisingly, sera from guineapigs N1Lipg#3 and N1Lipg#4 
derived after the third immunization bound to cardiolipin but not to sphingomyelin (Figure 3.36A), 
although no MPER specific antibodies were observed or exhibited additional virus inhibiting 
properties. Immune sera of two other guinea pigs and one goat which received N1Lip did not bind to 
lipid antigens. Rat sera from animals which received N3Lip and N4Lip also did not react with 
cardiolipin or sphingomyelin (Figure 3.37). 
 
 
Figure 3.36: Analysis of immune sera from guinea pigs (g) or one goat (z) immunized three times with N1 in 
liposomes (Lip) for reactivity against lipids. Dotted lines (PI) represent the cut-off value estimated by the mean 
value the pool of 4 preimmune sera from guinea pigs or preimmune serum of one goat immunized with N1Lip 
plus three times the standard deviation. Error bars represent the standard deviation (n=3). 
 
Summarizing the results above, none of the immune sera obtained after immunization with 
recombinant hybrid protein N3 or N3 and N4 in liposomes bound to either one of the lipids tested. 
Despite two guinea pig immune sera obtained after immunization with N1Lip reacted positive with 
cardiolipin at serum dilutions of 1:100 and 1:400, none of the sera obtained from the other animals 






























































  Discussion 
69 
 
Figure 3.37: Analysis of rat (r) immune sera immunized four times with N3 (A) or N4 (B) in liposomes for 
reactivity against lipids. Dotted lines represent the cut-off values estimated by the mean value from a pool of 4 
preimmune sera (PI) or immune serum of one rats immunized four times with empty liposomes (Liposomes) 














































Cardiolipin Sphingomyelin Cardiolipin Sphingomyelin
A B
dilutions dilutions dilutions dilutions




4.1 Protection against HIV infection 
A vaccine, which is cheap to produce, easy to apply and to handle would be the best strategy to 
keep the HIV-1 epidemic in bay. This goal seems to be unachievable at the moment and thus 
prevention programs are substantial in all countries with HIV incidence. New infections can 
primarily be prevented with condoms and also protection of mucosal HIV-1 entry sites by 
microbicides or other pre-exposure prophylaxis has been brought to focus in the recent years. 
Microbicides are also an essential option for partial prevention, especially for women who live in 
poor settings, since cooperation of the male partner is not required (Vail et al., 2004). In addition to 
that, sufficient antiviral treatment for HIV-1 infected, pregnant women by treatment before, during 
and after birth is urgently necessary to prevent child infection. 
 
With regards to HIV-1 vaccine development, the most discussed question is still which part of the 
immune system contributes to clearance of the virus and to prevent infection. The opinions are 
diverse, one half of the scientific field believes in essentiality of a B-cell stimulating vaccine capable 
to elicit bNAbs (Douek et al., 2006; Letvin, 2006), since only those antibodies will prevent entry of 
the virus into CD4+ cells and inhibit replication and integration (Han et al., 2007). Others postulate 
that the induction of cytotoxic T-cells, capable to prevent virus infection and / or eradicate the virus 
rapidly after primary entry of the host would be essential for clearance of the virus (Makedonas and 
Betts, 2011; Plotkin, 2010). Another hypothesis implied protection depending on immunogenic 
tolerance and suppression of CD4+ T-cell activation to inhibit effective virus replication after primary 
host entry. This approach recently came to focus when an oral vaccine comprising inactivated SIV 
with immunomodulatory Lactobacillus plantarum induced protection against homologous or 
heterologous SIV challenge (Lu et al., 2012). Despite extensive discussions in the field, antibodies 
are the first wall for virus entry and should thus be induced by a potential preventive vaccine. 
 
4.2 Hybrid proteins used as immunogens 
Aim of this project was to implement an innovative strategy in order to generate hybrid proteins as 
antigens for a HIV-1 vaccine for stimulation of HIV-1 preventive antibodies. These immunogens 
were composed of the HIV-1 FPPR and MPER, grafted into a scaffold of the transmembrane 
protein of PERV. 
As a first step in the project, the design of hybrid proteins was accomplished by aligning the TM 
protein sequences of several HIV-1 clades and PERV strains (3.2, Figure 3.1). When comparing 
the subdomains of both TM proteins, p15E and gp41, a major difference in sequence length of 
different subdomains was observed. The gp41 intraviral tail comprises approximately the same 
number of amino acids as the corresponding ectodomain of the same protein. In contrast to that, 
the intraviral tail of p15E represents only one quarter of the whole TM protein, which might have 
implications on presentation of the MPER and distinct epitopes (Postler and Desrosiers, 2013). 
Besides discrepancies between gp41 and p15E in amino acid sequence composition and length of 
the subdomains, distinct homologies were observed (Figure 3.1). On basis of these alignments, 
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combination of HIV-1 and PERV TM protein sequences for hybrid proteins were optimized. 
Epitopes in the FPPR and MPER of p15E which have been recognized by PERV neutralizing sera 
derived from animals immunized with the ectodomain of recombinant p15E were substituted with 
corresponding FPPR and MPER regions in gp41.  
  
Two different hybrid proteins N1 and N2 have been designed and were expressed, purified and 
used for immunization experiments in rats and guinea pigs to evaluate the impact of remaining 
lipophilic sequences such as the FP and the transmembrane region. Despite extensive optimization 
of purification procedures, these proteins turned out to be insoluble under native conditions. The 
purification procedures were performed with denaturing buffers, which hampered evaluation of 
protein properties by SPR. It was assumed that both hybrid proteins aggregated in native buffers, 
since N1 and N2 formed monomers and dimers already under denaturing and reducing conditions 
(3.3.1, Figure 3.4) which did not migrate though native Page (data not shown). Nevertheless, both 
antigens were used for immunizations since protein features remained unclear in lipid environment 
of the adjuvant which was co-delivered with the antigens. Immunization of rats with N1 or N2 
induced similar anti-rgp41 and anti-FPPR antibody titers, although no anti-MPER antibodies were 
observed in sera from animals immunized with N1. The N1 hybrid protein comprised its FP, 
transmembrane domain and truncated intraviral tail from HIV-1 in contrast to corresponding p15E 
derived regions in hybrid protein N2. These differences in N-terminal and C-terminal sequence 
composition had an impact on MPER presentation as previously proposed and was shielded by 
other protein domains (Sun et al., 2008). MPER-specific antibodies induced by N2 immunization 
bound a long MPER-comprising peptide in ELISA analysis of immune sera, but none of the 15-mer 
peptides used for epitope mappings on both, pepspot membrane and mircroarray chip. With 
regards to this result, those gp41-specific antibodies might have been specific for a conformational 
epitope exhibited by the whole MPER region but was not presented on shorter peptides. Despite 
the presence of these MPER binding antibodies in immune sera after immunizations with N2, no 
inhibition of virus infection by immune sera or isolated IgG after immunization with N1 or N2 was 
observed.  
 
In order to improve solubility of the hybrid proteins, two additional antigens were designed. 
Solubility of hybrid proteins N3 and N4 was enhanced by deleting the dispensable FP, the 
transmembrane domain and the truncated intraviral tail. Although the proteins were not soluble in 
PBS without addition of N-Lauroylsarkosine, concentration of the detergent was reduced and 
enabled evaluation on non-reducing SDS-PAGE. N3 and N4 showed trimers and oligomers with 
absence of reducing agents in the gel, indicating a variety of protein conformations and thus potent 
presentation of various epitopes.  
Initial immunizations of N3 in guinea pigs and rats induced anti-rgp41 antibody responses 
comparable to those observed with N1 or N2. Detailed evaluation of anti-gp41 antibody responses 
showed the induction of FPPR binding antibodies in all immunized animals. Of note, anti-MPER 
responses were observed in six of eight immunized animals and epitope mappings of these 
antibodies demonstrated binding to the 2F5 epitope. Deletion of FP, transmembrane domain and 
the truncated intraviral tail thus might have had an effect on presentation of this neutralizing epitope 
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((Montero et al., 2012), since antibodies binding to this epitope were not observed after 
immunizations with N1 or N2.  
In addition to that, absence of antibodies binding to other epitopes in the MPER than to those of 
2F5 (ELDKWA, core epitope (L)DKW) were surprising. 2F5 exhibited higher apparent affinity in the 
binding affinity assay (SPR) to both antigens compared to that measured for 4E10, indicating a 
better accessibility of the 2F5 epitope than other MPER domains. Nonetheless, those immune sera 
or isolated IgG were not capable to inhibit HIV-1 infection tested with the TZM-bl neutralization 
assay used.  
Immunization of a rabbit with N3 co-delivered with Montanide as adjuvant induced a weaker anti-
gp41 antibody response compared to previous antibody responses observed after the previous rat 
vaccination. Detailed evaluation of HIV-1 TM protein-specific antibody responses demonstrated 
FPPR binding antibodies but no MPER specific antibodies, although MPER antibodies were 
detected in rats after two immunizations with N3 in combination with complete and incomplete 
Freund´s adjuvant, respectively. This immunization schedule with only one booster immunization in 
combination with a different adjuvant was insufficient to induce a potent anti-gp41 antibody 
response, although Montanide and Freund´s adjuvant was described to have comparable antibody 
responses in rabbits when immunized s.c. or i.m. (Leenaars et al., 1998). 
Neutralization assay TZM-bl Reporter Assay Real-time Assay p24 ELISA 
Cell type TZM-bl cells C8166 PBMC C8166 




  N3g#1 - - - - 
N3g#2 - - - - 
N3g#3 - - - - 
N3g#4 - - + - 
Table 4.1: Summary of neutralization assays performed with guinea pig sera obtained after the fourth 
immunization with N3. The table describes the assay readout, cells and HIV-1 used for the corresponding 
assay. (+) and (-) describe positive and negative results for neutralization measured with the cited 
neutralization assay. TZM-bl reporter assay and the real-time assay were performed by the applicant. The p24 
neutralization assay was performed by Dr. Steve Norley (RKI). 
Immune sera of guinea pigs and rats contained antibodies binding to the 2F5 epitope, but did not 
neutralize in the TZM-bl neutralization assay. Thus, sera were additionally tested in other 
laboratories for virus inhibiting capacity. No significant neutralizing effect of sera and isolated IgG 
after the fourth immunization was observed in our TZM-bl cell-based, the real-time based 
neutralization assay with C8166 cells and an additional assay, using quantification of p24 as 
indication for inhibition of virus infection with two laboratory adapted HIV-1 strains (HIV-1NL4-3, 
HIV-1MN). Only sera of guinea pig N3g#4 showed a weak virus inhibition in the PBMC based real-
time assay, although isolated IgG from this serum did not show any neutralizing effect (Table 4.1).  
 
Immune sera N3 immunized guinea pigs were in addition sent to David Montefiori´s laboratory 
(Duke University Medical Center, Durhem, USA) in order to test the sera with other neutralization 
assays since the outcome might differ when testing the same serum in different assays as it was 
previously proposed (Fenyo et al., 2009; Heyndrickx et al., 2012). Hence, the sera were tested in 
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two different assays (Table 4.2), SIVmac293 and MuLV (murine leukaemia retrovirus) were used to 
evaluate non-HIV-1 specific neutralization. 
Despite the fact that no significant neutralization was observed with our assays, all immune sera 
obtained after the fourth immunization of the four guinea pigs immunized with N3 showed a weak 
neutralizing effect in the engineered CEM (A3R5) cell-based neutralization (Table 4.2) assay 
(Montefiori et al., 2012). In this assay, immune sera were incubated with a pseudotyped HIV-1 
clade C virus (Hoffenberg et al., 2013) with moderate sensitivity to antibody-mediated neutralization 
and subsequently added to A3R5 cells (modified CEM cells). Interestingly, the immune sera of all 
guinea pigs immunized with N3 showed a weak neutralizing effect. It should be noted, that sera of 
guinea pigs N3g#1 and N3g#4 unspecifically neutralized the control virus (SIVmac239) to a minor 
extent but sera were defined as neutralizing if ID50 values were three times higher compared to the 
negative control. Since it was demonstrated that immunization with hybrid protein N3 induced 2F5 
binding antibodies, neutralization of a the clade C isolate CH58 was surprising since clade C 
viruses were shown to be resistant to 2F5 mediated neutralization (Binley et al., 2004) and no 
neutralization was observed with neutralization sensitive HIV-1 strains in previously performed 
neutralization assays. In addition to this observation, the HIV-1 strain TRO.11 was previously 
published to be a HIV-1 clade B virus and was tested sensitive to 2F5 mediated neutralization (Li et 
al., 2005), although a mutation in the core epitope ((L)DKW) was observed by sequence 
alignments of the MPER (Table 4.3) which was shown to cause resistance to 2F5 mediated 
neutralization. 
Neutralization 
assay TZM-bl Reporter Assay A3R5 Reporter Assay 
Cell type TZM-bl cells A3R5 (modified CEM) 




  N3g#1 + - - - + + + 
N3g#2 - - - - - - + 
N3g#3 - + + + + - + 
N3g#4 + - - - + + + 
Table 4.2: Summary of neutralization assays performed by David Montefiori´s laboratory (Duke University 
Medical Center, Durhem, USA) performed with guinea pig sera obtained after the fourth immunization. The 
table describes the assay readout, cells and HIV-1 used for the corresponding assay. (+) and (-) indicate 
positive and negative result for neutralization. 
Immune sera of the four guinea pigs were also tested at the Montefiori´s laboratory in a TZM-bl 
neutralization assay (Montefiori, 2009), using four different clade B viruses. In this assay, weak 
neutralization activity was reported for the immune sera of guinea pig N3g#3 tested against all four 
clade B viruses, whereas virus inhibition was not observed when tested with the control virus. 
These results were surprising since the immune serum of N3g#3 showed no neutralizing effect in 
the TZM-bl neutralization assay. The weak inhibition of virus infection by immune sera from guinea 
pigs N3g#1 and N3g#4 might have been due to cytotoxic effects on the cells, although this was 
also observed in the other assays. Neutralization by immune sera of guinea pigs N3g#2 and N3g#3 
was not mediated to antibodies binding to the 2F5 epitope but maybe due to FPPR-binding 
antibodies or a small population of antibodies binding to a conformational epitope.  
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Of note, corresponding preimmune sera derived from guinea pigs immunized with N3 were not 
tested in both neutralization assays performed at Montefiori´s laboratory due to low serum volumes 
and thus specific neutralization of immune sera could not be objectively proven. 
HIV-1 isolate clade Accession Number FPPR Sequence 
NL4-3 B AF324493 AAGSTMGAAS-M-TLTVQARQLLSDIVQQQ 
MN.3 B ADI62634 AAGSTMGAAS-V-TLTVQARLLLSGIVQQQ 
W61D-TCLA B HM215359 AAGSTMGAAS-I-TLTVQARQLLSGIVQQQ 
SS1196.1 B AAW64257 AAGSTMGAAS-M-TLTVQARLLLSGIVQQQ 
RHPA4259.7 B JN944944 AAGSTMGAAS-I-TLTVQARLLLSGIVQQQ 
TRO.11 B AAW64260 AAGSTMGAAS-V-TLTVQARLLLSGIVQQQ 
CH58 C Salazar-Gonzalez et al. 2009 AAGSTMGAAS-M-TLTVQARLLLSGIVQQQ 
HIV-1 isolate clade Accession Number MPER Sequence 
NL4-3 B AF324493 E-LL-E-LD-K-W-AS-LWNWF-N-IT-N-WLWYIK 
MN.3 B ADI62634 E-LL-E-LD-K-W-AS-LWNWF-D-IT-N-WLWYIK 
W61D-TCLA B HM215359 E-LL-E-LD-K-W-AS-LWNWF-S-IT-N-WLWYIK 
SS1196.1 B AAW64257 E-LL-E-LD-K-W-EN-LWNWF-S-IT-N-WLWYIK 
RHPA4259.7 B JN944944 E-LL-A-LD-K-W-AS-LWSWF-S-IT-H-WLWYIK 
TRO.11 B AAW64260 E-LL-E-LD-S-W-AS-LWNWF-D-IS-K-WLWYIK 
CH58 C Salazar-Gonzalez et al. 2009 D-LL-A-LD-S-W-KN-LWNWF-D-IS-R-WLWYIK 
Table 4.3: Comparison of FPPR or MPER sequences between different HIV-1 isolates. 
The next immunization study was performed in rats with 250 µg N3 and N4 (250 or 500 µg) in order 
to evaluate the variation in strength of antibody responses between different immunization studies 
and different antigens. N4 comprised a truncated p15E backbone compared to N3 including the 
HIV-1 FPPR at the N-terminal end of the protein and MPER located at the C-terminal end. Immune 
sera of four rats immunized with N3 induced comparable anti-gp41 antibody titers as after previous 
N3 immunizations of rats, although MPER-specific responses were lower. A moderate MPER-
specific antibody response was only observed in animal N3r#7. Immune sera obtained from the 
other N3 immunized rats in the same group contained low titers of MPER binding antibodies, 
although MPER-specific antibodies of all animals bound to the 2F5 epitope.  
Lower anti-MPER antibodies were surprising, since the same immunization regimen, route and 
adjuvant was used for previous vaccinations. The only difference between the two immunization 
experiments remained a marginally different purification procedure, using N-Lauroylsarkosine as 
detergent which is frequently used to isolate transmembrane proteins and was not reported to be 
immunoinhibitory (Bader et al., 2004; Bilello et al., 2011; Hobb et al., 2009). In addition to that, both 
bNAbs bound N3 with a higher affinity compared to N4 in SPR analysis, which might explain lower 
antibody titers after N4 immunization compared to those induced by immunization with N3. 
 
Immunizations with N4 induced similar titers of gp41-specific antibodies compared with antibody 
titers observed after immunizations with N3. Of note, anti-MPER antibody titers were higher 
compared to titers observed after N3 immunizations, although the recombinant proteins differed in 
terms of a 26 AA deletion at the N-terminal end of the p15E backbone (3.4.1, Figure 3.8). In 
addition to that, immunization of 500 µg antigen induced lower anti-gp41 titers than 250 µg, which 
originates maybe in exceeding the optimal threshold of antigen amount for the rat organism. 
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Furthermore, high antigen dosage can influence affinity of vaccine induced antibodies (Gonzalez-
Fernandez and Milstein, 1998) 
Nevertheless, immune sera of animals N4r#2, N4r#4 and N4r#7 exhibited a weak inhibition of 
HIV-1NL4-3 infection compared to the corresponding pre-immune sera in the TZM-bl neutralization 
assay. This was defined as false positive for animals N4r#4 and N4r#7, since isolated IgG from 
these immune sera in additional neutralization tests remained negative for inhibition of virus 
infection. One immune serum derived from animal N4r#2 after the third immunization (S3) was 
tested positive in the TZM-bl neutralization assay, as well as in the real-time-based neutralization 
assay, although IgG isolated from this serum were negative for inhibition of virus infection in the 
TZM-bl neutralization assay. This effect could have been restricted to a distinct population of 
antibodies, which did not bind to the Protein G column and was therefore not purified. A cytotoxic 
effect of the serum on the cells by itself was ruled out, since cytotoxicity of the serum was 
negatively tested in the realtime-based neutralization assay with simultaneous detection of the 
GAPDH housekeeping gene and remained negative. Further tests of this serum were not feasible 
due the fact that the remaining serum was used for the real-time based neutralization assay. 
Therefore, a second immunization experiment was performed in rats with the same immunization 
regimen.  
 
The second immunization regimen with hybrid protein N4 induced similar anti-gp41 titers compared 
with the previous immunization. Immune serum of one rat obtained after the third immunization 
showed significant virus inhibition, although this effect was not observed when IgG isolated from 
this serum were tested in the TZM-bl neutralization assay. This also might be explained by a 
cytotoxic effect of immune sera on the cells or inability to isolate potential neutralizing antibodies 
with the Protein G columns. This was not retrospectively tested since the remaining serum was 
used for IgG purification.  
 
Furthermore, a goat was immunized with N4 in order to obtain enough immune serum to isolate 
HIV-1 MPER-specific antibodies. The immune serum obtained after the third immunization inhibited 
infection of TZMbl cells more than 50% and clearly showed a neutralizing effect, although this 
effect was diminished when testing the immune serum obtained from the goat six weeks later 
without an additional immunization in between. CHR/MPER-specific antibodies were isolated, but 
did not inhibit HIV-1NL4-3 infection in the TZM-bl neutralization assay. Immune serum of the goat 
obtained after three and nine weeks after the third immunization was in contrast tested negatively 
in Christiane Moog´s laboratory (Strasbourg University, France) with a PBMC-based single round 
assay combined with laboratory-adapted HIV-1 X4 clade B strains (SF162 and QHO) and a 
macrophage-based neutralization assay tested with HIV-1Bal. In these assays, IC80% and IC90% 
values were provided as result for neutralization capacity of the immune sera and might not reflect 
the presence of very few or weakly neutralizing antibodies in the immune sera obtained after the 
third immunization. Immune sera were also tested negatively for toxicity in this PBMC-based assay, 
which supports the fact that the immune serum obtained after the third immunization with N4 
specifically inhibited virus infection, although this was not restricted to affinity purified CHR/MPER-
specific antibodies. One explanation could be that inhibition of virus infection was due to FPPR-
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specific or conformational antibodies which did not bind the recombinant CHR protein used for 
isolation of CHR/MPER-specific antibodies. The neutralizing effect of the immune serum three 
weeks after the third immunization might also have been due to FPPR-binding antibodies or 
antibodies against the backbone, mediating inhibition of virus infection by ADCC or ADCVI (Forthal 
and Moog, 2009) which were not isolated during CHR/MPER-specific antibody purification.  
 
With regards to these findings it can also be suggested that reduction of virus infection in rat or 
goat immune sera was caused by IgM or IgA antibodies which were previously proposed to 
likewise mediate neutralization (Bukawa et al., 1995; Yang, 2009). IgM or IgA antibodies were not 
purified with the Protein G column due to specificity for IgG antibodies. Although IgA antibodies are 
predominantly secreted at mucosal sites and serum concentrations remain relatively low in HIV-1 
infected individuals (Alexander and Mestecky, 2007; Mestecky et al., 2004; Wei et al., 2012), gp41-
specific IgA were previously demonstrated to effectively neutralize HIV-1 (Bomsel et al., 2011; 
Tudor et al., 2009) and to protect nonhuman primates against vaginal SHIV challenges. In addition 
to that, vaccination with vaccinia virus secreted gp120 induced neutralizing antibodies from the IgA 
type, already detected 12 days after the second immunization (Moody et al., 2012).  
IgM antibodies are early induced in responses to foreign antigen and serum concentrations 
decrease within days to weeks, which additionally might explain transient effect of the neutralizing 
capability three weeks after immunization (Yang, 2009). Furthermore, vaccine induced IgM were 
also previously shown to have antiviral activity (Sheppard et al., 2007) after vaccination with vector-
expressed gp120. Since gp120 is relatively easy to access in contrast to gp41 despite heavy 
glycosylation, gp41-specific neutralization by IgM could have been impaired by steric hindrance of 
the large antibody subclass by itself.  
In addition, evaluation of binding antibody by ELISA and Western blot was performed with 
polyclonal antibodies. All classes of antigen specific antibodies were detected in the serum and 
differentiation of antibody classes might have been missed out due to the use of polyclonal 
secondary antibodies in Western blot analysis and ELISA.  
 
4.3 DNA vaccination of hybrid proteins 
DNA delivery-based HIV-1 vaccines comprise certain advantages, such as simplified 
manufacturing, stability with regards to storage and distribution or low application volumes. 
Although DNA vaccination is typically performed in order to induce cellular immune responses, a 
small number of studies described additional stimulation of antibody responses in small mammals, 
capable of neutralizing HIV-1 (Pissani et al., 2012; Richmond et al., 1998; Wang et al., 1993; Ye et 
al., 2011). In this immunization regimen, two different expression vectors were used to present 
hybrid antigens N1 and N5 in context with the cellular surface and provide in vivo folding and to 
mimic native-like structures and potential trimerization of Env proteins. Hybrid protein N1 
comprised the FPPR, MPER and the transmembrane domain of HIV-1 since comparison of MPER 
immunogenicity was impaired when using a non-HIV-derived transmembrane domains. 
Furthermore, both antigens comprised the HIV-1 MPER which should have been presented in a 
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lipid context since the presence of the membrane influences the presentation of neutralizing 
epitopes (Montero et al., 2012).  
 
Figure 4.1: Schematic illustration of hypothetical conformations engaged by hybrid antigens N1 and N5, 
presented on the cellular surface after DNA vaccination. (A) and (C) represent the model of N1 and N5 in a 
hairpin-like conformation, (A) induced by insertion of the lipophilic fusion peptide (FP) and the transmembrane 
domain into the lipid bilayer (A) and/or (C) promoted by interaction of MPER and FPPR due to absence of the 
FP. 
 
Despite membrane-bound presentation of both hybrid proteins and accessibility of the MPER as 
demonstrated by laser-scanning microscopy with fluorescent labeled 2F5 and 4E10, gp41-specific 
antibodies specifically binding to prokaryotically produced recombinant gp41 were not detected 
after DNA vaccination. In addition to that, immune sera of mice also failed to bind to lysate of 
HIV-1NL4-3 infected 293T cells. Importantly, immune sera obtained after immunization with purified 
hybrid proteins, recognizing purified antigen did not react with lysate of lysate of HIV-1NL4-3 infected 
293T cells. This was surprising since it was expected that antisera of mice immunized with the 
DNA vaccine would recognize native Env although maybe denatured to some extend in reducing 
SDS-PAGE and acidic acid used for the Western blot membrane. Since neutralization assays of 
preimmune and immune sera obtained after the third DNA vaccination showed unspecific inhibition 
of virus infection, it was not assumed that HIV-1 specific and conformational antibodies were 
induced. Immune responses of mice after vaccination with hybrid proteins purified from bacterial 
expression were low overall (3.7), indicating an insufficient induction of antibody responses against 
gp41 thoughout the DNA-immunization study in mice. This was surprising, since mice are most 
frequently used for the induction of antibodies in DNA vaccination experiments (Bower et al., 
2004a; Bower et al., 2004b; Hutnick et al., 2011; Law et al., 2007; Ljungberg et al., 2002). In 
addition to that, strong antibody responses were previously induced by DNA vaccination with both 
vector systems in the mouse organism (Behrendt et al., 2009; Forsell et al., 2007; Nordstrom et al., 
2005). DNA vaccines able to induce HIV-1 neutralizing antibodies comprised mainly gp120-derived 
antigens and are often used in DNA/VLP (Buonaguro et al., 2007; Harari et al., 2008; Kamdem 
Toukam et al., 2012; Ye et al., 2010) or DNA/protein (Bower et al., 2004b; Law et al., 2007; Pissani 
et al., 2012) immunization regimens. This demonstrates that DNA vaccination provides potent 
priming in a heterologous vaccination design but immunization with DNA remained insufficiently 
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antigen might have boosted induction of antibodies in this study, although changed the focus on 
presented antibody epitopes due different antigen expression.  
 
4.4 Structure-based antigen design 
Extensive investigation of HIV-1 Env structures and conformations as proteins, peptides or distinct 
structural changes within Env caused by binding of bNAb have given insights on potential in-vivo 
situations during virus entry. One major step was the publication of the HIV-1 gp41 crystal structure 
including FPPR and MPER (Buzon et al., 2010). Gp41 refolds into a thermostabile six-helix-bundle 
(SHB) formation (Lu et al., 1995) with a coiled-coil interaction of the NHR and CHR, which is 
required for cellular and viral membrane fusion (Buzon et al., 2010; Melikyan et al., 2000). Although 
the NHR forms the inner homotrimeric subunit within the SHB, the FPPR is positioned towards 
outside of the SHB (Buzon et al., 2010). Accessible positioning of the FPPR in the recombinant 
hybrid proteins used for this immunization studies support predominant anti-FPPR antibody 
responses observed in immune sera despite unknown orientation of the FPPR in the hybrid 
proteins. 
The crystal structure of gp41 in SHB conformation (Buzon et al., 2010) supports previous 
observations of hydrophobic FPPR and MPER interaction (Noah et al., 2008) which was shown to 
increase 2F5 affinity to its epitope (Fiebig et al., 2009). Moreover, interaction of FPPR and MPER 
might form a conformational epitope which is required to induce MPER-specific bNAbs (Denner, 
2011). 
Conformation-based antigen design is currently proposed to be “the” approach to develop a 
vaccine, capable to induce bNAb. Since the majority of those bNAbs recognize conformational 
epitopes which are not presented on linear antigens, complex refolding procedures, trimerization or 
scaffold presentation of proteins or distinct epitopes (Guenaga et al., 2011; Ofek et al., 2010a; Qiu 
et al., 2011) seem to be the most reliable approach at the moment to mimic in vivo-like HIV-1 Env 
structures. This is often performed with support of computational algorithms to optimize amino acid 
composition of scaffolds for optimal presentation of epitopes (Correia et al., 2011; Correia et al., 
2010). These techniques might also be useful for peptides or proteins designed to present 
discontinuous epitopes as described for a recently isolated bNAb (Zhang et al., 2012) which 
neutralized 34% of primary isolates and binds to an epitope overlapping the CD4 binding site and 
the trimeric NHR of gp41. 
 
Despite these extensive investigations on structure based antigen design, potential structures 
engaged by antigens might be disrupted after presentation of degraded antigens together with 
MHC Class II on antigen presenting cells. Classical stimulation of B-cells is predominantly T-cell 
dependent, relying on antigen processing and presentation in context with MHC class II molecules. 
After vaccination with proteins or peptides, the antigen is internalized for peptide presentation in 
context with MHC class II molecules by antigen presenting cells. Antigens are endocytosed into 
antigen presenting cells and cleaved with the help of fusion with acidic lysosomes. Peptides loaded 
on MHC class II molecules were described to be 12 to 25 amino acids long (Sercarz and 
Maverakis, 2003). Although a peptide comprising 20 amino acids still can engage certain 
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conformations but (i) may form other conformations as presented in the whole protein or (i) distinct 
conformations might be disrupted by lysosomal proteases and the acidic environment. The peptide 
presented in context with the MHC class II molecule is recognized by T-helper cells which are 
subsequently activated. Those activated T-helper cells then provide the stimulatory signal to 
activate the B-cell (Parker, 1993). Despite this mechanism, B-cells can also be activated without T-
cell help by antigens which comprise distinct specificities. Type 1 of T cell-independent antigens, 
such as LPS or CpG, elicit polyclonal B cell activation via Toll-like receptors (Obukhanych and 
Nussenzweig, 2006). Activation of the B-cell are also triggered by T-cell independent antigens of 
Type 2, which are able to crosslink the Ig receptors on the B-cell surface and results in subsequent 
differentiation into plasma cells, switching from IgM production to IgG/IgA (MacLennan et al., 
2003). Thus, only T-cell independent activation of B-cells might induce antibody responses which 
are specific for certain conformations and evaluated before immunization, although these IgG 
responses were described as not as robust as those for T-dependent antigens (MacLennan et al., 
2003). Since protein aggregates were previously described to activate B-cells by crosslinking the 
B-cell receptor (Rosenberg, 2006), vaccination with the recombinant hybrid antigens might have 
triggered this pathway. 
 
In addition to the difficulties regarding initial antigen presentation, the development of potent 
neutralizing immune responses requires about one to three years and breadth of these antibody 
responses is correlated with time after primary infection (Sather et al., 2008). Thus it can be 
suggested, that prolonged and consistent antigen stimulation is required for affinity maturation 
(Stamatatos et al., 2009; Walker and Burton, 2010) since bNAbs comprise about 10% to 30% of 
somatic mutations in the heavy chain (Saphire et al., 2001; Walker et al., 2009; Wardemann and 
Nussenzweig, 2007). Of note, early B-cell ancestors have low reactivity to HIV-1 Env (Bonsignori et 
al., 2011; Mouquet et al., 2010; Pancera et al., 2010), although a recent study proposed binding of 
the founder virus by the predicted, unmutated ancestor cell (Haynes et al., 2012; Ma et al., 2011). 
The prolonged antigen stimulation to achieve sufficient affinity maturation of corresponding 
antibodies might be enabled by constant expression of the antigen by a replication competent 
vector, although this approach will be difficult to implement for human use due to safety issues.  
 
4.5 Are MPER-specific bNAb autoreactive? 
Broadly neutralizing antibodies develop in about 2% of HIV-1 infected individuals after at least 
several months (Euler and Schuitemaker, 2012; Mikell et al., 2011; Sather et al., 2008). One of the 
main reasons for the seldom appearance of such antibodies was controversially discussed to be 
eliminated by natural B-cell tolerance mechanism to self-antigens, especially to lipids (Alam et al., 
2007; Haynes, 2005; Matyas et al., 2009a; Sanchez-Martinez et al., 2006b; Scherer et al., 2007).  
B-cells reactive to self-antigen with or without extended CDRH3 loop appear frequently (about 70-
75%) and are eliminated or inactivated by a number of physiological mechanisms down to a 
percentage of about 20%, which circulate in the blood  (Meffre et al., 2001; Shiokawa et al., 1999; 
Wardemann and Nussenzweig, 2007). Thus, the repertoire of mature and naïve B-cells, able to 
respond to antigens mimicking auto-antigenic peptides may be in combination with lipids remains 
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relatively small. Furthermore, the process of antigen-induced somatic hypermutation for the 
development of high-affinity antibodies can also lead to self-responsive B-cells (Mietzner et al., 
2008; Tiller et al., 2007). Naïve B-cell clones express the same Ig molecule with the same variable 
region on the membrane, which is used as antigen receptor. After binding to the corresponding 
antigen, the B-cell undergoes activation which is also described as clonal selection, predominantly 
after receiving the additional signal from a T-helper cell. If a naïve B-cell did not recognize a distinct 
antigen, it dies within a few days, which explains the high turnover of circulating B-cell populations. 
In addition to this mechanism, somatic hypermutation increases the affinity of produced antibodies 
after primary activation of the B-cell (Euler and Schuitemaker, 2012) which might then be depleted 
from the repertoire.  
 
One particular characteristic of bNAb was defined as an unusual extended complementary 
determining region in the heavy chain (CDRH3) which is induced by this somatic hypermutation. In 
case of gp120 specific bNAb, for instance PG9, comprise a hammerhead-like extended CDRH3 
which “dives” through the glycan shield for interaction and binds to the stem of the surface 
envelope protein (Ringe et al., 2012). PGT 141 also comprises an extended CDRH3 loop and a 
beta-hairpin at the tip to reach the protein beneath its glycan shielded surface, although reactivity to 
self-antigens was not detected (Walker et al., 2011). Thus, gp120-specific bNAbs have found a 
way to circumvent viral defence mechanism of glycosylation by direct interaction, but do not exhibit 
polyreactivity in the first place. On the other hand,  the gp120-specific bNAb 1b12 also bound to a 
number of lipid antigens, such as cardiolipin or phosphatidylserin, despite the fact that the epitope 
of 1B12 is not located in close proximity to the lipid surface of the virion (Haynes et al., 2005). 
 
When focussing on MPER-specific bNAb, 2F5 and 4E10 also were reported to exhibit polyreactivity 
and to react with self-antigens. The unusually long CDRH3 loop was described for both bNAb with 
regards to this issue (Cardoso et al., 2005; Ofek et al., 2010b), which was proposed to enable the 
antibody´s access to the hidden epitope located in the MPER. The mechanism of  primary 
interaction with the lipid membrane and  subsequent engagement with the MPER binding site 
seems reasonable in order to diffuse into the viral membrane with the aromatic residues in the long 
CDRH3 loop and to access the binding site in a better way (Alam et al., 2007; Buzon et al., 2010). 
Of note, MPER-specific bNAbs with a long CDRH3 loop undergo negative selection, which was 
previously demonstrated for 2F5 (Verkoczy et al., 2010) and mutations in the CDRH3 loop 
abrogated neutralization of HIV-1 and lipid binding (Alam et al., 2007). 
In contrast to these findings, the bNAb D5 does not comprehend an extended CDH3, although 
neutralization capacity also seems limited (Miller et al., 2005; Sabin et al., 2010). The recently 
identified bNAb CAP206-CH12 displays similarities with other MPER specific antibodies. The 
antibody comprises an extended CDR3 loop but was surprisingly not shown to be polyreactive 
(Morris et al., 2011). 
Taken toghether, there are indications that bNAb comprise distinct structural abnormalities, such as 
extended CDRH3 loops and polyspecific reactions, although these structural and behavioral 
abnormalities can not be applied to all bNAbs (Huang et al., 2012).  
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Although the induction of such polyreactive bNAb during HIV-1 infection demonstrates that such 
antibodies can develop, it cannot be excluded that B-cells reacting with the recombinant hybrid 
antigens or epitopes from these proteins were depleted from the repertoire by B-cell tolerance 
mechanisms. Although antisera derived after immunizations with hybrid antigens did not show 
significant inhibition of HIV-1 infection, those sera were screened for the induction of 
autoantibodies, binding to lipid antigens: cardiolipin and sphingomyelin. 
None of the rat immune sera derived after the fourth immunization with hybrid antigens N1, N2 or 
N3 reacted with cardiolipin or with sphingomyelin. Particularly with regard to the fact that some 
immune sera of rats immunized with N3 recognized the 2F5 epitope and 2F5 did not bind both 
lipids tested, this result was as expected. The findings concerning the interaction of 2F5 with lipids 
are controversially discussed (Haynes, 2005; Matyas et al., 2009a; Sanchez-Martinez et al., 2006a; 
Sanchez-Martinez et al., 2006b), although binding of 2F5 to sphingomyelin and cardiolipin was 
most likely due to large amount of coated lipid and high antibody concentration in the assay 
proposed by Haynes and colleagues (Haynes, 2005).  
The immune serum of one guinea pig immunized with N3 (N3g#3), which inhibited HIV-1 clade B 
primary isolate infection in the TZM-bl neutralization assay to some extent as tested by Montefiori´s 
laboratory, did not bind lipid antigens. 
 
In contrast to these findings, a MPER-specific bNAb 10E8 was recently isolated from a HIV-1 
infected individual, showing broader neutralization capacity compared to all previous identified 
MPER binding bNAbs 2F5 and 4E10 (Huang et al., 2012). In addition to that, frequency of 
antibodies with 10E8-like specificities was described with 8% of all tested sera derived from 
infected individuals and thus more frequently compared to the frequency of other MPER binding 
bNAbs (Sather et al., 2008; Sather and Stamatatos, 2010; Shen et al., 2009). 10E8 also comprises 
an extended CDRH3 loop as proposed for other bNAbs and binds an epitope overlapping the 4E10 
binding site (critical amino acids in bold: NWFDITNWLWYIR). Phosphatidylcholin-cardiolipin 
liposomes were surprisingly not bound by 10E8, despite the specificity to an epitope located even 
closer to the viral membrane than the 4E10 binding site. In contrast to the two other MPER-specific 
bNAb 2F5 and 4E10, the CDR3 loop of the antibody seems to interact directly with the binding site, 
has a smaller interaction site with the lipid membrane and was thus proposed to be less reactive to 
lipid surfaces. 
With regard to the findings that this bNAb did not bind to lipids and other autoantigens, these 
distinct properties of 10E8 may refute the hypothesis that MPER-specific are autoreactive due to 
close proximity of the antigen to the lipid virion surface. This was also supported by recent findings 
that the reactivity profile of MPER bNAb 2F5, 4E10 and Z13 largely differ from those of 
autoreactive antibodies derived from patients with anti-phospholipid-syndrom and lupus 
erythematosus (Singh et al., 2011). 
 
4.6 Liposomes as vaccine carrier 
The vast majority of antigens require T-cell dependent help, only a small number of antigens trigger 
T-cell independent activation of B-cells. Bacterial polysaccharides, polymeric proteins and LPS are 
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such antigens, comprising repetitive structures which are able to stimulating B-cells to elicit low-
affinity germ-line antibody responses in rodents without undergoing affinity maturation (Cerutti et 
al., 2013). Furthermore, liposomes possess these characteristics of Type 2 T-cell independent 
antigens to stimulate B-cells through the T-cell independent mechanism (Li et al., 2001). One major 
advantage of this is potential B-cell activation without CD4+ T-cell help, depending on denseness of 
conjugated or surface adsorbed antigen (Watson et al., 2012). This provides presentation of 
conformational epitopes maybe engaged by the liposome-attached antigen in contrast to processes 
and denatured peptides presented in context with MHC class II molecules. 
 
Liposomes in combination with MPLA were used in these immunization regimens to induce a 
potent anti-HIV-1 antibody response. The recombinant hybrid protein N1 comprised the TM domain 
and was thus primarily used for immunization experiments. Surprisingly, immunizations with N1Lip 
did not induce detectable anti-gp41 antibody responses in the immunized goat and low antibody 
titers in immunized rats although surface associated antigens were proposed to show potent 
antibody responses (Watson et al., 2012) with conformational binding properties (Dennison et al., 
2011a). Concentrations of N1Lip in both batches were measured prior immunizations and 
administered at same concentrations as used for immunization regimens with pure recombinant 
protein. SPR analysis of liposome preparations was planned to evaluate the protein´s orientation 
on the surface of the liposomes and antigen accessibility. However, SPR analysis could not be 
performed for binding analysis with mAb 2F5 since both liposome batches formed aggregates in all 
tested solvents.  
Liposome formulations were also prepared by Polymun with hybrid antigens N3 and N4, expecting 
adsorption on the surface of liposome since both antigens comprised neither FP nor the 
transmembrane domain. Anti-rgp41 titers after immunization with either N3Lip or N4Lip were higher 
compared to N1Lip immunizations, whereas it cannot be excluded that distinct proportions of hybrid 
antigens were not adsorbed to the liposomes and thus more accessible to the immune system. 
Aggregation and further shielding of potential antibody epitopes might further prohibited antibody 
responses, or antibodies were maybe only directed against the p15E backbone although p15E-
specific antibody responses remained low after primary hybrid protein immunizations, since 
immune sera after immunization with recombinant hybrid antigens were also tested for reactivity to 
p15E derived peptides in an additional microarray (data not shown). Orientation of the recombinant 
protein is not predictable during liposome preparation. The proteins might have been orientated 
towards the lumen of the liposomes or completely entrapped and were thus not accessible for B-
cell recognition and activation despite some disrupted liposomes.  
 
With regard to previous findings that neutralizing antibodies induced by derivatives of gp41 in 
liposomes induced antibodies that bound to the 2F5 and 4E10 epitopes as well as to lipid epitopes 
(Karasavvas et al., 2008; Matyas et al., 2009b), antisera obtained after hybrid protein/liposome 
immunizations were in addition tested for reactivity with lipid antigens cardiolipin and spingomyelin. 
Immune sera of two guinea pigs immunized with N1Lip bound to cardiolipin but not to sphingomyelin 
(3.8, Figure 3.36A), which was controversially discussed to be recognized by the bNAb 4E10 (Alam 
et al., 2007; Haynes, 2005; Haynes et al., 2005; Matyas et al., 2009a; Scherer et al., 2007). Due to 
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the fact that measurable anti-MPER were not observed in those antisera, this recognition was 
maybe restricted to lipid-specific antibodies induced by liposome immunization but this was 
unfortunately not evaluated during this study. On the other hand, immune sera obtained after N3Lip 
or N4Lip immunization unspecifically inhibited HIV-1NL4-3 infection (3.6, Figure 3.27B) but did not 
bind to the tested lipids, showing that virus inhibition was not caused by cardiolipin or 
sphingomyelin binding antibodies. Despite that, cytotoxic effects of immune sera were partially 
excluded by the real-time neutralization assay. Taken together, immunization of hybrid antigens 
with liposomes were poorly immunogenic, especially with regards to immunogenicity of the MPER 
and did not induce neutralizing antibodies. In order to avoid potential anti-lipid antibodies which 
might exhibit some autoreactivity to human lipids, this approach for vaccination development 
should be re-evaluated. 
 
4.7 Measuring neutralization with in-vitro assays 
The efficacy of a vaccine with regards to induction of neutralizing antibodies can only be evaluated 
by testing immune sera after vaccination in a neutralization assay prior challenge experiments in 
primates. A wide range of neutralization assays with certain variants are currently applied to detect 
antibodies in serum responsible for inhibiting HIV infection, mainly differentiating within the used 
reporter system. Most assays are complex and require from three days to more than a week 
incubation time, which can be the source of small errors and increased deviation in inter-assay 
comparability (Heyndrickx et al., 2012; Polonis et al., 2008; Polonis et al., 2009). These variable 
parameters are preparation of virus, virus dose, target cells and growing density, concentration of 
antibodies, treatment of sera before the assay (complement deactivation) or freeze/thaw cycles of 
the tested immune sera. Thus, standardization of neutralization assays is required to allow 
comparable evaluation of potency and quality of neutralizing antibodies in serum. Two of the most 
critical parameters in the assay are the choice of target cells and decision for pseudotyped viruses, 
laboratory adapted HIV-1 strains or primary isolates. This step is critical to evaluate since cell line-
based model systems might not reflect the situation in vivo, although these assays are easier to 
standardize (Fenyo et al., 2009) compared to PBMC-based assays. The choice of virus is also 
challenging since laboratory adapted strains are more sensitive to neutralization compared to 
primary isolates (Daar et al., 1990; Mascola et al., 1996).  
Neutralization of HIV-1NL4-3 by immune sera after vaccination was initially measured with a TZM-bl 
cell-based in these immunization studies. Sensitivity of the this neutralization assay remained high 
since 2F5 was used as positive control and neutralization of the reference antibody could be 
measured down to a concentration of 2.5 µg/ml. Measurement of high sensitivity on the other hand 
might bear the risk of detecting inhibition of HIV-1 infection which is maybe not antibody mediated. 
Thus, potential neutralizing sera were further tested in a real-time based neutralization assay with 
either stimulated PBMCs or another lymphocyte cell line to address possible cytotoxic effects of 
immune-sera which were not distinguished from antibody-mediated neutralization in the TZM-bl 
neutralization assay. One of the main disadvantages of PBMC-based neutralization assays might 
be reproducibility due to non-homogenous stimulation or variability of the donor cells (Trkola et al., 
1999).  




Of note, a hybrid protein approach comprising p15E and the MPER of gp41 in order induce 
neutralizing antibodies was proposed years ago by Luo et al. (Luo et al., 2006).  In this study, two 
different antigens were designed, one by substitution of the E2 region in p15E by the MPER of 
gp41 and the other one by fusion of the MPER to the C-terminal end of p15E. Immunization of 
rabbits induced neutralizing antibodies in three out of nine animals measured with pseudotyped 
clade B viruses. Of note, immune sera of rabbits immunized with p15E tested in the neutralization 
assay also neutralized HIV-1 up to 50%, showing non-HIV-1 specific inhibition of virus infection. In 
their neutralization assay, 50% inhibition of virus infection was observed with an antibody 
concentration of 0.03 µg/ml, although our ID50 was measured at 2 µg/ml. It is not described how 
much pseudotyped virus was used for the assay. Since (i) pseudoviruses were described to be 
easier to neutralize (Fenyo et al., 2009) and (ii) ID50 values strongly depend on virus type and 
concentration, both assays are difficult to compare. 
 
The sensitivity of neutralization assays might be the restricting factor since the protective antibody 
level is unknown, especially at mucosal sites. Passive immunization experiments in non-human 
primates shed some light on concentrations of bNAb required to protect from HIV-1 challenge. A 
comparative assay of HIV-1 positive sera and passive immune monkey sera demonstrated that 
serum of protected monkeys showed a 50% reduction of infection (ID50) at dilutions ranging from 
1:125 to 1:300 which seem comparable to the levels detected in sera of infected individuals 
(Hessell et al., 2009a; Mascola and Montefiori, 2010).  
 
A whole new field developed in the recent years in order to detect low titers of neutralizing 
antibodies in serum or even in mucosal tissue or lavage fluids of vaccinated individuals. The 
knowledge about protective titers also increased in the last 10 years, thus predominantly focusing 
on physiological in-vivo concentration of virus at mucosal sites and antibodies required for 
neutralization (Mestecky et al., 2011). The most prominent example for that represents detection of 
IgGs in vaginal fluids of macaques with neutralizing properties and ADCC activity after 
immunization with gp41 subunit antigens embedded in virosomes which was already approved for 
human use (Bomsel et al., 2011).  
 
The different outcomes of 16 neutralization assays using a panel of viruses and different target 
cells was extensively evaluated by the NeutNet Report (Fenyo et al., 2009), testing sensitivity, 
standardization and variability when using PBMC- or engineered cell-line-based assays, 
pseudotyped viruses or primary isolates in 16 reference laboratories. Measuring in vitro 
neutralization reveal first hints for protection in vivo – although this correlation is not always 
applicable. The main outcome of the study showed that neutralization assays are difficult to 
standardize. In order to evaluate the effect of a vaccine in model organisms with regard to induction 
of neutralizing antibodies, different neutralization assays with a panel of viruses and different target 
cell was recommended (Fenyo et al., 2009; Heyndrickx et al., 2012).  
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4.8 Prevention from HIV-1 infection 
A large number of different approaches to establish a defending system able to prevent HIV-1 
infection have been proposed in the recent years. Since the general approach to achieve protection 
by vaccination with HIV-1 derived proteins, peptides, expressed in vivo from DNA-vectors or VLPs 
were not very successful, rethinking and evaluation of other approaches gained attention in the 
whole vaccine field.  
 
One example of new approaches thinking outside the box was a recent study performed by Lu and 
colleagues (Lu et al., 2012). Since initial virus replication after infection potentially depends on 
activation of CD4+ T-cells in case of X4 virus this replication may be prevented by inhibition of this 
activation (Andrieu and Lu, 1995; Fauci, 1996). Administration of anti-inflammatory agents 
prevented macaques from SIV infection after mucosal challenge which was hypothesized to be 
caused by inhibition of immune activation (Li et al., 2009). With regards to this study, an oral 
vaccination regimen in Chinese macaques comprising bacteria which favour immune tolerance and 
inactivated SIV was performed (Lu et al., 2012). The vaccine induced regulatory T-cells, 
suppressing in vivo CD4+ T-cell activation and induced in all but one animal sterile protection after 
high dose intrarectal challenge. These results are remarkable since animals were immunized only 
once with an antigen which was simply to produce and to deliver.  
 
Another interesting idea to prevent HIV-1 infection was proposed by Balazs and colleagues (Balazs 
et al., 2012) by immunization of humanized mice with a specialized adeno-associated virus vector, 
optimized for the expression of human IgG. Mice were immunized with the vector, expressing five 
different bNAbs (2F5, 4E10, b12, 2G12 or VRC-01). Only mice expressing b12 and VRC-01 were 
protected after intravenous challenge with HIV-1, mice expressing the other antibodies were partly 
protected, maybe due to lower antibody expression levels in vivo. Measuring antibody 
concentration expressed after one-time immunization with the antibody-expressing vector 
demonstrated continuous high level expression of antibodies over twelve weeks, showing long-
term effectiveness. With regards to only one vaccination required and relatively persistent 
production of bNAb over a distinct period of time, this approach seems applicable for further 
preclinical trials.  
  
Although a vaccine would be the golden goal to prevent transmission of HIV, a new drug came to 
focus in the past year. Tenofovir in combination with emtricitabine are nucleoside and nucleotide 
analogue reverse transcriptase inhibitors (NRTIs), blocking the viral reverse transcriptase, 
respectively. The active component tenofovir disoproxil fumarate in combination with emtricitabine, 
trade name Truvada ®, was introduced to the European market in 2005 for antiretroviral therapy 
but only in combination with other therapeutic agents for the treatment of HIV infection. In addition 
to this indication, tenofovir was tested as vaginal gel in the CAPRISA 004 trial. The reduction of 
HIV-1 infection among African women when used before and after sexual exposure (Abdool Karim 
et al., 2010) was promising, although the efficiency was reduced when the setting was re-tested by 
the NIH. Truvada ® was also introduced to the US market in July 2012 for the indication of 
  Summary 
86 
 
prevention in HIV-negative adults, especially for homosexual or heterosexual sero-discordant 
couples. Effectiveness of Truvada in humans was reported to be 75% protective in discordant, 
heterosexual partners with a maximum of 90% protection when the drug was taken on regular 
bases (Donnell et. al 2012, reported at CROI), which supports the previous studies (Baeten et al., 
2012; Mujugira et al., 2011). This indication was controversially discussed in the scientific field and 
the media. One package of the medication is estimated with 800 Euros and therefore limited to 
countries which can afford these high costs of treatment and prophylaxes.  
 
With regards to these findings, a combination of vaccine and PrEP might also work synergistically 
to additionally reduce the risk of HIV-1 infection (Excler et al., 2011). Since vaccines seem to be 
more effective in challenge regimens using repeated low dose applications of virus, PrEPs can 
already reduce virus concentration prior contact.  Nevertheless, despite large improvements of 
microbicides, a vaccine capable to prevent infection during a greater period of time is inevitable. 




A vaccine against HIV-1 to keep the pandemic in bay is one of the major goals in vaccine 
development. Although the scientific field of vaccine development is largely supported with 
extensive fundings, attempts to design a vaccine to induce potent protection only remained 
successful in the macaque model, but not in human trials. In order to address this aim, different 
hybrid antigens were designed, comprising sequences of the HIV-1 and PERV transmembrane 
protein. P15E, the transmembrane protein of PERV was used as scaffold protein, since 
immunization with the ectodomain of different gammaretroviruses resulted in the induction of 
neutralizing antibodies in various animal species. These neutralizing sera recognized epitopes 
located in the MPER and in the FPPR of p15E. Alignments of gp41 and p15E showed a sequence 
homology within the MPER (F/YEGWFN in the case of gammaretroviruses and NWFNIT, the 4E10 
epitope, in case of HIV-1) despite the evolutionary distance between PERV and HIV-1. Based on 
these findings, both epitope regions of p15E recognized by neutralizing sera were substituted by 
corresponding sequences derived from gp41 of HIV-1. One gp41 sequence contained the epitopes 
of 2F5 and 4E10 in the MPER and the other corresponded to the FPPR. Structural interaction of 
the MPER and the FPPR had been suggested as a reason for an increased binding of 2F5 to its 
epitope in the presence of peptides corresponding to the FPPR. In addition, a direct interaction of 
FPPR and MPER sequences during infection and a stabilization of the 6-helix-bundle formation by 
peptides corresponding to the MPER and FPPR have been demonstrated. These results allow 
speculations that an interaction of the FPPR with the MPER may be required to induce neutralizing 
2F5-like and 4E10-like antibodies. 
 
On the basis of above mentioned considerations, four different recombinant hybrid proteins (N1, 
N2, N3, N4) were designed, produced by E. coli overexpression and purified up to a purity of 95%. 
These four antigens were used for immunization studies in guinea pigs, rats, goats and one rabbit 
in a three week immunization regimen. Humoral antibody responses were evaluated after each 
immunization with focus on anti-gp41 specific binding antibodies and antibody recognition sites 
within gp41. Immune sera were furthermore tested for inhibition of HIV-1 infection.  
Immunization studies with recombinant hybrid proteins N1 or N2 induced antibodies predominantly 
binding to the FPPR. Weak MPER-specific antibody responses were observed in rat sera after 
immunization with N2, these immune sera did not inhibit HIV-1NL4-3 infection. Immunization of 
guinea pigs, rats and one goat with N3 or N4 also induced antibodies binding to the FPPR of gp41, 
but also to the 2F5 epitope (ELDKWA) located in the MPER. Immune sera of guinea pigs and rats 
immunized with N3 did not show any inhibition of virus infection as tested in the TZM-bl 
neutralization assay. Although immune sera of rats and the goat immunized with N4 also 
recognized the same epitopes as after immunization studies with N3, immune sera of one rat and 
the goat showed a weak neutralizing effect after the second boost. However, IgG or CHR/MPER-
specific antibodies isolated from these immune sera did not neutralize HIV-1NL4-3.  
 
Nonetheless, the strategy of hybrid proteins used as antigens was successful in focusing the 
antibody response towards the desired MPER epitope and immune sera after vaccination with N4 
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showed a weak neutralizing effect. Specific investigations regarding the mechanism of HIV-1 
neutralization mediated by antibodies after immunization with p15E may contribute to improvement 
of hybrid protein design and thus the likelihood to induce potent HIV-1 neutralizing antibodies. 




Eine der größten Herausforderungen in der Impfstoffentwicklung weltweit ist die Entwicklung eines 
Impfstoffs gegen HIV-1 um damit die HIV-1 Pandemie einzudämmen ist. Obwohl hohe Summen für 
Forschungsmitteln auf diesem Gebiet investiert werden, konnte bis heute kein Antigen und kein 
effektiver Immunsierungsplan gefunden werden, welche die Infektion mit dem Retrovirus komplett 
verhindern kann. In dieser Arbeit wurde eine Strategie gewählt, die auf Immunisierungsstudien mit 
Hybridproteinen basiert. Für diese Studien wurden redombinante Hybridproteine produziert, die 
aus Sequenzen des transmembranen Hüllprotein von HIV-1 und jenem des porcinen endogenen 
Retrovirus (PERV) bestehen. Das transmembrane Hüllprotein p15E von PERV wurde hier als 
Proteingerüst verwendet, da in Immunisierungsstudien mit der Ektodomäne von p15E in 
verschiedenen Tierspezies die Induktion von neutralisierenden Antikörpern gezeigt werden konnte. 
Jene PERV neutralisierenden Seren erkannten sowohl Epitope in der fusionspeptid-proximalen 
Region (FPPR), als auch in der membrane-proximalen externen Region (MPER) des 
transmembranen Hüllproteins. Alignments von gp41 und p15E zeigten eine Sequenzhomologie in 
der MPER (F/YEGWFN bei PERV und NWFNIT, im 4E10 Epitop bei HIV-1) trotz unterschiedlicher 
Evolution beider Retroviren. Aufgrund dieser Sequenzhomologie wurden jene Epitope in der FPPR 
und MPER von p15E, die von neutralisierenden Seren erkannt wurden, durch korrespondierende 
Sequenzen in gp41 ersetzt. 
 
Ziel dieser Arbeit war es, Immunisierungsstudien mit diesen Hybridproteinen durchzuführen und 
die induzierte Antikörperantwort zu charakterisieren. Hierfür wurden vier verschiedene 
Hybridantigene (N1, N2, N3, N4) konstruiert, in E. coli exprimiert und bis zu einer Reinheit von 95% 
aufgereinigt. Diese vier Antigene wurden für Immunisierungsstudien in Meerschweinchen, Ratten, 
Kaninchen und Ziegen verwendet, wobei die Tiere in einem 3 Wochenabstand immunisiert wurden. 
Nach jeder Immunisierung wurden die Antiseren der Versuchstiere auf die Induktion von HIV-1 
spezifischen Antikörpern untersucht, sowie die Epitope jener Antiköperpopulationen bestimmt. 
Zusätzlich wurden die Seren auf virusinhibierende Wirkung von HIV-1 untersucht. 
Immunsierungen mit N1 oder N2 induzierten eine FPPR-fokussierte Immunantwort in Ratten und 
Meerschweinchen. MPER-spezifische Antikörper konnten nur in N2 immunisierten Ratten 
festgestellt werden, jedoch konnte keine HIV-1 neutralisierende Wirkung der Immunseren nach der 
Immunisierung mit den Hybridproteinen N1 oder N2 nachgewiesen werden. Immunisierungen von 
Meerschweinchen, Ratten und einer Ziege mit den Hybridantigenen N3 und N4 induzierten FPPR 
spezifische, sowie MPER bindende Antikörper, die das gleiche Epitop erkannten wie der 
breitneutralisierende Antikörper 2F5. Immunseren oder isolierte IgGs von Meerschweinen und 
Ratten zeigten keine Inhibition der HIV-1NL4-3 Infektion in den TZM-bl und C8166 Zell-basierten 
Neutralisationsassays nach Immunisierung mit N3. Nur für das Immunserum eines 
Meerschweinchens konnte eine schwache Neutralisation in dem PBMC Neutralisationsassay 
nachgewiesen werden, allerdings nicht für die isolierten IgGs aus diesem Immunserum. Trotzdem 
die Immunseren von Ratten und einer Ziege nach der Immunisierung mit N4 die selben Epitope 
erkannten wie nach den Immunisierungstudien mit N3 konnte eine virusspezifische, schwache 
Neutralisation von HIV-1NL4-3 durch ein Rattenserum und dem Ziegenserum nach der dritten 
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Immunisierung mit N4 gezeigt werden. Dieser neutralisierende Effekt wurde allerdings nicht durch 
IgG oder MPER-spezifischen Antikörpern vermittelt, welche aus dem Serum isoliert wurden.  
Obwohl die Seren nach Immunisierung mit N4 nur einen schwachen neutralisierenden Effekt 
zeigten, stellt der Ansatz von Hybridproteinen einen innovativen Ansatz zur MPER gerichteten 
Vakzinentwicklung dar. Die genauere Untersuchung des Mechanismus zur Induktion von 
neutralisierenden Antikörpern durch Immunisierung mit dem Transmembranprotein p15E könnte 
dabei helfen, weitere Hybridproteine zu optimieren und damit eine stärker neutralisierende 
Immunantwort zu erlangen.   
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Maps of hybrid protein expression vectors for DNA immunization (DREP) 
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Real-time based neutralization assays with sera from animals immunized 
with N3 
 
A.1: Neutralization assays based on PHA stimulated PBMC (A) and C8166 cells (B,C) with sera from animals 
immunised with N3 (A,B) or N4 in different dilutions (1:20 and 1:50) (C). Corresponding preimmune sera (PI) 
or animals immunized with PBS only (CTRL) were used as negative control sera. Isolated and concentrated 
IgG from sera of animals immunised with N3 were diluted 1:20. C8166 cells or PBMC infected with HIV-1NL4-3 
were taken as positive control (infection). 
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